Evolutionary and deep mining models for effective biomarker discovery by Alzubaidi, AHA
Evolutionary and Deep Mining
Models for Effective Biomarker
Discovery
Abeer Hamza Abd Alzubaidi
School of Science and Technology
A thesis submitted in partial fulfilment of the requirements of
Nottingham Trent University for the degree of
Doctor of Philosophy
September 2019
Copyright Statement
This work is the intellectual property of the author. You may copy up to 5%
of this work for private study, or personal, non-commercial research. Any re-use
of the information contained within this document should be fully referenced,
quoting the author, title, university, degree level and pagination. Queries or
requests for any other use should be directed in the owner of the Intellectual
Property Rights.
i
This thesis is dedicated to my parents
With love and eternal appreciation.
I hope you’re proud of your little girl
I can see your smile from Heaven.
Acknowledgements
I would like to express my deepest appreciation to my supervisory
team. Im deeply indebted to Dr Jonathan Tepper for the dedicated
support and guidance through the process of researching and writing
this thesis. Dr Tepper continuously provided encouragement and was
always willing to assist in any way he could throughout the research
project. I am also grateful to Dr Tepper for insightful suggestions,
which have contributed greatly to the improvement of the thesis. I
would like to express my deepest gratitude to Prof Ahmad Lotfi for the
regular advice and encouragement. The door to Prof Lotfi office was
always open and he was prepared to sit and listen to me. My sincere
thanks are also extended to Dr Benjamin Inden for his supervisory
role and support throughout this research project. I take this op-
portunity to express my sincere appreciation to Dr Georgina Cosma,
Prof David Brown, and Prof Graham Pockley for their support and
encouragement throughout the process.
I gratefully acknowledge the funding received towards my PhD from
the Ministry of Higher Education and Scientific Research in Iraq. I
would like to thank my friends Dr Maria Bisele and Dr Edwin Ab-
durakman for the wonderful times we shared. Big thank you to my
sister, Ms Zaineb Alzubaidi who was always there for me and gave me
lots of support. The people with the greatest indirect contribution to
this work are my husband and my children. I owe my deepest grat-
itude to my husband Captain Hamid Alhasnawi for being extremely
supportive and understanding of my ambition. My children: Shahad,
Ali, and Fatimah, you have inspired me to aim for extraordinary and
made me more fulfilled. I appreciate all your patience and support,
love you.
Abstract
With the advent of high-throughput biology, large amounts of molecu-
lar data are available for purposeful analysis and evaluation. Extract-
ing relevant knowledge from high-throughput biomedical datasets has
become a common goal of current approaches to personalised cancer
medicine and understanding cancer genotype and phenotype. How-
ever, the datasets are characterised by high dimensionality and rel-
atively small sample sizes with small signal-to-noise ratios. Extract-
ing and interpreting relevant knowledge from such complex datasets
therefore remains a significant challenge for the fields of machine learn-
ing and data mining. This is evidenced by the limited success these
methods have had in detecting robust and reliable biomarkers for can-
cers and other complicated diseases. This could also explain the lack
of finding generic biomarkers among the identified published genes for
identical diseases or clinical conditions.
This thesis proposes and evaluates the efficacy of two novel feature
mining models established on the basis of the evolutionary compu-
tation and deep learning paradigms to position and solve biomarker
discovery as an optimisation problem. Deep learning methods lack the
transparency and interpretability found in the evolutionary paradigm.
To overcome the inherent issue of poor explanatory power associated
with the deep learning, this research also introduces a novel deep min-
ing model that helps to deconstruct the internal state of such deep
learning models to reveal key determinants underlying its latent rep-
resentations to aid feature selection. As a result, salient biomarkers
for breast cancer and the positivity of the Estrogen and Progesterone
receptors are discovered robustly and validated reliably across a wide
range of independently generated breast cancer data samples.
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Chapter 1
Introduction
The term feature mining refers to emerging statistical data analysis and com-
putational intelligence techniques with the goal of knowledge discovery based on
a better understanding of the data. Feature mining can also refer to the pro-
cess of endowing explanatory capability within the statistical and computational
paradigms used. Accordingly, feature mining can be described as the discovery
of the underlying structure of the data. The knowledge domain addressed by
the research discussed in this thesis is that of clinically relevant ‘biomarkers’ for
cancers of interest. A biomarker is formally defined as “a biological characteris-
tic that is objectively measured and evaluated as an indicator of normal biologic
processes, pathogenic processes, or pharmacologic responses to a therapeutic inter-
vention” [116]. According to World Health Organisation (WHO), International
Programme on Chemical Safety1, a biomarker is defined as “Any substance, struc-
ture or process that can be measured in the body or its products and can influence
or predict the incidence of outcome or disease”. Based on both definitions, a
biomarker can be described as a quantifiable biological indicator for detecting
diseases, monitoring its progression, and estimating susceptibility to treatment
therapy. Clinical tests based on biomarkers have been applied in medical practice
for decades for diseases diagnosis and prognosis and drug discovery [14].
Advances in molecular science and the recent availability of microarray data
have led to an exponential growth in volume, variety, and complexity of biologi-
1http://www.inchem.org/documents/ehc/ehc/ehc222.htm
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cal information. The completion of the first sequenced human genome [200, 300]
is one of the main triggers of evolution in biology. Microarray technology al-
lows for thousands of genes from a given cell or tissue sample to be examined
simultaneously heralding a new era of research in relatively nascent fields such as
computational biology and bioinformatics. These changes and others constitute
what is called high throughput or high dimensional biology that produces omics
data, which is discussed in details in Chapter 2. The availability of omics data
repositories such as The Cancer Genome Atlas (TCGA) [314] brings tremendous
opportunities for clinicians, bioinformaticians, statisticians and data scientists to
benefit from this abundance of cancer data to build a wide range of more accurate
models of the mechanisms underlying cancer and related diseases. Furthermore,
analysing omics data over several research studies can allow for more innovative
discoveries and findings, and this is further illustrated in Chapter 3, along with
the impact of the wealth of such data on the research community.
Biomarker identification from omics data has become a key goal to approach
precision medicine. Precision medicine aims to exploit this explosion of molecular
data together with individual patient characteristics to personalise medical treat-
ment [56]. Therefore, the next frontier in the move towards personalised cancer
medicine is to develop sophisticated knowledge discovery models that can detect
biomarkers underlying the variations of control (i.e. individuals without disease)
and cancer (i.e. individuals with the disease) groups. The extraction of relevant
knowledge from omics data can contribute to answering serious etiologic questions
about cancer and developing effective procedures to prevent, detect, manage, and
treat this heterogeneous complicated disease. Omics data is characterised by high
dimensionality, complexity, relatively small sample sizes and the amount of noise.
Omics datasets typically contain tens of thousands of molecules (e.g. genes).
The problem with high dimensional data was coined firstly by Richard Bellman
as ‘the curse of dimensionality’ [19]. The curse of dimensionality term refers to
various phenomena that arise when dealing with data that comprise hundreds or
thousands of variables [92].
Having tens of thousands of variables means that the number of possible in-
put configurations is exponential. However, not all of this information is relevant
because the feature spaces of such data comprise large amounts of irrelevant and
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noisy features, including genes with unreliable measurements that can be con-
sidered indistinguishable from noise. Moreover, when the dimensionality of a
dataset increases, the number of possible variable value combinations exponen-
tially increases, and therefore the available samples become sparse. In addition
to such ‘curse of dimensionality’ issues, the number of genes of omics data vastly
exceeds the number of observations, thus, the available biological samples become
even more sparse, making the process of discovering a robust subset of relevant
molecular markers a very challenging task. As a result, the problem of omics data
analysis is more likely to be that the relevant variations underlying the data is
not adequately exploited due to an insufficient number of biological samples (i.e.
a couple of hundreds), which in turn have a low signal-to-noise ratio as well as
their response groups are more likely to have considerable disparate sizes.
High dimensional complex data generated by omics technology has signifi-
cantly challenged traditional statistical techniques and machine learning methods
due to a range of subsequent issues, such as the curse of dimensionality, overfit-
ting, bias-variance trade-off, model robustness, interpretability, and computa-
tional cost. Machine learning models applied to this data will have to mitigate
against the high risk of becoming too sensitive to the variations in the data used
for model fitting and less sensitive to variation in the unseen data during model
evaluation, so that the models will have to minimise ‘overfitting’ the data. Conse-
quently, achieving the trade-off between these bias-variance quantities is becoming
more challenging where situations of overfitting (low bias and high variance) or
underfitting (high bias and low variance) being easily achieved whilst good gener-
alisation (low bias and low variance) remaining notoriously elusive. Furthermore,
a knowledge discovery model that focuses on detecting an informative subset of
candidate biomarkers from such small datasets could be very sensitive to which
observations are included in the data modelling phase of data mining raising the
issue of model robustness, where different outcomes could be obtained due to the
little variations in the data. In order to mitigate against these limitations and
boost the level of accuracy, the complexity of models has been increased, where
increasing the complexity of a model is more likely decreasing its explainability;
due to the trade-off between model complexity and interpretability. Herein, it
is relevant to emphasise the importance of adding some explanatory capability
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to the model used by health practitioners and decision-making professionals for
prediction relevant to precision medicine. Moreover, handling high-throughput
omics data could be computationally intensive, and the potential for the process
to become intractable is increased dramatically if the utilised model is slow to fit.
Classical statistical techniques based on univariate and multivariate approaches
have been extensively exploited as analytical tools in biology and medicine to de-
tect statistically significant changes in the behaviour of gene/protein expressions
among different biological conditions. In other words, biomarker discovery at the
molecular level depends on the principle that the discrimination between healthy
(control) and diseased patient groups of samples can be determined by the differ-
ential expression levels, intensity values, or activity of genes, proteins, and other
molecules. For example, intensity values of highly predictive proteins for cancer
patients differ significantly from samples in the control group. Therefore, genes
or proteins that exhibit significantly the greatest variations across different condi-
tions can be considered as potential biomarkers for a disease or clinically relevant
outcome. Accordingly, the comparison between control and cancer groups was
the traditional approach to recognise any statistically significant variations, which
could lead to discovering any potential biomarkers. However, biological samples
of microarray or mass spectrometry data are usually defined with thousands or
tens of thousands of variables. From a statistical perspective, inferring useful
knowledge from such data using those traditional methods is difficult because
they cannot exploit enough of the relevant variations underlying the data. This
is particularly true when analysing biological datasets with statistical models that
make inherent specific assumptions about the data, such as linearity, normality,
and homogeneity of variances that do not necessarily resemble the true function,
leading to poor estimation. The detailed evaluation of utilising traditional sta-
tistical techniques for knowledge discovery from omics data is critically discussed
in Chapter 2.
The research interest has therefore transferred to machine learning algorithms
that allow the discovery of interesting complex patterns, which are often missed
by the traditional statistical techniques. Since the advent of the big data revo-
lution and the increasingly ubiquitous availability of terabyte data storage and
giga- and tera-flop compute power, machine learning methods have become an
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invaluable tool in computational biology and its cognate disciplines. Machine
learning methods have been incorporated in diverse problem domains in health-
care area, leading to many successful applications, ranging from cancer diagnosis
and prognosis, medical imaging, to predictive modelling and decision support.
Due to the fact that the performance of machine learning methods depends on
the data, high throughput complex data generated by omics technology has sig-
nificantly challenged these learning models. The curse of dimensionality issues
combined with the challenge of relatively small sample sizes made it no longer
applicable for machine learning algorithms to be employed alone for omics data
analysis because the number of representative samples required to exploit enough
of the relevant variations underlying the data and achieve an acceptable level of
accuracy is growing exponentially. The detailed and critical discussions of em-
ploying machine learning methods for knowledge extraction from omics data are
presented in Chapter 2.
This has motivated the development of more sophisticated feature mining
models to support knowledge discovery for prediction purposes, which has be-
come a core process in the construction of high dimensional classification models.
Feature mining aims to detect interesting complexity from the unknown structure
of omics data that could not be discovered by traditional statistical techniques or
machine learning methods alone. Consequently, a variety of different methodolo-
gies and techniques from the fields of statistical data analysis and computational
intelligence are integrated in the hope of achieving better performance than using
approaches from one field alone. Detailed discussions of various feature mining
paradigms are considered in Chapter 2, particularly for high dimensional prob-
lems. However, omics data has the additional challenge of small sample sizes
such that the number of features is much greater than the number of samples,
putting even more pressure on such feature mining models for extracting robust
and reliable molecular markers. This is evidenced by the limited success these
methods have had in detecting robust and reliable biomarkers for diseases, such
as cancers. It can also explain why the discovery of meaningful biomarkers from
such datasets remains a major challenge in personalised cancer medicine, and
also could illustrate the lack of finding generic biomarkers among the identified
published genes for identical clinical conditions.
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As a result, the problem of biomarker discovery from High Dimensional Small
Sample Size (HDSSS) omics data is complicated and requires more sophisticated
approaches that can address these challenges. The significance of choosing the
right methodology for each step of an effective feature mining model applied to
omics data is emphasised in the research presented in this thesis. The aim of the
knowledge discovery models can be achieved by understanding the key research
challenges, using the proper techniques, not the available and popular ones, and
careful attention to performance estimation in order to report significant and
reliable findings.
1.1 Aims and Objectives
The overarching aim of this research is to develop effective feature mining models
that robustly aid the extraction of knowledge from HDSSS omics data in a way
that is transparent and supports the endeavour of precision medicine.
In order to accomplish this aim, the following objectives will be met:
• Identify and characterise suitable and reliable high quality HDSSS omics
datasets for cancers of interest (e.g. TCGA datasets).
• Empirically establish effective data pre-processing methods that maximise
the ability of the feature mining models to identify salient biomarkers.
• Critically evaluate state-of-the-art evolutionary computation and deep neu-
ral network methods for biomarker discovery.
• Develop novel feature mining models and related innovations which mitigate
against the limitations reported in the research literature, whilst maximising
their strengths for biomarker discovery.
• Determine and mitigate against the sensitivity of the feature mining models
to imbalanced group datasets.
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• Investigate and establish most appropriate model selection methods (in-
cluding objective functions) to effect the simplest model with the highest
level of generalisation for each model class.
• Explore and implement a technique for interpreting salient features identi-
fied within the deep feature learning model.
• Investigate and implement appropriate validation and evaluation metrics
for estimating the generalisation and robustness performance of the feature
mining models.
• Identify appropriate validation criteria to verify the validity of the biomark-
ers discovered by the feature mining models with the specific criteria of
predictivity, stability, and generalisability.
1.2 Contribution of the Thesis
The first fundamental issue addressed by this research was the reliable extrac-
tion of important biomarker information from HDSSS omics data. The research
explored a number of disparate paths within the cognate disciplines of compu-
tational intelligence and computational biology. The first path was conducted
by investigating the direction of solving the biomarker discovery as an optimi-
sation problem. Biological data generated by omics technology has thousands
of variables and to identify relevant genes to the response groups or conditions,
an extremely large number of evaluations is required. Therefore, feature min-
ing approaches that can guarantee to find the optimal subset of features are
computationally expensive and infeasible in most practical cases. Optimisation
methods attempt to identify the best possible subset of features from the expo-
nential search space of omics data with the least amount of effort. Therefore,
the primary contribution of this thesis is to develop an ensemble evolutionary
mining model based on a hybrid selection approach to navigate through large
genomic and proteomic data and detect an ensemble subset of stable predictors.
Different paradigms of feature selection based on the optimisation method have
been investigated to find the most appropriate measurement for a HDSSS prob-
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lem. Consequently, the ensemble hybrid selection approach is integrated with
the parallel adaptive search of the evolutionary method so that the curse of di-
mensionality issues can be handled and the robustness of the selected subsets of
candidate predictors can be enhanced.
What has driven us to the second direction of this research is that a fea-
ture learning model that can discover relevant knowledge automatically from
large-scale data, without the need for hand designed features that require do-
main expertise or ad-hoc specific methodologies or techniques is highly desirable.
Therefore, the second path of our research is investigating the usefulness of state-
of-the-art Deep Learning to mitigate against the mentioned limitations on the
basis of automatically capturing enough of the meaningful abstractions latent
with the available biological samples. Deep learning methods provide superior
performance over traditional learning approaches by handling the curse of di-
mensionality, improving the generalisability, and making meaningful use of the
data in a wide range of problem domains such as computer vision, natural lan-
guage processing, and speech recognition. Recently, in the healthcare area, deep
learning methods have brought about breakthroughs in medical imaging such as
CheXpert [146], a large dataset that contains 224, 316 chest radiographs of 65, 240
patients for chest radiograph interpretation.
In many of these problem domains, a large number of samples are typically
available to train a deep learning model where the signal-to-noise ratio is quite
high. The key challenge is to capture the generic factors of variations that un-
derlie the unknown structure of the data in a way that can significantly enhance
the generalisation to unseen observations. This is, however, not the case in bioin-
formatics research where high throughput omics datasets are characterised by
a small number of biological samples (i.e. hundreds of patient samples), which
in turn have a low signal-to-noise ratio. Therefore, for omics data analysis, the
problem is more likely to be that the relevant variations underlying the data
can not be adequately captured due to an insufficient number of biological sam-
ples. As a result, it may seem somewhat counterintuitive to use deep learning
methods for HDSSS datasets due to the fact that these learning models typi-
cally require substantial data to constrain their parameters and learn a useful
hypothesis. Applications of deep neural network methods for knowledge discov-
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ery from HDSSS omics data remain scarce. This necessities introducing new deep
learning-inspired paradigms that can approximate enough of the relevant varia-
tions represented by those biological samples. Therefore, the second contribution
of this thesis is introducing a new deep feature learning model that can capture
enough of the complexity of interest represented by the available biological sam-
ples. More specifically, the proposed deep learning model is introduced based on
a set of non-linear sparse Auto-Encoders that are deliberately constructed in an
under-complete manner to force the network to discover enough of the interesting
complexity underlying the biological samples. The ability of using a stacked set
of neural auto-encoders alleviates the issue of vanishing gradients and therefore
provides a robust deep learning model to automatically identify the complex fea-
tural representations necessary to capture the important variations within the
original dataset. The proposed deep feature learning model is utilised to discover
and interpret important signals from omics data that aid prediction relevant to
precision medicine.
The proposed deep feature learning model applies multiple levels of projections
to the input features to abstract the problem and capture high-level dependen-
cies for achieving high-level of generalisability. This would be a powerful learning
model for high dimensional classification problems. However, for the problem
of biomarker identification, it is hard to interpret which subsets of genes were
dominant within the internal representations and responsible for deriving such
predictions. Therefore, a fundamental issue with the deep learning paradigm is
the lack of explanatory power, and their inability to unambiguously state which
input features are responsible for its behaviour. To overcome the inherent issue
of poor explanatory power associated with the deep learning paradigm, we en-
deavour in a new direction of research that focuses on deconstructing the internal
mechanism of such deep learning models based on a new weight interpretation
method. The learning process of the deep learning relies mainly on sensibly fit-
ting the weight configurations to define the model’s input-output function. This
reflects the fact that the weight is the main indicator of variable’s importance, in
which the weight of each variable reflects its contribution through the network,
so that the signal with a larger positive or negative weight has a greater impact.
Therefore,the third contribution of this thesis is proposing a new technique called
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deep mining to sculpt inside the deep feature learning model and open the so-
called black box of the network for biomarker identification. A model that is
able to state which phenotypes are key determinants is a crucial element of pre-
diction systems used by health practitioners and decision-making professionals.
It is therefore important we are able to provide some explanatory capability to
our deep learning model. Our novel deep mining model provides yet another
arrow within the quiver of bioinformaticians for discovering and evaluating new
biomarkers that may help further the endeavour of producing more effective and
personalised medicine.
The application of the proposed feature mining models to the utilised omics
datasets has led to the fourth contribution of this research, which is discovering rel-
evant, robust and reproducible biomarkers for breast cancer and the positivity of
Estrogen and Progesterone receptors. The detected biomarkers are validated re-
liably across a wide range of independently generated breast cancer data samples
that are collected from completely different studies. The fundamental concepts
of omics data, breast cancer, and understanding the role Estrogen Receptor and
Progesterone Receptor play in this heterogeneous complex disease are detailing
covered and discussed in Chapter 2.
In this thesis, the principle has been emphasised that the discovered molec-
ular markers should meet the following criteria to act as true biomarkers, which
are Predictivity, Stability, and Generalisability. Predictivity is introduced to ex-
amine the capability of the discovered biomarkers to separate patients in the
cancer group from those in the control group with a good level of certainty. The
lack of overlap among the published genes or proteins for identical diseases or
clinical outcomes is essentially caused by the lack of robustness or stability of
the selected genes across samples. Therefore, stability is utilised to investigate
how the variations in the training data can affect the feature preferences of the
proposed feature mining models, and to fight the sparsity of data points in a
high-dimensional space. “If the same features are selected in multiple indepen-
dent iterations, they more likely are reliable biomarkers” [100].
Generalisability is employed to test the potential of the proposed feature min-
ing models to detect generic biomarkers from multiple independent datasets that
are collected from completely different studies so that the highest evidence can be
10
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provided. The research study [287] has hypothesised that “External validation us-
ing data from a completely different study provides the highest irrefutable evidence
that a tool validates”. From a large body of research that focuses on biomarkers
discovery, few studies have adopted another independent dataset for validation
purposes despite the availability of the data generated by TCGA program with
high standard samples. That could explain why the number of clinically validated
biomarkers is very few, despite the numerous proposals in the literature.
1.3 Thesis Outline
This thesis is structured as follows:
Chapter 2: Literature Review
This chapter provides the groundwork for informing how best to achieve the
stated objectives by providing a summary of the key concepts and research direc-
tions in the area of cancer biomarker discovery from omics data. It starts with an
introduction to breast cancer and the fundamental types of data generated from
omics technologies. Subsequently, this chapter provides a critical discussion of
the current approaches to biomarker discovery found in the literature. Chapter
2 investigates the appropriateness of different experimental methodologies, vali-
dation and evaluation metrics for verifying the outcomes of the feature mining
models constructed using HDSSS data.
Chapter 3: Datasets and Experimental Methodology
This chapter explains the datasets used to perform omics data modelling and
analysis and the experimental methodologies and evaluation metrics applied to
estimate the robustness of the discovered biomarkers. The chapter starts by
explaining the data pre-processing methods that are utilised for filtering out ge-
nomic datasets from genes with unreliable measurements. Then, the sources of
high quality HDSSS omics datasets for cancers of interest are illustrated with
an emphasis on gaining the maximum benefit from these publically available
datasets. In this project, 18 datasets have been utilised to examine the potential
of the presented feature mining models to discover robust and generic knowledge.
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The cancer datasets, evaluation metrics, and validation approaches used to anal-
yse them are discussed in detail in this chapter.
Chapter 4: Evolutionary Mining Model
This chapter covers the design, implementation, and application of the ensem-
ble evolutionary mining model proposed for biomarker identification from omics
data. It starts with an introduction to why and how to solve the problem of
biomarker discovery using optimisation methods. Subsequently, an overview to
one of the most powerful optimisation methods, the Genetic Algorithm, is in-
troduced. Thereafter, Chapter 4 discusses the experimental design of the evolu-
tionary mining model, which integrates the Genetic Algorithm and the ensemble
hybrid selection approach. Feasible choices for each step of the experimental de-
sign are investigated and justified. The performance of the proposed evolutionary
mining model is evaluated using the datasets and the experimental methodology
mentioned in Chapter 3.
Chapter 5: Deep Mining Model
This chapter covers the design, implementation, and application of the deep min-
ing model proposed for biomarker discovery from omics data. It provides an
introduction to the fundamental components necessitated to develop an effective
deep feature learning model that can exploit the unknown structure of omics
data effectively. Consequently, the design steps of the deep mining model based
on an unsupervised data-orientated approach is introduced to discover and inter-
pret important signals from proteomic and genomic data. Furthermore, Chapter
5 discusses a new weight interpretation technique that is proposed to add ex-
planatory power to our deep learning model, helping to alleviate one of the most
challenging problems associated with the deep learning paradigm. The proposed
deep mining model is evaluated using the datasets and experimental methodology
introduced in Chapter 3.
Chapter 6: Biomarkers and Bioinformatics
The generic biomarkers for breast cancer discovered by our feature mining mod-
els have been validated in terms of predictivity, stability, and generalisability
12
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in Chapters 4 and 5. In this chapter, the clinical relevance of the discovered
biomarkers will be evaluated with respect to current bioinformatics research into
breast cancer. It is important to emphasise that, at the time of writing, there
is no research that has found or examined the combination of these biomark-
ers or some of them simultaneously. Furthermore, the association between each
biomarker and the hormone receptors recognised in this PhD work is discussed
to identify the type of existent relationship.
Chapter 7: Conclusion and Future Work
This thesis concludes with a discussion of the crucial challenges underlying the
problem of inferring knowledge from HDSSS omics data, a summary of the con-
tributions made to help alleviate these challenges and finally, potential future
directions for this research and cancer biomarker discovery.
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Literature Review
2.1 Introduction
Current computational models and tools for detecting breast cancer and un-
derstanding the role Estrogen Receptor and Progesterone Receptor play in this
heterogeneous disease are detailing reviewed in this chapter. A short overview of
breast cancer, available omics data and the central dogma of molecular biology
are first considered together with the challenges these pose for any data mining or
computational model that may be used for biomarker discovery. Current state-
of-the-art approaches for knowledge extraction are then subsequently reviewed
along with strengths, limitations and challenges. An emphasis is made in this
chapter on critical underlying issues of validating and evaluating the empirical
results of biomarker discovery models proposed for HDSSS omics data. Increasing
the awareness of the key research challenges allows for more efficacious solutions
by understanding the required computational and statistical resources.
2.2 Breast Cancer
Breast cancer is the most common neoplasm in women and the second leading
cause of cancer-related mortality in females worldwide [18]. Mammography is
the standard tool that has been used for detecting breast cancer [114]. How-
ever, several issues have been raised about this procedure including the risk of
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false positives, over diagnosis of indolent disease, and lowering the sensitivity of
recognising tumours in women with dense breast tissue [40, 224, 316]. Magnetic
Resonance Imaging (MRI) offers a powerful alternative and provides excellent
imaging even around dense breast tissue [26]. However, a high risk of obtaining
false positives could lead to needless, stressful and expensive procedures [137].
Therefore, there is a critical necessity for measurement of molecular markers that
could estimate the potential occurrence of a disease, and providing the probabil-
ity of specific outcomes to the clinician for treatment stratification. Recognition
of breast cancer at early stages can bring better prognosis with a 5-year survival
rate of up to (90%), however, when breast cancer spreads to distant organs, this
survival rate declines drastically to (20%) [90]. Detection at the early stages
and monitoring breast cancer remain major challenges for healthcare profession-
als. Moreover, the aetiology of breast cancer is still ambiguous, where breast
cancer can differ significantly in regards to clinical, pathological, and biological
properties.
Breast cancer begins when healthy cells change and grow out of control, form-
ing a mass called a tumour. A tumour can be malignant or benign. A benign
tumour means a tumour can grow but will not spread. A malignant tumour can
grow and spread to other parts of the body. A malignant tumour has an abnor-
mally high level of Estrogen Receptor and Progesterone Receptor in the nucleus.
According to the website of National Cancer Institute (NCI)1, Estrogen Receptor
is “a protein found inside the cells of the female reproductive tissue, some other
types of tissue, and some cancer cells. The hormone estrogen will bind to the
receptors inside the cells and may cause the cells to grow. Also called ER”. The
NCI’s website2 defines Progesterone Receptor as follows: “A protein found inside
the cells of the female reproductive tissue, some other types of tissue, and some
cancer cells. The hormone progesterone will bind to the receptors inside the cells
and may cause the cells to grow. Also called PR”. Testing the tumour for Estrogen
Receptor and Progesterone Receptor is a standard part of the initial evaluation
of breast cancer diagnosis and treatment planning. The analysis of Estrogen and
1https://www.cancer.gov/publications/dictionaries/cancer-terms/def/estrogen-receptor
2https://www.cancer.gov/publications/dictionaries/cancer-terms/def/progesterone-
receptor
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Progesterone Receptors by Immunohistochemistry (IHC) is considered currently
the most commonly used method to test the tumour for both hormone receptors
in cancer cells from a sample of tissue, which may come from a biopsy [97].
If breast cancer cells have high ER, the cancer is described as ER-positive
(ER+), and if breast cancer cells have high PR, the disease is specified as PR-
positive (PR+) cancer. ER and PR expressions have been utilised as robust
indicators for the evaluation of breast cancer. All newly diagnosed invasive breast
cancer patients and breast cancer recurrences should be examined for both ER
and PR according to the recommendations of the American Society of Clinical
Oncology and the College of American Pathologists [123]. According to cancer
research UK, ∼ 37000 out of 50000 new cases are distinguished by the presence
of ER. However, it has been shown that the expression of ER and PR receptors
changes during the development of breast cancer and in response to systemic
therapies [199].
For patients with ER+, particular treatments that block the activity of ER
are recommended. ER activation plays a significant role in different biological
processes like cell development and cell death [160]. The mechanism of blocking
ER activity relies essentially on changing ER function in such a way that ER
is becoming unable to regulate gene expression [259]. According to Carroll [46]
“Oestrogen Receptor (ER) is a transcription factor that regulates gene expression
events that culminate in cell division”. Several expression profiling studies have
illustrated that the expression of hormone receptors is linked with diverse genetic
variations [231,267,268]. That means several mutated genes can affect the devel-
opment and progression of breast cancer and contribute to its heterogeneity [29].
As a result, investigating molecular characteristics of the tumours that could act
as risk factors of breast cancer is considered a serious aetiologic question [104].
This research project aims to identify mRNA markers from gene expression data
that underlie the biological processes of ER and PR receptors.
With the advent of omics technologies, various biological molecules like genes,
transcripts, proteins, metabolites, and other species have been provided. The next
section provides an introduction to the central dogma of molecular biology and
the fundamental types of data generated from omics technologies.
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2.3 Omics Data
In 1957, a symposium of the Society for Experimental Biology in London pre-
sented one of the fundamental ideas of molecular biology, which is called the
central dogma, and then it was published by Francis Crick in 1958 [61]. The
concept of the central dogma of molecular biology specifies the transfer of genetic
information within the biological system. This sequential process is shown in
Figure 2.1 and involves the following processes: Replication, Transcription, Re-
verse Transcription, and Translation. Replication (DNA to DNA): is the process
of copying all of a cell’s DNA. Transcription (DNA to RNA) is the process, in
which the DNA is transcribed to RNA, which carried the needed information
to protein. Reverse Transcription (RNA to DNA): in this process, the RNA
is reserved transcribed to DNA. Translation (RNA to protein): is the process in
which the RNA is decoded to make a protein. Crick states that “once (sequential)
information has passed into protein it cannot get out again” [121].
Different measurements provided by current technologies can be performed
on and beyond distinct layers of the dogma to produce the so-called omics data,
as shown in Figure 2.1. The fundamental aim of omics technologies is detecting
genomics, transcriptomics, proteomics and metabolomics in a specific biological
sample. Further to the role of omics technology in providing a great insight to
the physiological system, they play a significant role in developing diagnosis and
prognosis systems, investigating biomarkers at the molecular level, advance phar-
macogenomics studies and expand our knowledge about the aetiology of complex
diseases.
Omics fields can be grouped as follows [152]:
- Genomics is the systematic study of an organism’s genome. The genome
can be defined as the complete set of genetic information (DNA sequence)
of a cell or organism. Conventional methods have analysed genes inde-
pendently, whilst recent microarray technology measures genetic variants
between individuals and the expression of thousands of genes simultane-
ously in order to reveal if any abnormality is associated with a trait [138].
The most popular differences in genetic information between humans are
Single Nucleotide Polymorphisms (SNPs), where a SNP is a variation at a
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Figure 2.1: The central dogma of molecular biology [121] and the types of omics
data generated from each layer of dogma.
single DNA site [83]. Therefore, SNPs have been explored for detecting dis-
eases with a genetic determination and in pharmacogenomics for assessing
the efficacy of drug therapies.
- Transcriptomics is the study of the mRNA within a cell or organism. The
transcriptome is the total mRNA transcripts that reflect the gene activity
within the cell. Microarrays have been utilised in several areas of bioinfor-
matics, and it is used in transcriptome to measure mRNA and summarises
the actively expressed genes.
- Proteomics is the large-scale study of proteins, including their structure
and function, within a cell or organism [289]. The proteome is the set of all
expressed proteins in a cell or organism. Proteomics is another interesting
area of research after genomics because it can provide more comprehension
to the complex biological procedures due to its direct role in cell physiol-
ogy. The proteome is considered a reflection of genomic and environmental
factors. Therefore, it may hold a promising piece of knowledge, which can
address different biological questions of interest [276]. However, a large
number of proteins is produced.
- Metabolomics is the study of global metabolite profiles in a cell or organism
[113]. The metabolome is the outcome of integrating the transcriptome
and the proteome [296]. Thus, changes in the metabolome are related to
changes in this product. The metabolome involves the smallest domain size
18
2. Literature Review
comparing with other omics data. Among different metabolite molecules,
which are illustrated in Figure 2.1, the research interest has been focused
recently on lipidomics due to their significant role in several diseases such
as obesity, atherosclerosis, stroke, hypertension and diabetes [124].
High-throughput technologies allow thousands of variables to be examined
simultaneously in a biological sample within a single experiment. Thus, it has
the potential to detect key molecules that can answer the biological questions
of interest so that new treatment strategies and drugs can be provided. The
potential research directions for biomarker discovery using the state-of-the-art
approaches proposed in the literature will be discussed in the next sections.
2.4 Statistical Techniques for Biomarker Discov-
ery
This section offers a brief introduction to traditional statistical methods applied
in disease biomarker discovery studies. Conventional statistical techniques used
to be the standard methods for the analysis of biomedical data such as hypothesis
testing, correlation, regression, and clustering analysis. Statistical methods based
on the univariate approach (e.g. [193]) assess the optimality of each variable in-
dependently from the others assuming there is no interaction between them. The
univariate analysis produces a list of features, sorted according to their discrim-
inative power in separating the samples of different response groups. However,
omics data analysis based on univariate tests can increase the risk of obtaining
‘spurious’ markers by misclassifying genes as differentially expressed when they
are not. When a large number of genes is available, the risk of obtaining false
positives is increased due to the challenge of multiple comparisons [228,270]. Al-
though several procedures have been introduced in the literature to tackle the
multiple comparisons problem such as the Benjamini-Hochberg [25,242], and the
Bonferroni correction [263] as well as procedures in pattern mining established
by [312, 313], some issues have been raised about them [14]. In this research,
finding robust biomarkers for cancers of interest is a discovery-based approach,
and more information about hypothesis-based style can be found in [197].
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On the other hand, the conceptual simplicity and the lower demands of uni-
variate statistical techniques still attract researchers to utilise them as a pre-
processing step to reduce the dimensionality of the data in preparation for more
complex multivariate modelling or learning (e.g. [310]). Among a wide range
of univariate statistical methods, t−test is widely utilised as a pre-processing
step [183, 262]. In genomic data, it has been shown that there is a non-trivial
proportion of genes that have unequal group variances [72]. Thus, it is impor-
tant to consider that the unequal variance t−test is more appropriate to find
discriminative features than other hypothesis testing methods.
High-throughput omics data are multivariate, where the biological outcome
is distributed in several biomarkers that need to be assessed simultaneously
rather than independently. Statistical techniques based on multivariate approach
(e.g. [181]) consider the effect of variables jointly rather than individually. Many
successes in biology and medicine have been achieved using these conventional
statistical methods (e.g. [202,304]). However, extracting and interpreting relevant
knowledge from high dimensional and complex omics data remain significant chal-
lenges for these classical models. The main drawback of these models is that they
make specific assumptions about the data such as linearity, normality and homo-
geneity of variances that do not necessarily resemble the true function, leading
to poor estimation [204]. This is evidenced by the limited success these methods
have had in discovering robust and reliable molecular markers for diseases such
as cancers. Therefore, high dimensional data analysis has become an active area
of statistical research [75].
The trade-off between model complexity and the possibility of overfitting
has re-acknowledged conventional multivariate linear methods. Moreover, the
simplicity of the theoretical concepts of linear models like these suggested by
Hotelling [139] and Fisher [96] still attracts us nowadays, to be employed as a
powerful methodology that can understand the underlying structure of the data
and summarise it in simpler ways. “simple methods typically yield performances
almost as good as more sophisticated methods” [125]. However, it still seems hope-
less to adopt these simple models alone for handling high dimensional problems
rather they can be useful on top of other sophisticated methods.
Many of the early microarray analysis studies have utilised clustering tech-
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niques for the aim of biomarker identification. In the machine learning domain, a
clustering approach is referred to as Unsupervised Learning and with other tech-
niques like Discriminant Analysis, Statistical Learning is formed. It is significant
here to differentiate the mechanism of Principle Component Analysis (PCA) [246]
that looks to find a low-dimensional representation of the observations that ex-
plains a good fraction of the variance from the clustering analysis that looks to
find homogeneous subgroups among the observations. For PCA, in addition to its
linearity, it is impossible to estimate the amount of information that is preserved
in a space defined by the first few principle components as well as there is no uni-
versally agreed method for reliably recovering key determinants (i.e. genes) from
the principal components. For clustering analysis, diverse techniques have been
introduced in the literature, such as hierarchical clustering (e.g [299]), k-means
clustering [203], and Self-Organising Maps (SOMs) [168]. Research has shown
that none of these clustering analysis methods have consistently outperformed
the others, therefore, diverse clustering methods are typically applied to complex
molecular data for producing ensemble outcomes.
Clustering analysis partitions the data space into smaller distinct clusters or
regions so that the observations within each cluster are quite similar to each other
and dissimilar to observations in other clusters. For example, assigning samples
to similar cancer subtypes. As a result, the hypothesis of cluster analysis depends
on the similarity notion that measures a distance between patterns, which has
diverse forms (e.g. Euclidean, Manhattan). The new groups may not be related
to the status of these samples so that interactions can be uncovered in the data. In
the biomarker identification context from genomic or proteomics data, clustering
methods attempt to find genes or proteins that exhibit similar expression patterns
(e.g. [107]). However, the major drawback of using clustering analysis for high
dimensional data is that the number of distinct regions grows linearly with the
number of parameters. While with a deep neural network, it has been shown
that the number of distinct regions can grow exponentially with the number of
parameters using sparse representations. More information about the difference
between clustering and multiclustering can be found in the research paper [23].
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2.5 Machine Learning Methods for Biomarker
Discovery
The term of Machine Learning (ML) refers to the capability of an algorithm to
learn from data. Many different definitions have been introduced to specify a
machine learning. A brief definition has been provided by Mitchell in 1997 [211]:
“A computer program is said to learn from experience E with respect to some
class of tasks T and performance measure P, if its performance at tasks in T, as
measured by P, improves with experience E”. According to this formal definition,
learning refers to the ability to execute the task, while the task can be defined as
processing a set of examples, and an example is a collection of features and desired
responses or groupings. The training process relies on learning an underlying and
previously unknown structure of the data from the training examples so that the
learned model can assign an unobserved example to its target. Where learning
typically involves a search procedure over the parameter or rule space to identify
a range of values or settings that minimises the cost function. Let’s assume X is
a d-dimensional vector, where X ∈Rd, and Y is the response group, where Y ∈ R,
which takes two numerical values {0,1} or {-1,1}. The classification function f
represents the systematic information that X provides about Y , where f : Rd
→ {0, 1}.
Since the advent of high-throughput biomedical data, ML methods have be-
come an invaluable tool in computational biology and its cognate disciplines.
Although the characteristics of most ML methods are well understood, the perfor-
mance of these learning models depends on the data. High dimensional complex
data generated by omics technology has significantly challenged ML models due
to various phenomena ranging from the curse of dimensionality, overfitting, bias-
variance trade-off, model robustness, interpretability, and computational cost.
Simple classification models cannot be developed using all the available features.
Even if other learning models can be constructed, the large dimension spaces of
omics data contain many irrelevant and noisy variables that do not contribute
to reduce the misclassification rate, rather degrade the prediction performance
to the level of random guessing. As a result, the curse of dimensionality issues
of omics data made it no longer applicable to use ML methods alone because
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the number of examples needed to represent the number of the variations in the
data and achieve an acceptable level of classification accuracy is growing expo-
nentially. Therefore, feature mining has become a critical pre-processing step
before the data is applied to the ML model. Reducing the number of features
contribute to reducing the number of samples required to achieve a good-level of
generalisation. Therefore, for high dimensional problems, choosing the appropri-
ate methodology for the feature mining stage seems to be an essential precursor
to the machine learning stage, since ML models will be trained using reduced fea-
ture spaces. However, dealing with small sample sizes datasets is another critical
issue that needs to be properly handled for true estimation.
Complex classification models with highly fitted decision boundaries discrim-
inate the training observations optimally. That means, training error rate (the
percentage of training samples misclassified by the learned model) consistently
decreases with the increase of model complexity. However, they might not be able
to assign the testing samples to their response groups correctly due to the trade-
off between model complexity and the possibility of overfitting. That means, the
learner becomes infeasibly flexible such that it is becoming too sensitive to the
variance found in the training set and as a consequence becoming less sensitive to
any additional variation found in testing data. Therefore, classification models
with complex boundaries are likely to overfit to training data causing poor gen-
eralisation ability on testing data. For example, a quadratic curve might fit the
data points perfectly, however it might not generalise well. While linear classifiers
with simple hyperplane decision boundaries tend to suffer less from overfitting
and generalise well. That means, the underlying variations in the data can be
better allowed with a simple straight line contributing to reducing the risk of
overfitting.
Therefore, in this thesis, powerful but not too adaptable classification models
are utilised in this research to assess the predictive power of the selected biomark-
ers, which are Support Vector Machine and Bagging Decision Tree. These learning
techniques are selected due to their empirical power and success in the same or
similar domains. The aim of proposing the feature mining models is to derive can-
cer markers whose behaviour differs significantly across the biological conditions,
thus the utilised learning models can be employed to develop reliable prediction
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systems. Consequently, the accuracy of these classification model built on the
dataset containing only the informative genes is listed as one of the main criteria
to assess the quality of the discovered biomarkers.
2.5.1 Support Vector Machine
Support Vector Machine (SVM) [35] is one of the most robust classification models
that is well-proven across a wide range of settings, especially for high dimensional
biomedical data [20,217]. In a classification problem, SVM finds its boundaries in
the d−dimension space that can distinguish observations of differentiated groups.
In a d−dimension space, the boundary is called a hyperplane, where the hyper-
plane can be defined as a flat affine subspace of dimension d − 1. Having a set
of n examples (xi, yi), i = 1, 2, ..., n, where xi ∈Rd, and yi ∈ R, which takes two
numerical values {1,-1}. A hyperplane can be defined by the equation:
wTx + b = 0 (2.1)
where w is a d−dimensional coefficient vector and the bias term b is the offset of
the hyperplane from the origin. The decision rule to classify new observations is:yi = −1 if wTxi + b < 0yi = +1 if wTxi + b > 0. (2.2)
This could be valid for multiple hyperplanes, thus which of the possible sep-
arating hyperplanes should be chosen. SVM chooses the best separating hyper-
plane (i.e. the decision boundary), which maximises the margin of separation
(i.e. the maximum safety distance between the boundary and the training points
that are closest to the boundary) by solving the following optimisation task:
min
w
=
‖w‖2
2
(2.3)
Subject to : yi(w
T .xi) + b ≥ 1, i = 1, 2, ..., n (2.4)
the size of the margin is 1‖w‖ , thus minimising ‖w‖ leads to maximise the margin,
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Figure 2.2: An example dataset described by two genes of a linear separator that
maximises the margin between positive samples and negative samples, the red
dots on the right side represent the positive group; and the blue dots on the left
side represent the negative group. There are three support vectors. One point of
the positive group on the right dashed line, and two negative samples on the left
dashed line.
where each data point lies in the correct side of the separating hyper-plane as
shown in Figure 2.2. The training data points that are closest to the decision
boundary are called the support vectors.
For a learning model with best separating hyperplane, the risk of overfitting
could be increased due to its high sensitivity to the change in training points.
Therefore, a hyperplane that allows some training observations to be misclassified
could achieve a better job in classifying testing observations. In the maximal
margin classifier, every point must be on the correct side of the hyperplane and
the margin. A compromise between maximising the margin and minimising the
cost of misclassification is required. Therefore, the support vector machine or
soft margin classifier allows some points to be on the incorrect side of the margin
or even the hyperplane. The soft-margin relaxes the constraints of Equation 2.3
by imposing a penalty on the length of the margin for every point that is on the
wrong side of the decision boundary and as follows:
min
w,ξ
=
‖w‖2
2
+ C
n∑
i=1
ξi (2.5)
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Figure 2.3: SVM soft-margin allows some data points to be misclassified or within
the margin through slack variables ξi.
Subject to : yi(w
T .xi) + b ≥ 1− ξi, ξi ≥ 0 (2.6)
The slack variables ξi are measures of the margin violations for the training data
points, such as ξi < 1 for the training points that are correctly classified, ξi = 1
for the training points on the separating hyperplane, and ξi > 1 for the training
points that are misclassified (Figure 2.3). That means that the data point that
locates strictly on the correct side of the margin does not impact the model, and
only the support vectors can affect SVM classifier. The fact that only the support
vector points can affect the decision rule of SVM classifier makes it more robust
classifier, due to its low sensitivity to the behaviour of training points that locate
far from the hyperplane. Parameter C determines a penalty for misclassification
- (the trade-off between maximising the margin and minimising the number of
misclassified training points). Therefore, it is important to reduce the risk of
overfitting and enhance generalisation performance.
2.5.2 Bagging Decision Tree
Decision trees are widely utilised classification techniques due to their simplicity
and comprehensibility. Decision trees represent the relationships between features
hierarchically such that the relationships and the values of each feature contribute
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Figure 2.4: An illustration of a decision tree constructed using a gene expression
dataset of four genes.
to constructing a classification model that can be used to assign new observations
to their response groups correctly. To illustrate the hierarchical structure of
decision trees, let’s discuss how to construct decision trees and how to use that
construction to estimate the response groups of a new observation. Figure 2.4
presents a decision tree model constructed from a gene expression dataset that
consists of four genes: x1, x2, x3, x4, and two response groups: grp1 and grp2.
The nodes that are represented by solid-line rectangles in Figure 2.4 represent
the selected genes and their expression values, which should be good cut-points to
best assign the samples into their response groups. The leaves that are represented
by dashed-line rectangles in Figure 2.4 involve the percentage of observations that
are classified to their response groups based on different gene expression values
that are obtained by navigating the tree from the top (i.e. the root node) to the
bottom (i.e. the leave).
The tree starts where all the training examples belong to a single region and
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a series of splitting rules are developed further down of the model. Therefore, a
new observation will eventually be dropped down the tree into a decision node
(i.e leave) where no further evaluations are required. The splitting criterion relies
on maximising the information about the response groups, so that how well the
new split can discriminate observations of grp1 from grp2. Diverse tree induction
techniques have been developed for performing the splitting rule and selecting
candidate predictors such as homogeneity or purity of the group distribution
associated with each node. The entropy [251] and the Gini impurity index [42] are
well-known measurements of node’s purity. Therefore, the Gini impurity index is
utilised in this research to measure the total variance over the K response groups,
and it can be defined by the equation:
G =
K∑
k=1
pˆmk(1− pˆmk), (2.7)
where pˆmk is the proportion of training examples in the mth region that belong
to kth response group. If all pˆmk are close to 0 or 1, the value of the Gini
impurity index will be small. Small Gini index means that a node predominantly
has training examples that belong to the same response group. If the node is
pure, the index will be equal to 0, and 0.5 when the response groups of the
training sample of a node are equally represented. However, the sensitivity of
the decision tree to the training examples leads to generate variant classification
models causing overfitting and leading to poor generalisation performance when
applied to new observations. Therefore, aggregating multiple trees like bagging
or boosting can considerably improve the predictive accuracy and robustness of
the learning model.
Bagging is widely utilised in the context of decision trees since they notoriously
suffer from high variance. Bagging is a portmanteau of “Bootstrap aggregating”.
As mentioned previously, bootstrapping is a resampling technique that generates
multiple training sets from the original dataset by repeatedly sampling with re-
placement, and it is used to measure the uncertainty of the statistical properties
of learning models. To account for variance in performance estimation of a learn-
ing model, training sets generated as bootstrap samples from the original dataset
are used to construct multiple classification models and then averaging the ob-
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tained results. Therefore, the bootstrapped training sets are used to construct
Bagging Decision Trees (BDT), then the obtained predictions of individual trees
are averaged. In the testing stage, the response group of a new observation that
is predicted by each tree model is recorded, and the most commonly predicted
response group among all the predictions of the tree models is assigned to the
new observation.
2.6 Feature Mining Approaches for Biomarker
Discovery
In 1986, George Box [39] stated that “a large proportion of process variation
is explained by a small proportion of the process variables”. In the context of
biomarker discovery, detecting a small group of robust molecular markers under-
lying the variations of different groups of samples would be the most cost-effective
procedure in developing reliable and explainable diagnosis and prognosis models.
Therefore, a large body of research in the literature has adopted feature mining
techniques, which can map a high number of features into smaller useful repre-
sentations, which can be utilised thereafter for the development of various ML
systems. In general, the feature mining approach can be classified into two major
techniques, which are feature extraction and feature selection. Feature extraction
involves a linear or nonlinear transformation of the original data from large fea-
ture space to a relatively lower dimensional space by minimising information loss
(e.g. Principle Component Analysis [246], Auto-Encoders [24]). The extracted
features are combinations of the original ones, different and more likely smaller,
thus a disadvantage of this technique is that it is difficult to determine which
subsets of the original features constituted the new transformed representation.
Feature selection, on the other hand, involves searching the search space of
a dataset to find the best possible subset of features with respect to evaluation
measures. The identified features are a compact and informative subset of the
original ones. Unlike feature extraction, no new latent representations are formed.
This property of not altering the original features has led to the widespread study
of the feature selection approach because it enhances the comprehensibility of the
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obtained results. The research of feature selection remains an active area in ML
domain (e.g. [94,142,266,272]). ML methods coupled with feature selection tech-
niques have been widely utilised in bioinformatics research [2, 82, 144, 201, 250].
The feature selection approach has contributed to improving the predictive per-
formance and robustness of classification models and decreasing its computational
cost. The importance of feature selection can also be found in adding an expla-
nation to the problem at the hand. In our research problem, the utilised genomic
and proteomic datasets contain thousands of genes or proteins whose relevance
to the response groups is not recognised by domain experts. Discovering a small
subset of robust biomarkers helps biologists and variants thereof to investigate the
relation of these molecular markers to the disease or clinically relevant outcomes.
The success of the feature selection approach mainly depends on consider-
ing two aspects: effective search methods to navigate the search space of the
data and find the best possible subset of candidate predictors; and evaluation
measurements to assess the quality of the features and guide the search process.
Therefore, the biomarker discovery problem is discussed in the next sections based
on two forms: how to search exponential dimension spaces of omics data and how
to assess the optimality of features.
2.6.1 Evaluation Measurements
An effective selection method needs an effective evaluation criterion to detect rele-
vant features. Different selection paradigms have been proposed, which are mainly
filter, wrapper, and embedded. These paradigms can be grouped into classifier-
independent approaches - (filter methods) and classifier-dependent approaches -
(wrapper and embedded methods). The embedded methods [175] incorporate
the feature selection process as part of the training process to reduce the compu-
tational time required for reclassifying different subsets, which is undertaken in
wrapper methods.
Filters assign importance scores to features based on statistics of the data,
without dependency on any particular classifier [120]. Univariate filters are the
most common filter methods such as Welchs t-test [315], mutual information [301].
Saeys et al. [250] have highlighted the practical features of those filter techniques
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by claiming that “even when the subset of features is not optimal, they may be
preferable due to their computational and statistical scalability”. Multivariate fil-
ter techniques such as minimal-Redundancy-Maximal-Relevance (mRMR) [229],
and Fast Correlation-Based Filter (FCBF) [332] take the interdependence be-
tween features into consideration, thus better outcomes could be obtained. How-
ever, they tend to be computationally more expensive and statistically less scal-
able than univariate filter methods.
Wrapper methods simultaneously analyse groups of features based on an ac-
curacy criterion involving a classifier and is therefore a classifier-dependent ap-
proach [167]. Wrappers consider the underlying dependencies among features
and may perform better than filters. However, for such high dimensional data,
the high risk of computational cost and overfitting restricts the use of wrapper
methods to estimate the goodness of combinations of predictors for a given clas-
sification task. In this project, the merits of filters and wrappers are integrated
into a hybrid evaluation measurement to estimate the optimality of the candidate
subsets of features and will be optimised to discover the best possible combination
in these large feature spaces - (as discussed in Chapter 4). The hybrid selection
approach is considered another class of feature selection proposed to handle the
curse of dimensionality (e.g. [28,119,192]).
A review study of the feature selection techniques applied to bioinformatics,
including microarray and mass spectrometry data, has highlighted the multivari-
ate selection algorithms as one of the most promising future lines of research
for the bioinformatics community [250]. However, multivariate selection methods
are more likely to identify several subsets of candidate predictors with similar
classification accuracies making it difficult to ascertain the optimum subset. The
feature preferences based on multivariate selection methods could be very sensi-
tive to data sampling, thus it can be considered less robust and more unstable
than filters. This is especially valid for multivariate selection methods, which
search through a dataset with high dimensional feature space and a small num-
ber of cases. Therefore, the development of bespoke ensemble feature selection
approaches is considered the second line of future research, particularly for knowl-
edge discovery from HDSSS datasets [126]. Ensemble feature selection is similar
to ensemble learning in that it relies mainly on performing multiple selectors, and
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the outcomes of these independent selectors are integrated into ensemble results
(e.g. [100,173]).
Abeel et al. [2] introduced an ensemble feature selection method based on
Support Vector Machine - Recursive Feature Elimination (SVM-REF) and boot-
strapping method to address the challenges of sampling variation for biomarker
identification from high-throughput microarray datasets. A number of different
selectors are used, and the outputs of these separate selectors are aggregated and
returned as the final (ensemble) result. Several ensemble feature selection meth-
ods introduced in the literature [329] adopted the bootstrap procedure to address
the challenges of sampling variation when using HDSSS data. The bootstrap
method is a resampling technique that generates data sets by repeatedly sam-
pling with replacement from the original data. However, each bootstrap set has
significant overlap with the original data, which could lead to an optimistically
biased estimation of the performance. Therefore, in this project, an ensemble
selection approach based on repeated cross-validation procedure is employed to
enhance the robustness of the finally selected subsets of predictors where no over-
lap can be found between the validation partition k and the k − 1 training sets,
which is crucial factor for estimating the feature preferences as well as prediction
performance reliably.
2.6.2 Search Methods
Biomarker discovery can be viewed as a feature selection problem. Suppose we
have a dataset D of n observations {xi, yi}, where xi is a d−dimensional feature
vector, and yi is the target class. A biomarker discovery problem is to find a
nFeat−dimensional vector of key genes, where nFeat < d, whose expressions
assign new observations into their response groups yi with a good level of cer-
tainty. However, due to the high dimensionality of omics data, the search space,
S, grows exponentially when the size of d increases due to the relationship S = 2d.
Therefore, finding the optimal subset of genes from these large-scale datasets can
be computationally expensive for traditional search algorithms and infeasible in
most situations because it requires an extremely large number of evaluations.
Therefore, solving high dimensional selection problems has shifted towards more
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suitable optimisation algorithms such as Evolutionary Computation (EC) algo-
rithms [69], and EC term refers to all biologically inspired techniques.
During 1950−1960, several computer scientists and engineers separately stud-
ied the notion that evolution can be utilised as an optimisation tool for engineering
problems [111]. The notion relies mainly on the iterative evolution of a popula-
tion of candidate solutions to a given problem towards the optimal solution using
genetic operators. It retraces the natures path to find the best possible solution
in as little search time as possible. Therefore, EC methods have been successfully
applied for solving a variety of optimisation and feature mining problems [101].
Genetic Algorithms (GA) [134, 135], Ant Colony Optimisation (ACO) [76, 77],
Particle Swarm Optimisation (PSO) [84,163] are all classic examples of EC algo-
rithms. The collection of algorithms that utilise procedures inspired by natural
systems like survival and reproduction of the fittest are known as Evolutionary
Algorithms (EA).
Several studies have worked on comparing various EC algorithms in different
aspects and for diverse kinds of problems including feature selection (e.g. [85,
324]). However, any effort to summarise or compare EC methods may depend
on choosing which areas to be covered. The parallel adaptive search of a GA has
been adopted in a wide range of potential areas in order to obtain solutions to
high dimensional, complex, and nonlinear problems. The GA method has been
employed to solve feature selection problems (e.g. [43,143,154,223]). A study by
Siedlecki and Sklansky [261] revealed that the GA had a solid capability to reduce
the time needed for finding the best possible set of features from large datasets
compared to other traditional algorithms. Subsequently, several researchers have
shown the advantages of using GA as a search algorithm for feature selection
[172,241,327].
In the literature, various evaluation measurements have been combined with
the GA to solve feature selection problems (e.g. [50, 63, 282, 319]). A review
of EC methods for feature selection in classification problems [70] has discussed
integrating the GA with diverse evaluation paradigms and emphasised the hybrid
selection approach as promising for large datasets. In this thesis, an ensemble
evolutionary mining model based on a hybrid selection approach, which combines
the merits of univariate and multivariate statistical techniques is introduced to
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navigate through the high dimensional spaces of omics data and identify a subset
of informative and robust predictors.
2.7 Deep Learning Methods for Biomarker Dis-
covery
As discussed in the previous section, feature mining has become a core process in
the construction of prediction systems for HDSSS omics data. The performance
of such prediction models relies heavily on the features on which they are given
to associate with particular outcomes. Therefore, it is highly desirable to develop
a feature learning model directly from the raw high dimensional data so that
high-level abstract features can be automatically captured and used for prediction
purposes. This automatic feature learning can advance the move toward Artificial
Intelligence (AI) where high-level abstractions can be automatically discovered
and used in a similar way to that of the human brain. “An AI must fundamentally
understand the world around us, and we argue that this can only be achieved if
it can learn to identify and disentangle the underlying explanatory factors hidden
in the observed milieu of low-level sensory data” - Bengio et al. [22].
In the neural network literature, the emphasis has been made on the composi-
tion of multiple levels of nonlinearity and the transformation of the input signals
from low-level representations into high-level abstractions [130, 248]. This type
of deep feature learning allows us to mitigate against the curse of dimension-
ality and enhance the generalisability for high dimensional complex recognition
problems. Deep learning (DL) can be defined as deep feature learning methods
that consist of multiple layers of non-linear functions that are connected in a
hierarchical fashion, where the output of units in one layer feed as input into the
next or preceding layers so that complex functions can be constructed using the
well-known stochastic gradient descent algorithm, back-propagation [177].
Deep feature learning models have been incorporated in diverse areas of Bioin-
formatics (e.g. [7,11,161,165,340]). Furthermore, such deep neural network mod-
els have been applied across different problem domains in healthcare area like clin-
ical imaging (e.g. [44, 51, 195, 331]), electronic health record (e.g. [209, 233, 291]),
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and wearable sensor (e.g. [122, 253, 341]). Moreover, DL models have produced
superior performance over traditional methods in a wide range of domains such
as computer vision (e.g. [170, 277]), natural language processing (e.g. [58, 275]),
speech recognition (e.g. [1, 73,129]), and remote sensing (e.g. [309,343]).
These deep feature learning models typically require substantial data to con-
strain their parameters and learn a useful hypothesis. Therefore, in many of these
problem domains, a large number of samples are typically available to train a deep
network model. Furthermore, the datasets are characterised by high signal-to-
noise ratios, thus the deep feature learning models attempt to discover high-level
abstract features that can recover the data and boost the generalisability. The
problem of deep feature learning from HDSSS omics data is a significant chal-
lenge as there are relatively few patients, compared to the huge number of features
stored about them. That means the number of variations underlying the high
dimensional genomic or proteomic data is not adequately exploited due to an
insufficient number of biological samples, which in turn have a low signal-to-noise
ratio. Therefore, new DL-inspired paradigms are required to sufficiently model
the meaningful complexity represented by those biological samples.
The most popular form of deep learning is the supervised approach. When
the desired outcomes are known, the learning process relies on fitting the model
to reduce the distance between the desired outcomes and the actual outputs
and thus to adjust the internal parameters to shorten that distance according to
some cost function (e.g. sum of the squared errors or log likelihood). Supervised
learning procedures do not typically allow for self-taught learning where the model
is free to identify and exploit more subtle patterns in high dimensional spaces
[303]. Therefore, an unsupervised pre-training approach is utilised in this work
to be an essential characteristic of the deep feature learning model proposed to
exploit the unknown structure of HDSSS omics data for the goal of discovering
useful knowledge. Moreover, research has shown that for a small dataset, the
unsupervised pre-training approach that will be discussed in the next section
produces better generalisation error [87].
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2.7.1 Unsupervised Pre-training Approach
A novel unsupervised pre-training approach was presented by a group of renowned
researchers in 2006 to advance the traditional method of training DL models:
Restricted Boltzmann Machines (RBMs) [131] by Geoffrey Hinton, Auto-encoder
variants [24] by Yoshua Bengio, Sparse coding variants [237] by Yann LeCun.
“A fast learning algorithm for deep belief nets” paper, which was published in
2006 by Geoffrey Hinton et al. [131], introduced RBMs based on very interesting
notions. Mainly, a deep neural network model can be learned based on the
unsupervised pre-training approach hidden layer by hidden layer ‘sequentially’,
where within each layer, the net attempts to discover a useful representation
of its input, which may be a previous hidden layer of activations. This greedy
recursive approach to transforming the data starting from the input layer, to form
a hidden layer, which is then provided as input to a process to form another hidden
layer provides a powerful means to create high-level abstract representations from
detailed low-level representations. Moreover, previously learned knowledge by
the greedy layer-wise approach can be passed as input to a supervised classifier
model, such as an SVM or perceptron. That means the learning task can be
conducted using a semi-supervised approach, with the goal of learning to discover
a good representation of X that shapes the input distribution P (X), which is
also relevant in part to discover the target P (Y |X). Therefore, the discovered
representations by the DL models can be shared between tasks. The identification
of salient invariant features that make sense for several tasks is a highly desirable
property.
The successful training approach presented by Hinton et al. [131], followed
by Yoshua Bengio et al. [24] introducing Auto-Encoder based approaches to pre-
training. The Auto-encoder approach to pre-training the weights to the hidden
layers of a deep net is predicated on using backpropagation to learn the iden-
tity function of each layer (except the output layer) of the network, one layer
at a time. For example, starting with the input layer, a feedforward network
with one hidden layer is used to reproduce the input layer values on the out-
put layer (a task known as the identity function). The resulting hidden layer
is then used as input to another feedforward network, which is trained to learn
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the identity function to form a new hidden layer and so on. These hidden layers
can then be stacked in-between the original input layer and the output layer to
form the deep net. The weights between the input and hidden layer of the re-
spective auto-encoders are the weights used within the deep network and are now
considered to be the pre-trained weights. The output layer can now be added
and a global-fine tuning stage applied, based on supervised criterion using stan-
dard backpropagation [132]. Several studies have demonstrated the potential of
the Auto-Encoder to discover intrinsic structure in high dimensional spaces and
obtain better classification performances [150, 220, 260, 302]. Ranzato et al. at
NIPS2006 (i.e. Neural Information Processing Systems) [237] presented a Sparse
Coding Variants by adding the sparsity penalty on the hidden layer in order to
boost the free energy of all units.
In this thesis, a new deep feature learning model is proposed, based on a set
of non-linear sparse Auto-Encoders constructed on the under-complete represen-
tations to discover and interpret important signals from omics data that can be
utilised to develop approaches to personalised and precision medicine. Learning
sparse compressed representations of increasing complexity from HDSSS omics
data forces the neural network to discover a small fraction of the possible factors
that can recover a large proportion of variations underlying the data. These types
of expressive representations capture high-level abstract features, which are char-
acterised of being invariant to most of the irrelevant projections while collectively
perceiving the information that approximates the input distribution.
2.7.2 Interpretation Methods for Deep Learning
Deep feature learning models perform multiple levels of transformations to the
input features in order to abstract the problem. That means, the discovered
representations are combinations of the original features, different and more likely
smaller. Thus, identifying which features constituted the latent representations
and were responsible for deriving such predictions is very challenging. However,
a model that is able to state which phenotypes are key determinants is a crucial
element of prediction systems used by health practitioners and decision-making
professionals. It is therefore important to provide some explanatory capability to
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such deep learning models.
In the literature, few attempts have investigated going beyond the prediction
to understand the machinery of the deep feature learning model and interpret its
outcomes. Tan et al. in [284] and later in [283] have examined the significance
of each neuron by computing its activity value in a single layer Auto-Encoder
and for each sample. Such models are considered shallow Auto-Encoder models
as they typically only contain one hidden layer in-between the input and output
layer. For example, the shallow network in [284] contains 100 hidden neurons
and [283] auto-encoder contains 50 hidden neurons in order to allow the manual
interpretation of these nodes, which cannot be generalised to the deep models
with higher capacities.
More complex hierarchical representations can be formed by recursively au-
toencoding the hidden layer of the original shallow autoencoder - this is known
as stacking the autoencoder. Danaee et al. [66] map back the lower dimensional
representations of the Stacked Denoising Auto-Encoder (SDAE) to the original
data to detect what they called the Deeply Connected Genes (DCGs). The inter-
pretation method of SDAE results in a 500 × G matrix, where G is the number
of genes in the gene expression data and 500 seems to be the code dimension.
The authors state that genes with the largest weights in the detected matrix are
the DCGs. However, it is not clear how they defined the DCGs especially when
each gene has 500 values and there is no evidence whether they have considered
the largest weights in the positive or the negative direction. On the other hand,
for biomarker discovery models, the predictivity, stability, and generalisability
should be considered equally in order to report practically significant findings.
Therefore, in this research project, a new weight interpretation method is
proposed to add explanatory power to the proposed deep feature learning model
and identify a reduced set of highly predictive and robust biomarkers that are
generic across independently generated datasets. The presented weight interpre-
tation method will shed light on the innovative way to provide the explainability
to such DL methods, and it can be utilised as a promising tool to discover unex-
plored knowledge in different domains.
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2.8 Approaches for Validating Predictive Per-
formance
The main objective of identifying robust biomarkers is to develop a reliable pre-
diction system that generalises well when applied to new cases. Generalisability
of a classification model can be defined as its ability to correctly estimate the
response groups of unobserved sample cases (that were not included in the train-
ing data). Practically, if a classifier is fit in a setting far from its true function,
estimation bias error is encountered. Variance error is reported when a classifier
differs over the variation in the data. Variance refers to the amount of change that
a classification model would have if it is estimated using different training sets.
The classification model is learned using training data, and different training sets
may fit different classifiers. However, in the typical case, the estimation of the
classifier should not differ significantly when it is learned using variant training
sets. If the classification model suffers from high variance, the little variation in
the data could lead to the large variation in the classifier.
As a result, high bias and low variance refer to underfitting, where overfitting
refers to low bias and high variance. The relative rate or the trade-off between
bias-variance quantities should be achieved to some extent so that the expected
test error is minimised when a classification model has low bias and low variance
simultaneously. Therefore, the bias-variance trade-off term refers to the relation-
ship between bias, variance and test error. It is called trade-off due to the fact
that low biased and high variance model or high biased and low variance model
can be obtained easily and the real challenge is to find a learning model that can
improve on this trade-off.
To quantify the performance of the classification model, the training error
rate, which is the proportion of misclassified training samples, is usually utilised.
However, the interest is in testing or generalisation error rate that results from
classifying test samples that were not seen during the learning process because
the training error rate can differ from the generalisation error rate. Therefore, the
simplest popular approach is to partition the original data using Cross Validation
(CV) approaches into training and validation sets. The training data is used to
develop the learning model, while validation data is used to validate its predic-
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tive performance. The CV procedure has been utilised in many machine learning
tasks like classification and regression to estimate the generalisation error rate.
However, there is an increased risk of obtaining high variability in the estima-
tion error with a small dataset. Therefore, the choice of the suitable validation
method for such datasets should be considered carefully in order to report reli-
able estimations. A discussion on the appropriateness of various CV approaches
is provided, along with the advantages and limitations of each approach.
2.8.1 Hold Out Validation Approach
This approach includes holding out a set of available observations, where the
model is fit on the training samples and validated on the held out samples. The
validation error of hold out approach, that is assessed in terms of misclassification
rate, estimates the generalisation error. However, the validation error can vary
according to which samples are involved in the training set and which samples
are involved in the validation set. Moreover, since the model is trained using only
the samples that constitute the training set, the learning model usually performs
worse when fitting on fewer examples. Leaving more examples for the validation
set leads to increase the estimation bias error, while having more training exam-
ples could lead to degrading the estimation process. As a result, the validation
estimation of hold out approach is impractical with small sample size data.
2.8.2 Leave One Out Cross Validation Approach
The Leave One Out Cross Validation (LOOCV) approach involves temporarily
leaving out one sample from a dataset of size n, and then training the classifica-
tion model on the remaining n − 1. Therefore, the LOOCV procedure tends to
overcome the limitation of wasting the data by holdout validation approach, es-
pecially for small datasets. Since only the excluded observation was not included
in the learning procedure, the biased error can be minimised. However, validating
the performance of the classification model based on a single observation causes
highly variable estimation. The LOOCV procedure is iterated n times (i.e. n
is equal to the total number of observations), in each iteration a different case
is taken out. Therefore, LOOCV is computationally expensive, since the model
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Figure 2.5: An illustration of k-fold cross validation approach.
has to train n times. This can be very time consuming when the analysis model
comprises two processes: mining and learning since both processes should be per-
formed solely on the training dataset. The potential for the training process to
become intractable is increased dramatically if every single model is slow to fit.
2.8.3 k-fold Cross Validation Approach
The k−fold CV approach randomly splits a dataset into k non-overlapping par-
titions or folds of roughly equal size, where k − 1 partitions are used to fit the
model, and the remaining set is used to validate its performance as shown in
Figure 2.5. The k− fold CV method is used usually to overcome the drawbacks
of holdout and LOOCV approaches by having fewer data to waste than hold-
out approach and k times less expensive than n times of LOOCV procedure.
Furthermore, k− fold validation procedure guarantees that there is no overlap
between the samples of both sets which is a key factor for estimating the gen-
eralisation error rate of the prediction models accurately. In stratified CV, the
folds are stratified so that each fold contains approximately the same proportions
of response groups as in the original data, and there is evidence that this can
enhance the estimation process [320]. The bias error is minimised with LOOCV
method when k = n, however, our concern is not coming only from the risk of
high bias. For small sample size datasets, the risk of high variance is increased,
thus the k−fold is more appropriate than LOOCV estimator, which shows high
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variance. Commonly used values of k are 5 and 10 because these values have been
proven empirically to estimate generalisation error rate that can provide a good
compromise for bias-variance trade-off [148]. Repeated k− fold cross validation
procedure should be employed to account for variance in performance estimation,
and average results should be reported [41].
2.9 Metrics for Estimating Predictive Perfor-
mance
When developing a machine learning model to perform classification, the main
objective is to develop a classifier function from labelled training samples and
measure its predictive performance on testing samples (that were not seen during
the training process). Binary classification is the problem, where the observations
belong to two response groups: Positive vs Negative. In medicine and biology,
the positive group refers to cases affected by a medical condition, where the
negative group refers to control cases. True Positives (TP) are the cases when
the actual group is positive, and the predicted group is positive (e.g. when the
model assigned the case to a cancer group, and the patient is actually suffering
from cancer). True Negatives (TN) are the cases when the actual and predicted
groups are negative (e.g. when the model assigned the case to control group
and the case is not having cancer). False Positives (FP) are the cases when
the actual group is negative (disease free), and the predicted group is positive
(when the model assigned the patient to the diseased group and the case is not
having cancer). False Negatives (FN) are the cases where the actual group that
the patient belongs to is positive (i.e. suffering from cancer), and the model
predicted the patient as belonging to the group without the disease. A variety of
evaluation metrics are derived from these measurements.
Accuracy is the most common and simple evaluation metric, and it can be
defined as the number of correct predictions (TP + TN) classified by the model
overall predictions (TP +TN +FP +FN). However, the confidence of the class
prediction (e.g. 0.57 or 0.97) is discarded in the accuracy assessment metric.
Therefore, the estimation of the accuracy metric may not be reliable for datasets
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whose response groups have considerable disparate sizes, due to its bias towards
the majority. True Positive Rate (TPR), Sensitivity, or Recall metric measures
the proportion of positives (TP/(TP+FN)),(e.g. the proportion of actual cancer
cases that were assigned by the model to the cancer group). True Negative Rate
(TNR), or Specificity metric measures the proportion of negatives (TN/(TN +
FP )) (e.g. the proportion of control cases, that were diagnosed by the model as
non-cancerous). Precision or Positive Predictive Value (PPV) metric measures
the ability of not diagnosing positive case as negative (TP/(TP + FP )) (e.g.
the proportion of cases that were diagnosed as having cancer, and they actually
had). A model with a high level of performance should have a high percentage
of precision and recall.
The Area Under the Curve (AUC) of the (Receiver Operating Characteristics)
(ROC) can be utilised for measuring the predictive performance of learning mod-
els. The focus of AUC is essentially on two measurements, which are TPR and
FPR. By considering other evaluation metrics, the recall is identical to TPR, thus
essentially the difference is between precision and FPR. The precision metric re-
lies on false positives while FPR measures the true negatives. In imbalanced class
data, when the majority are the negative cases, high percentage of TN are more
likely to be existent in the FPR due to (FP/FP+TN), resulting in smaller FPR.
On the other hand, the majority of negative cases would not impact the precision
due to the fact that this metric quantifies the number of TP out of (TP + FP ).
Therefore, precision tends to the positive group than to the negative group. As a
result, in imbalanced group data, when the minority are positive cases, and the
interest is on identifying correct positives than correct negatives, the precision
metric can be utilised for reliable estimation. In this research project, we have
imbalanced group breast cancer datasets, where the majority of samples for both
response groups are positives (ER+, PR+). Detecting the negative cases will be
hard due to the insufficient number of cases. Therefore, AUC based on FPR and
TPR can quantify the quality of the classification model when the positives are
the majority.
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2.10 Internal and External Validation
To assess how well our feature mining models work, we need to quantify their
performances. To evaluate the performance of a model, the objectives of the
model should be identified. The aim of proposing these mining models is to
discover biomarkers that have good predictive power to distinguish the positive
observations from the negatives effectively. That means the predictive perfor-
mance of classification models is employed to assess the quality of the discovered
biomarkers. In the literature, the assessment of feature mining methods has been
restricted to the predictive performance of a classification model built on the se-
lected subset of candidate predictors. Although most omics data analysis studies
aim to select differentially expressed genes, to be used as biomarkers, there are
only very few genes in common. Therefore, the reliability of the reported genes
and their biological significance have raised doubts and questions [145]. The lack
of overlap among the published genes is essentially caused by that various se-
lected subsets of features produce similar predictive performances. Selecting a
set of relevant predictors from small datasets could be very sensitive to which ob-
servations are included in the mining stage. Therefore, evaluating the outcomes
of feature mining models based on the metric of classification’s performance is
not sufficient to detect true biomarkers from false positives robustly.
To detect true biomarkers, another criterion should be examined. The sta-
bility of selection is considered as another important aspect. Stability refers to
the insensitivity of the feature mining model to the variations in training data.
In other words, stability examines how the variations in the data can impact the
feature preferences of the feature mining models. The stability can be conducted
on the same dataset by having multiple random training-validation partitions,
thus it can be described as an internal validation metric. If with different sets
of training samples, the identified subsets of features differ radically, then the
feature mining model is unstable. If the model is unstable, the confidence in the
discovered biomarkers is decreased to prevent drawing unreliable biological con-
clusions. Jurman et al. [153] state that the predictivity and the stability of the
detected biomarkers should be considered equally. The researchers in [110] argue
that “Identifying reproducible yet relevant features is a major challenge in biolog-
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ical research”. Therefore, data scientists need to assure not only the predictive
power of the selected predictors but also their robustness to the variations in the
data. In the literature, different metrics have been proposed to quantify the sta-
bility like a ranking, a weighting or a subset of features [67,81,112,155,258,306].
However, there is no universally accepted measure to estimate the true stability of
a model’s generalisation performance. Also, most of the stability measurements
like scoring or ranking methods need a threshold to produce a stable subset.
Thus, in this research, the stability of the proposed feature mining models is ex-
amined through the consistency of selection over different splits of a dataset. “If
the same features are selected in multiple independent iterations, they more likely
are reliable biomarkers” [100].
The external validation of feature mining models is of significant importance
due to its role in evaluating whether the proposed models will produce generic
biomarkers over multiple independent datasets, which are collected from different
sources and for different perspectives. However, few studies in the literature have
adopted another dataset that is collected from different studies for validation de-
spite the abundance of publicly available omics data. Recently, a review study
in metabolomics [198] has stated that more than 900 research papers have been
introduced during five years for biomarker discovery in this field only, however,
the number decreases dramatically when some validation metrics are adopted.
According to [33] “External validation is essential before implementing prediction
models in clinical practice”. The discovered generic biomarkers can be used to
develop reliable prediction models that would be helpful in making trustable clin-
ical decisions. If the features are discovered across multiple independent datasets,
they are more likely to be true biomarkers. “External validation using data from
a completely different study provides the highest irrefutable evidence that a tool
validates” [287].
2.11 Discussion
This chapter discusses the major research challenges of extracting relevant knowl-
edge from HDSSS omics data, using the state-of-the-art approaches presented in
the literature. Classical statistical techniques utilised in biology and medicine for
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biomarker discovery were covered in Section 2.4 with an emphasis on its tech-
nical advantages and limitations. The greatest challenges for ML algorithms to
handle is the high dimensionality and relatively small sample size of omics data,
overviewed in Section 2.5 and the directions for addressing these issues were dis-
cussed. Therefore, the feature mining was presented in Section 2.6 as one of the
main possibilities that can be employed to address the curse of dimensionality
issues and detect a small group of candidate predictors that could not be de-
tected using conventional statistical techniques and learning methods alone. The
feature mining approach was discussed in terms of how to assess and how to
search thousands of genes, as illustrated in Section 2.6.1 and Section 2.6.2. The
critical discussion of both Sections 2.6.1 and 2.6.2 highlighted the importance
of solving the biomarker identification problem from HDSSS omics data as an
optimisation problem leveraging the advantages of EC method and the hybrid
evaluation measurement. Furthermore, the requirement for an ensemble feature
mining model is asserted to enhance the robustness of the identified subsets of
candidate predictors.
The latest innovations in DL was explored in Section 2.7 to investigate its po-
tential to formulate nonlinear models that are able to effectively discover salient
invariant biomarkers from omics data. The incorporation of deep neural network
models in different problem domains was reviewed in Section 2.7, emphasising the
importance of having substantial data to train these models effectively. Therefore,
the technological gaps and needs for the development of new DL-inspired models
were stated for the goal of inferring useful models from HDSSS omics data. The
groundwork for the new deep feature learning model was laid in Section 2.7.1 by
considering the unsupervised pre-training approach to be an essential character-
istic of a DL model developed to exploit the unknown structure of HDSSS omics
data.
The main obstacle of such DL models is the lack of transparency, which means
the inability to understand why the models behave as they do. This may not be
an issue for some domains because it can easily validate the obtained results.
However, providing explainability to diagnosis and prognosis systems is a crucial
factor to develop a reliable prediction model that can be understood by clinicians,
and thus it can be employed in clinical practice. Therefore, Section 2.7.2 explored
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the few attempts in the literature that have been conducted to understand the
machinery of the deep networks and interpret its outcomes, along with its main
limitations and drawbacks. Therefore, in this thesis, we develop a novel weight in-
terpretation method to add explanatory power to our deep feature learning model
for determining the candidate input features that force the different biomarker
classification behaviours.
The assessment of the outcomes of the proposed feature mining models for
biomarker identification from omics data involves several underlying issues that
need to be properly handled in order to report reliable findings. Therefore, di-
verse quantitative quality metrics for validating and estimating the prediction
performance were discussed in Sections 2.8 and 2.9, while the external validation
using multiple independently generated datasets was explained in Section 2.10.
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Datasets and Experimental
Methodology
3.1 Introduction
This chapter focuses on the datasets and the experimental methodologies used for
model fitting and selection and therefore to validate the feature mining models
proposed. Typical high-throughput biological data are more likely to contain a
large number of noisy variables and molecules with unreliable measurements that
can be considered indistinguishable from noise. This chapter discusses the meth-
ods of filtering out genes from genomic datasets that are not reliably expressed.
This thesis utilises 18 publically available HDSSS biomedical datasets to exam-
ine the potential of the presented feature mining models to discover robust and
generic biomarkers.
Four breast cancer datasets are illustrated in this chapter, along with the ex-
planation of the pre-processing step required to produce the required information.
The adopted breast cancer datasets are linked into two response groups, which are
Estrogen Receptor (ER) status and Progesterone Receptor (PR) status forming
eight breast cancer datasets. Moreover, the breast invasive carcinoma datasets
are collected from different studies, but using the same microarray technology,
are integrated in a number of different approaches to have more substantial and
balanced group data. The integration provides an additional nine breast cancer
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datasets: three breast cancer datasets with ER groups, and six datasets with
PR groups. On the other hand, the ovarian cancer dataset was employed in the
preliminary experiments performed in this research to develop and validate the
proposed models. The empirical assessment of the performance of the introduced
feature mining models was conducted in terms of the objectives of these models,
which are predictivity, stability, and generalisability.
3.2 Filtering Methods
Gene expression datasets typically contain thousands of genes, not all of these
information are relevant. Bichsel et al. [32] state that “very few genes are in fact
significantly changed in expression in a way that is distinguishable from biological
and measurement variation and noise”. Therefore, the genes that seem to gener-
ate uninformative signals can be considered as noise. In the microarray literature,
several studies have revealed the potential of filtering out genomic datasets from
genes with unreliable measurements to enhance the detection of differentially ex-
pressed genes [106, 208, 281, 292]. Diverse filtering methods, based on different
criteria, have been proposed for excluding genes that are not reliably expressed
or represent experimental noise.
Gene expression datasets typically contain genes that exhibit little variation
in their profile. A gene with small profile variance across the samples would not
differ significantly among response groups. In this thesis, a filtering method based
on variation criterion is utilised to remove gene expression profiles with a variance
less than the 10th percentile from further analysis. Furthermore, gene expression
datasets could have genes whose range of values may not well distributed (spiking
behaviour). A filtering method based on low entropy criterion is utilised in this
research to measure the amount of information about a variable and remove genes
with low entropy expression values (i.e less than the 10th percentile). A more
detailed discussion of these rudimentary filtering methods can be found in [166].
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3.3 Breast Invasive Carcinoma Datasets
The development of the breakthroughs for extracting useful knowledge from omics
data is at the core of personalised and precision medicine. However, we are able
to benefit from these biological data only if they are publicly available. Recently,
there is increasing pressure from funding providers and the patient community
to gain the maximum benefit from produced data by sharing it with the re-
search community regardless of whether biomedical studies are funded publicly
or privately [169]. Analysing omics data over several research studies can help to
control the risk of false positives, offer possibilities to innovative discoveries, and
to report significant and reliable findings [57]. The availability of biomedical data
repositories such as The Cancer Genome Atlas (TCGA)1 and the International
Cancer Genome Consortium (ICGC)2 bring tremendous opportunities to health
care research to benefit from this abundance of cancer genomic data.
TCGA is a collaboration between the National Cancer Institute (NCI)3 and
the National Human Genome Research Institute (NHGRI)4 to understand the
molecular basis of cancers, through the utilisation of genome analysis technolo-
gies. TCGA is one of the largest genomic data repositories, including more than
eleven thousand cases, representing 33 cancers. TCGA has produced different
types of genomic datasets like somatic mutation, copy number, gene expression,
miRNA expression, DNA methylation, reverse protein phase array and clinical
information for different types of cancers. These biological datasets are publicly
available for every clinician, bioinformatician, statistician, and computer scien-
tist to employ them for developing a wide range of analysis models. Since the
completion of the TCGA project, TCGA data analysis is becoming a priority in
order to provide a better understanding of the complicated mechanism of cancer
so that the inferred knowledge can be transferred to personalised and precision
medicine [164].
With the availability of a vast amount of genomic data, several web portals
have been created to help researchers and graduate students to access and use
1http://cancergenome.nih.gov
2https://icgc.org
3https://www.cancer.gov/
4https://www.genome.gov/
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these cancer datasets, using different types of exploration and analysis tools. cBio-
Portal [48,102] is an open-access repository for multidimensional cancer genomics
datasets, and was originally developed at Memorial Sloan Kettering Cancer Cen-
ter (MSKCC)1. cBioPortal aims to minimise the complexity of accessing various
genomics projects and allow for diverse analysis and visualisation tools to be
utilised. In this research, three breast cancer datasets were downloaded from the
cBioPortal website, which are Breast Invasive Carcinoma (TCGA, Nature 2012),
Breast Invasive Carcinoma (TCGA, Cell 2015), and Breast Invasive Carcinoma
(TCGA, Provisional).
3.3.1 Breast Invasive Carcinoma (TCGA, Nature 2012)
This dataset originated as part of the TCGA (i.e the cancer study identifier
is brca tcga pub), and it was used by a collaborative study between NCI and
NHGRI published in 2012 [219]. The study was conducted on 825 patients with
breast cancer invasive tumours and found that four main subgroups of breast can-
cer are caused by various types of genetic and epigenetic variations. According to
the website of the National Institutes of Health (NIH), “TCGAs comprehensive
characterisation of their high-quality samples allow researchers an unprecedented
look at these breast cancer subgroups”. Various genomic and clinical datasets are
included in (Nature 2012) data. The focus of the research in this thesis is on
mRNA expression data. The mRNA expression data was carried out using Ag-
ilent microarray and contains 17268 genes and 526 observations. Two response
groups were defined in this research, which are ER Status and PR Status. The
samples with missing values/others (e.g. Performed but Not Available, Not Per-
formed, Indeterminate) in both response groups were removed from the analysis
as illustrated in Figure 3.1.
The integration of the mRNA expression data and ER clinical data, which
has 780 observations, resulted in a dataset of 519 observations. According to the
group distribution, 401(77.26%) are samples with ER+ tumours, and 118(22.74%)
are ER- samples. The unification of the mRNA expression data and PR clini-
cal data, which has 777 observations, resulted in a dataset of 518 observations,
1https://www.mskcc.org/
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Figure 3.1: The description of (Nature 2012) dataset showing the unification of
clinical data and mRNA expression data.
340(65.64%) being patients with PR+ tumours, and 178(34.36%) being PR- sam-
ples. Each mRNA sample contains 17268 genes. The filtering methods (which
are described in Section 3.2) were utilised before the feature mining models take
place to filter out the less reliably expressed genes from mRNA expression data.
The number of remaining genes in (Nature 2012) dataset with ER groups is 13612
and 13619 with PR groups. Figure 3.1 illustrates the number of mRNA samples
before and after the unification with the ER and PR clinical data, ER and PR
group distribution across samples, and the number of mRNAs before and after
performing the filtering methods.
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Figure 3.2: The description of (Cell 2015) dataset showing the unification of
clinical data and mRNA expression data.
3.3.2 Breast Invasive Carcinoma (TCGA, Cell 2015)
The availability of TCGA data with high standard samples has motivated us to
adopt other breast cancer datasets to examine the generalisability of the proposed
feature mining models to a wider population. This dataset originated as part of
the TCGA (i.e. the cancer study identifier is brca tcga pub2015), and it was used
by the analysis study [55], which found that mixed tumours can be assigned into
their subgroups using genetic features. Different genomic and clinical datasets
are involved in (Cell 2015) data. The focus of the research in this thesis is on
mRNA expression data. The mRNA expression dataset was carried out using
Agilent microarray and contains 17213 genes and 421 observations. The samples
with missing values/others (e.g. Not Available, Indeterminate) in both response
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groups were removed from the analysis, as explained in Figure 3.2.
The integration of the mRNA expression data and ER clinical data, which
contains 776 observations, resulted in a dataset of 415 observations. According
to the group distribution, 323(77.83%) are patients with ER-positive tumours,
and 92(22.17%) are ER- samples. The unification of the mRNA expression data
and PR clinical data, which has 773 observations produced a dataset of 414
observations, in which 273(65.94%) are PR+ patients, and 141(34.06%) are PR-
samples. The number of the remaining genes of the mRNA expression dataset
after applying the filtering methods is 13604 genes with ER groups and 13612
genes with PR groups as shown in Figure 3.2.
3.3.3 Breast Invasive Carcinoma (TCGA, Provisional)
This dataset originated as part of the TCGA (i.e. the cancer study identifier is
brca tcga), and it was used by the analysis study [234]. The study was conducted
on 1098 breast cancer invasive tumours to estimate the prognosis of invasive breast
cancer. The outcome is that ten genetic variations were detected to be statistically
associated with histologic grade, which is one of the most important microscopic
features. Diverse biomedical datasets are involved in (Provisional) data, including
copy number alterations, gene mutation, mRNA and protein expression, clinical
and pathological data. The focus of the research in this thesis is on mRNA
expression data. The mRNA expression dataset was carried out using Agilent
microarray and contains 17814 genes and 529 observations. The samples with
missing values/others (e.g. Not Available, Indeterminate) in both response groups
were removed from the analysis, as shown in Figure 3.3.
The integration of the mRNA expression data and ER clinical data, which
has 1046 observations resulted in a dataset of 519 observations. According to
the group distribution, 402(77.46%) tumours were derived from ER+ samples,
and 117(22.54%) tumours were derived from ER- samples. The unification of the
mRNA expression data and PR clinical data, which contains 1043 observations
produced a dataset of 518 observations. The number of cases that were derived
from patients with PR+ tumours is 341 out of 518, so the percentage of positives
is 65.83%, while 177(34.17%) tumours were derived from PR- samples. After
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Figure 3.3: The description of (Provisional) dataset showing the unification of
clinical data and mRNA expression data.
performing the filtering methods, the number of remaining genes of the mRNA
expression dataset is 14035 genes with ER groups and 14041 genes with PR
groups. Figure 3.3 illustrates the number of genes and mRNA samples before
and after the pre-processing step, along with the distribution of both ER and PR
groups across samples.
3.4 The Integrated Breast Invasive Carcinoma
Datasets
In this section, the breast invasive carcinoma datasets that are collected from
different studies, but were carried out using Agilent microarray, which are (Na-
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ture 2012), (Cell 2015) and (Provisional) are integrated in a number of different
approaches to enhance the imbalanced class distribution of these datasets and
also to have more substantial data. Moreover, the integration of the breast in-
vasive carcinoma datasets helps to investigate the consistency of selection of the
proposed feature mining models to a wide range of variations in breast cancer
samples. To ascertain achieving the best possible balanced group datasets, three
integrated datasets are created with ER groups, and six integrated datasets are
created with PR groups, as discussed in the following sections.
3.4.1 The Integrated Datasets with ER groups
This section discusses the mechanism of integrating the breast invasive carcinoma
datasets with ER groups. To attain a good-level of balanced group distribution,
(Nature 2012), (Cell 2015) and (Provisional) datasets are fused jointly in three
different approaches:
3.4.1.1 NCP1 Dataset
This dataset was created, based on the integration of the negative samples of
(Cell 2015) and (Provisional) datasets with (Nature 2012) data, which has 519
samples, 401 tumours were derived from patients with ER+, and 118 tumours
came from ER- samples. The number of the negative samples of (Cell 2015) is
92, and of (Provisional) is 117. These ER-negatives were integrated with (Nature
2012) dataset to generate an integrated dataset called NCP1, which has 728
observations, as shown in Figures 3.4. The distribution of ER groups is that
401(55.08%) are samples with ER+ tumours and 327(44.92%) are ER- samples.
As illustrated in Figure 3.4, the unification of the genes across the breast invasive
carcinoma datasets resulted in a dataset that contains 13212 genes.
3.4.1.2 NCP2 Dataset
Alternatively, the creation of this dataset depends on that the negative samples of
(Nature 2012) and (Provisional) datasets were added to (Cell 2015) data, which
has 415 observations, 323 being patients with ER+ tumours and 92 being ER-
samples. The ER- samples of (Nature 2012) (i.e. 118), and the ER- samples
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Figure 3.4: The description of NCP1 dataset showing the unification of (Nature
2012), (Cell 2015), and (Provisional) datasets.
Figure 3.5: The description of NCP2 dataset showing the unification of (Nature
2012), (Cell 2015), and (Provisional) datasets.
of (Provisional) (i.e. 117) were integrated with (Cell 2015) data to produce an
integrated dataset called NCP2, which has 650 observations. The class distribu-
tion of NCP2 dataset is that 327(50.31%) are ER-negatives, and 323(49.69%) are
ER+ samples, as illustrated in Figure 3.4. The unification of the genes over the
breast invasive carcinoma datasets resulted in a dataset that comprises of 13212
genes.
3.4.1.3 NCP3 Dataset
This dataset was created based on integrating the negative samples of (Nature
2012) and (Cell 2015) datasets with the (Provisional) data, which has 519 obser-
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Figure 3.6: The description of NCP3 dataset showing the unification of (Nature
2012), (Cell 2015), and (Provisional) datasets.
vations, 402 being patients with ER+ tumours and 117 being ER- samples, as
shown in Figure 3.6. The ER-negatives of (Nature 2012) (i.e. 118) and the ER-
negatives of (Cell 2015) (i.e. 92) were integrated with (Provisional) data to create
an integrated dataset called NCP3 of 729 observations. The group distribution of
the NCP3 dataset is that 327(44.86%) are ER-negative samples and 402(55.14%)
are patients with ER+ tumours, as clarified in Figure 3.6. Consequently, the
integration of the genes over the breast invasive carcinoma datasets resulted in a
dataset that contains 13212 genes.
3.4.2 The Integrated Datasets with PR groups
This section discusses the procedure of integrating the breast invasive carcinoma
datasets that were carried out using the same microarray technology with PR
groups. To achieve a good-level of balanced class distribution, two of the three
datasets are fused jointly in six different approaches:
3.4.2.1 NC Dataset
This dataset was created based on fusing the PR- samples of (Cell 2015), which
are 141 with (Nature 2012) data, which has 518 observations, 340 being patients
with PR+ tumours, and 178 being PR-negative samples, as shown in Figure 3.7.
The integrated dataset NC has 659 observations, 340(51.59%) being PR+ patients
and 319(48.41%) being PR- samples. As explained in Figure 3.7, integrating the
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Figure 3.7: The description of NC dataset showing the unification of (Nature
2012) and (Cell 2015) datasets.
genes across the datasets resulted in a dataset that contains 13249 genes.
3.4.2.2 CN Dataset
Alternatively, creating this dataset was based on that the PR-negative samples of
(Nature 2012), which are 178 were added to (Cell 2015) dataset, which has 414
observations, 273 being patients with PR+ tumours, and 141 being PR-negative
samples. The integrated dataset CN contains 592 observations, 273(46.11%) be-
ing PR-positives, and 319(53.89%) being PR-negatives, as illustrated in Figure
3.8. The unification of the genes over the datasets resulted in a dataset that
contains 13249 genes.
3.4.2.3 NP Dataset
This dataset is created based on the combination of the negative samples of the
(Provisional) dataset (i.e. 177) with (Nature 2012) data, which includes 518
observations, 340 being samples with PR+ tumours and 178 are PR- samples.
The integrated dataset NP comprises 695 observations, 340(48.92%) being PR-
positive patients and 355(51.08%) being PR- samples, as clarified in Figure 3.9.
The integration of the genes over the datasets produced a dataset that involves
13528 genes.
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Figure 3.8: The description of CN dataset showing the unification of (Cell 2015)
and (Nature 2012) datasets.
Figure 3.9: The description of NP dataset showing the unification of (Nature
2012) and (Provisional) datasets.
3.4.2.4 PN Dataset
Alternatively, the creation of this dataset is based on that the negative samples
of (Nature 2012) dataset were added to (Provisional) data, which has 518 obser-
vations, 341 being samples with PR+ tumours and 177 were derived from PR-
samples. The integrated dataset PN involves 696 observations, 341(48.99%) are
PR-positives and 355(51.01%) are PR-negatives, as shown in Figure 3.10. uni-
fying the genes across the datasets generated a dataset that comprises of 13528
genes.
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Figure 3.10: The description of PN dataset showing the unification of (Provi-
sional) and (Nature 2012) datasets.
Figure 3.11: The description of CP dataset showing the unification of (Cell 2015)
and (Provisional) datasets.
3.4.2.5 CP Dataset
In this dataset, the PR- samples of (Provisional) were added to (Cell 2015)
data, which has 414 observations, 273 being samples with PR+ tumours and
141 being PR- samples. The integrated dataset CP contains 591 observations,
as illustrated in Figure 3.11, 273(46.19%) being PR-positives and 318(53.81%)
being PR-negatives. The integration of the genes over the datasets leads to a
dataset with 13314 genes.
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Figure 3.12: The description of PC dataset showing the unification of (Provi-
sional) and (Cell 2015) datasets.
3.4.2.6 PC Dataset
Alternatively, this datasets was created based on the combination of the PR-
samples of the (Cell 2015) with (Provisional) data, which has 518 observations,
341 being PR-positives and 177 being PR-negatives. The integrated dataset PC
comprises of 659 observations, 341(51.75%) being PR-positives and 318(48.25%)
being PR- samples. Unifying the genes over the datasets resulted in a dataset
that has 13314 genes.
3.5 METABRIC Breast Cancer Dataset
This dataset was generated from METABRIC [62], [68] and downloaded from
cBioPortal, where the cancer study identifier is brca metabric. The dataset
contains diverse biomedical datasets, including clinical data and two genomic
datasets: gene expression, and copy number alterations. An integrative analysis
study [230] performed on copy number alterations and gene expression profiles in
2000 primary breast cancer tumours emphasised the significance of genome-based
stratification of breast cancer.
The mRNA expression dataset was carried out using Illumina Human v3 mi-
croarray and contains 24368 genes and 1904 observations. The integration of
mRNA expression dataset and ER clinical data, which has 1980 cases, generated
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Figure 3.13: The description of (METABRIC) dataset showing the unification of
clinical data and mRNA expression data.
a dataset of 1904 observations, 1459(76.63%) being samples with ER+ tumours,
and 445(23.37%) were derived from ER- samples. The unification of mRNA ex-
pression dataset and PR clinical data that contains 1980 observations, resulted
in a dataset of 1904 observations, 895(47.01%) being PR-negatives, comparing
to 1009(52.99%) instances coming from patients with PR+ tumours. After elim-
inating the least promising genes from the analysis, the number of remaining
genes of mRNA expression dataset with ER and PR groups is 19732. Figure 3.13
provides a summary of the number of samples and genes of mRNA expression
dataset before and after the pre-processing step.
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3.6 Ovarian Cancer Dataset
Ovarian cancer dataset is publicly available on the FDA-NCI Clinical Proteomics
Program Databank website1. The dataset was utilised in the preliminary con-
ducted experiments to develop and validate the introduced models. This high-
resolution ovarian cancer dataset was generated using the WCX2 protein array
to identify serum (blood-derived) proteomic patterns that differentiate the serum
of patients with ovarian cancer from that of women without ovarian cancer. It
contains records collected from 216 observations with 15000 features. Each sam-
ple has one of two possible response groups: Normal or Cancer. According to the
group distribution, 121 (56%) instances were derived from patients with cancer,
and 95 (44%) instances were derived from women without cancer.
3.7 Experimental Methodology
This section discusses the validation approaches and evaluation metrics applied
to understand the performance of the proposed feature mining models.
3.7.1 Area Under the ROC Curve
The AUC metric is utilised as the main performance estimation metric to assess
the quality of the classification models. As discussed in Chapter 2, AUC is more
reliable than accuracy, more discriminative than other estimation metrics and
can be measured over the range of TPR and FPR [188,189]. Receiver Operating
Characteristic (ROC) curve in Figure 3.14 shows TPR and FPR for the designed
classification model using the marker on the figure. The FPR of (0.00) indicates
that 0% of the validation samples are assigned incorrectly into the positive group.
The TPR of (1.00) corresponds to 100% of the validation samples that are cor-
rectly classified to the positive group by the learned model. A perfect result is a
right angle to the top left of the figure.
The ROC curve can be summarised into a single value by measuring the Area
Under the ROC curve (AUC), which is a measure of the overall quality of the
1https://home.ccr.cancer.gov/ncifdaproteomics/ppatterns.asp
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Figure 3.14: An example of Receiver Operating Characteristics (ROC) curve.
classification model. AUC resides in the range of [0, 1], and if the AUC value is
equal to 1, it means the predictive performance is perfect (i.e. the classification
model correctly assigned all the unseen new cases that it was given during the
validation stage). If AUC = 0.5, this refers to classification by chance (random
guessing), and if AUC = 0, this refers to an inverted perfect classification. Largest
AUC of 1.00 indicates the optimal performance of the trained model, as shown
in Figure 3.14. Thus, AUC is utilised to evaluate the predictive performance of
the classification models. In this project, the AUC metric is computed with a
confidence level of 0.99 to obtain a considerable level of validity and certainty.
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3.7.2 Stability and Generalisability
Let S = {s1, s2, s3, , sn}, be a set of data samples, which can be partitioned
into k non-overlapping data subsets of equal size P = {p1, p2, , ..., pk}. Each
subset contains approximately the same proportions of response groups as in the
original data. This stratified CV procedure is repeated k iterations. At each
iteration i ∈ {1, 2, 3, ..k}, the feature mining model is applied on P \ pi. Over
iterations, a set of subsets of features FS = {fs1, fs2, ..., fsk} is produced. When
FS is obtained, the consistency of feature selection can be examined to define the
most frequently selected features over k iterations. The consistency of selection
is more likely to be correlated with the predictive power of features so that the
most consistently selected features should be the most relevant, whereas the least
consistently selected features should be less relevant. Estimation of the predictive
performance of learning models is an essential step, since it guides the process
of model selection, and evaluates the quality of the chosen model. As mentioned
earlier, for small datasets, there is an increased risk of obtaining high variability
in the estimation error. Therefore, the choice of a suitable CV approach for small
datasets has been considered carefully in order to report reliable estimations. The
5−fold CV method is empirically established due to achieving a good compromise
when attempting to address the Bias-Variance trade-off.
In this research, the generalisability metric is utilised in the mining stage in
order to investigate the capacity of the proposed feature mining models to gen-
eralise to wider populations by detecting generic molecular markers for breast
cancer from multiple independent genomic datasets that are collected from com-
pletely different studies. The generic biomarkers are discovered by examining
the selected subsets of stable predictors, which are identified from each breast
cancer dataset by the ensemble feature mining model over CV iterations. If the
stable predictors are also detected across a wide range of independently generated
breast cancer data samples, the more likely they are true biomarkers. As a result,
predictivity, stability, and generalisability are considered equally in this research
project for the goal of assessing the relevancy, robustness, and reproducibility of
the discovered biomarkers across multiple independent datasets so that reliable
biological findings can be reported.
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3.8 Discussion
“The data generated by the TCGA program comprised a vast resource that inves-
tigators will be analysing for years to come. The resource of information about
breast cancer genomes will undoubtedly fuel a myriad of discoveries by the can-
cer research community” - The director of NHGRI, Eric D. Green. As cancer
genomic data has become more accessible, the research presented in this thesis
adopts multiple independent cancer datasets, to increase the potential of discov-
ering true biomarkers and decrease the risk of false positive. These genomic and
proteomic datasets are the inputs to the proposed feature mining models for the
aim of knowledge discovery. Validating and evaluating the identified biomark-
ers from these HDSSS omics data involves several underlying issues that need
to be properly handled using the suitable experimental methodologies, effective
evaluation metrics and independent validations.
The internal validation that is based on stability criterion and repeated 5-
fold CV procedure, is employed to generate variant training sets to examine the
consistency of selection of the proposed feature mining models, and variant val-
idation sets to estimate the testing error rate reliably. The external validation
that is based generalisability criterion, is utilised to examine the potential gen-
eralisation of the proposed mining models across multiple independent datasets.
Furthermore, the sensitivity of the feature mining models to the variations in the
breast cancer samples is investigated further using the integrated datasets. The
predictivity criterion is applied using two classifiers, which are Support Vector
Machine, and Bagging Decision Trees. The response groups of the breast can-
cer datasets before the integration approaches have considerable disparate sizes,
where the majority are the positives (i.e. ER+ and PR+). Therefore, the AUC
estimation metric is adopted to assess the performance of these prediction models
with a confidence level of 0.99 in order to obtain a considerable level of validity
and certainty.
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Evolutionary Mining Model
4.1 Introduction
The key challenge of the problem of knowledge discovery from omics data is
searching through its high dimensional search space. The search space, S, which is
the total number of possible candidate subsets of genes or proteins to be assessed
is equal to 2d, and d is the number of variables in the genomic or proteomic
data, which is typically thousands or tens of thousands. That means that an
extremely huge number of evaluations is required to find the optimal subset of
candidate features, which is infeasible or computationally expensive. As discussed
in details in Chapter 2, the best possible subset of key genes can be identified using
Evolutionary Computational (EC) methods, a group of optimisation algorithms,
which retrace the natures path to find a solution to a high dimensional complex
problem in as little search time as possible. The EC methods navigate through the
search space of possible candidate solutions to identify a feasible solution, which
is a subset of predictors in our research problem, with respect to an objective
function. As mentioned earlier in Chapter 2, Genetic Algorithm (GA) can be
considered as one of the most powerful EC methods applied to feature selection
problems [261], thus it is adopted in this research as the search strategy for the
feature mining model. The objective function is utilised to estimate the goodness
of combinations of genes so that progress toward the best possible subset can be
evaluated. Assessing the feasibility of a subset of genes to solve the problem at
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the hand is a key factor to guide the search process of GA toward a good solution.
Therefore, this chapter introduces the GA, the methodology employed for
fitness evaluation based on a hybrid selection approach. The experimental setup
of the proposed evolutionary mining model is discussed, along with a detailed
explanation of each step of that design. Furthermore, the experimental findings
generated from the application of the ensemble evolutionary mining model to the
adopted cancer datasets are presented and discussed.
4.2 Genetic Algorithm
The Genetic Algorithm (GA) adopts the phenomenon of adaptation as a compu-
tational process for solving general-purposes complex problems [134]. The GA is
an EC method, starts with a set of initial candidate solutions (individuals), called
population. The GA process creates the next population of individuals iteratively
by replacing the current (parent) population with the offspring using a kind of
natural selection with operators inspired by genetic variations namely selection,
crossover, mutation and elite-preservation. The selection operator selects those
individuals in the current population to be parents based on their fitness values.
Individuals in the parent population that have the highest fitness values are cho-
sen as elite individuals to be passed directly to the next population. During the
reproduction process, the GA introduces some variations in the offspring. The
crossover operator exchanges subparts of two selected individuals in the current
population, while mutation operator randomly makes changes to the allele values
of some locations in a single individual. The parent population is replaced with
the offspring to form the next individuals. Over successive generations, the pop-
ulation evolves toward the best possible solution and the algorithm stops when
a stopping criteria is met (e.g. the optimum is found, or a pre-defined number
of generations is reached). The choice of a method for each step of the search
process can significantly affect the behavior of GA. However, in the literature,
there is a large body of research that has shown theoretically and experimentally
that there are no universally optimal methods [69].
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4.3 Experimental Design of the Evolutionary Min-
ing Model
This section explains the design of the evolutionary mining model for the prob-
lem of biomarker identification from omics data. Given the genomic or proteomic
dataset D, which is a n × d matrix of the training set, where d represents the
number of variables, and n is the number of samples. As shown in Figure 4.1,
the design starts with passing D to the univariate approach to reduce the di-
mensionality of the data for the next optimisation phase, by eliminating the least
promising genes. The selected genes by the univariate approach are sampled uni-
formly at random to create the initial population of the GA forming the initial
candidate subsets of genes. The quality of each subset is assessed using the mul-
tivariate approach. The settings of how new search points of the next population
are generated from the members of the parent population are explained in the fol-
lowing subsections. Appropriate choices for each step of the setup is empirically
established, considering the fact that the interaction between GA components is
conducted in highly nonlinear approaches.
4.3.1 Univariate Approach
A univariate approach is utilised firstly as a pre-processing step to reduce the ex-
ponential search space of genomic and proteomic data for the next optimisation
stage. The evolutionary process of GA together with the multivariate evaluation
approach assess the optimality of the candidate subsets of features, which are se-
lected using the univariate approach. Therefore, this preliminary step contributes
to decreasing the number of features that will be passed to the fitness function,
based on Linear Discriminant Analysis for identifying the best combination of
genes. The univariate approach is based on a statistical test that is applied to
each gene individually to examine if there is any statistically significant differ-
ences between negative (normal) and positive (cancer) patients on the basis of
that gene value. Therefore, the two-sample t−test [249] assigns a P-value to each
gene as a measure of its effectiveness in distinguishing observations of different
groups and thus the least discriminative genes are discarded. The gene will be
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Figure 4.1: Steps of the experimental design of the evolutionary mining model.
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considered relevant if the P-value is less than the significant level of the test (i.e.
0.05). Therefore, t−statistics check whether these two groups of samples are
significantly different or not, as follows:
t =
x¯− y¯√
s21
n1
+
s22
n2
(4.1)
where x¯ and y¯ are the sample means, s1 and s2 are the sample standard deviations,
and n1 and n2 are the numbers of samples in the positive and negative groups.
Two-sample t−test method tests the null hypothesis that the two data vectors
are from populations with equal means, without the assumption that the popu-
lations also have equal variances. This is also called the Behrens-Fisher problem,
which uses Satterthwaites approximation for the effective degrees of freedom. The
degree of freedom v for the unequal variance t−test is given by [215]:
v =
( 1
n1
+ u
n2
)2
1
n21(n1−1) +
u2
n22(n2−1)
(4.2)
where
u =
s22
s21
(4.3)
This test is sometimes called Welchs t−test. The selected features will form
uniformly at random the initial candidate solutions of GA to be assessed using
the multivariate approach.
4.3.2 Initial Population
The question that needs to be answered is how to represent the individuals of GA’s
population. A population is an array of individuals, where individuals represent
potential solutions to the problem at hand, which are combinations of genes or
proteins for the biomarker discovery problem. Thus, for our research problem, an
individual is a fixed-length vector of nFeat genes, to which the fitness function can
be applied. So, for example, individuals of gene expression dataset is described
by nFeat genes: 〈RPS11, PNMA1, MMP2, ZHX3, ERCC5, ..., CTSC〉. The
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actual space is the finite set of real numbers representable using floating-point
representation. GA creates the initial population, which is a matrix p × nFeat,
where p represents the number of individuals that are generated randomly from
the selected features of the previous phase. Where nFeat is the number of genes
in each candidate solution, which is equivalent to the desired number of features
to be detected.
4.3.3 Multivariate Approach
A multivariate approach based on Linear Discriminant Analysis (LDA) is adopted
to measure the optimality of each subset of genes. In statistics, Discriminant
Analysis is a well-known method for capturing the characteristics of the data that
can best distinguish the samples in one group from those in another. When the
actual groups are known, the interest is to form a rule based on the features that
best characterise the differentiation between the disparate groups. According
to Fishers rule [96] “vectors in one class behave differently from vectors in the
other classes, and the variance within the classes differs maximally from that
between the classes”. LDA finds linear combinations of variables in a way that
the variability within-class is small and between-class is large, in order to discover
structure in the dataset that guarantees maximal separability.
Suppose A is a n× d matrix of the training set, where d represents the num-
ber of variables, and n is the number of samples. Each sample is represented by
x = (x1, ..., xd). For K response group, the label Y ranges from 1 to K. The
sample space of training dataset is divided into K disjoint groups (G1, ..., Gk).
The within-class variability can be obtained by calculating the separability (i.e.
the distance) between the means of different response groups, which results in W
matrix of d × d. While the between-class variability depends on calculating the
distance between the mean and the samples of each response group, which pro-
duces the B matrix of d×d. LDA finds the linear combination Aa of the variables,
so that the proportion of between-class to within-class is given by a′Ba/a′Wa.
LDA assumes that the data within a group k follows a multivariate normal
distribution with mean µk and covariance Σk. When the class densities have the
same covariance matrix, Σk = Σ for all k, the discriminant rule is based on the
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Figure 4.2: An illustration of the fitness score of each individual.
square of the Mahalanobis distance and is linear in x, and given by the following
general form [79]:
f(x) = arg min
k
(x− µk)Σ−1(x− µk)′ (4.4)
The population mean vectors and covariance matrices are estimated from a train-
ing set by the sample mean vectors and covariance matrices µˆk = x¯k and Σˆk = Sk.
For the constant covariance matrix case, the pooled estimate of the common co-
variance matrix is utilised as follows [79]:
Σˆ =
∑
k
(nk − 1)Sk/(n−K). (4.5)
The discriminative individual is the combination of genes that can maximise
the separation of positive observations from negative ones, such that the classi-
fication error rate of the multivariate model is minimised. GA assigns a fitness
score for each individual in the current population according to its discriminative
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power as shown in Figure 4.2. Then, a sorted list of fitness values is created.
4.3.4 Ranking Scaling
A scaling function is utilised to convert the fitness scores of the multivariate
evaluation approach to scaled values that are more appropriate for the next phase.
Firstly, the ranking scaling function ranks each subset of features according to its
location in the sorted list of fitness scores, for example, the rank of the best subset
is 1, and the next best subset is 2. Then, the ranking scaling function scales the
fitness scores of each subset on the basis of its rank, for example, the scaled score
of a subset with rank n is proportional to 1/
√
n. As a result, the scaled value of
the best subset is proportional to 1, and the scaled value of the next best subset is
proportional to 1/
√
2. The GA algorithm aims to minimise the misclassification
rate of LDA, subsets with low scores have high scaled values. The utilisation
of the ranking scaling function results in removing the impact of the spread of
the fitness scores. Moreover, poorly ranked subsets become more closely equal
in value using the square root compared to rank scoring. It is important here to
emphasise the impact of the scaling function on the performance of GA. If the
scaled fitness values are different, the highest scaled subsets reproduce rapidly,
and that could lead to the insufficient exploration of the search space. On the
other hand, if there is a little variation in the scaled fitness values, all subsets
may be reproduced equally leading to slow convergence. The subsets of the next
generation are selected according to their scaled fitness values. Subsets with high
scaled values have a higher chance of selection.
4.3.5 Selection
The first genetic operator in the GA reproduction process is the selection, which
specifies how to choose subsets in the parent population to generate offsprings for
the next generation. Therefore, the selection operator could act like driving the
search process of GA towards interesting parts of the search space by mimicking
the concept of the survival of the fittest. The GA lays out a line in a way where
each subset is assigned to a segment of the line that is proportional to the scaled
fitness score of that subset. The GA moves along the line in steps of equal size and
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Figure 4.3: Histogram of parent individuals.
selects a parent subset from the segment it lands on. The first step is a uniform
random number less than the step size. A subset of features can be chosen more
than once to be a parent, and that means the features of the subset contribute
to form more than one offspring as shown in Figure 4.3. Some of the subsets in
the current population that have the best-scaled fitness values are chosen as elite.
These elite subsets are passed directly to the next population. The fraction of
subsets in the parent population are guaranteed to survive to the next generation
is equal to (i.e. 0.05 multiplied by the size of the population).
4.3.6 Reproduction
Beside elite children, GA combines pairs of subsets in the parent population
to produce crossover children for the next generation. The crossover operator
generates a random binary vector and selects the genes from the first parent
subset where the binary vector is equal to 1, and the genes from the second parent
subset where the binary vector is equal to 0 and combines the genes to form the
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Figure 4.4: An illustration of the average distance between individuals at each
generation.
new offspring. For the crossover operator, the amount of variation introduced
when generating a new subset may rely on the number of the crossover points, so
when the number is increased, adequate amount of variations can be produced.
However, adopting a fixed number of crossover points causes that for a subset,
genes that are close together are more likely to be inherited as a combination
than if these genes are separated. Therefore, selecting the number of crossover
points based on stochastic schema leads to produce crossover points anywhere
from zero to nFeat − 1. The fraction of the next generation that is reproduced
by crossover is 0.8.
At the mutation stage, GA makes random changes in the subsets in the pop-
ulation to create mutated children. Since the values of genes of GA’s individuals
are real numbers, a small perturbation of an inherited gene value is the natural
way to implement mutation. Therefore, the mutation operator adds a random
number to each entry of the parent subset chosen from a Gaussian distribution
G(0, σ) with a mean of zero and a standard deviation of σ. For mutation operator,
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Figure 4.5: An illustration of the algorithm’s evolution over generations.
the amount of introduced variation when creating new offspring may rely on how
many genes are to be mutated and the amount of change in a genes value. The
case when the number of mutated genes is low (e.g. one gene) and the amount of
change is increased; this can be effective when the genes contribute independently.
However, this may not be effective when there is an interaction between genes
because improvements in GA performance require mutating multiple genes simul-
taneously. Therefore, mutating all genes contributes to a significant improvement
in GA’s performance.
To avoid any disruption that might result from the perturbation of multiple
genes, GA controls the average amount of mutation through generations by de-
creasing the standard deviation linearly so that the amount of mutation decreases
to 0 at the final step. As shown in Figure 4.4, the average distance between in-
dividuals at each generation is large, in order to make progress and the diversity
declines in the last generations due to the drop in the mutation . Therefore, the
mutation operator contributes to the diversity of the population and increases the
likelihood that the algorithm will search a broader space and generate individuals
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with better fitness values. The parent population is replaced with the produced
children to constitute the next generation. The algorithm iterates until the av-
erage relative change in the best fitness function value over generations is less
than or equal to (i.e. 1e-6). Over successive generations, the population evolves
toward the best solution as shown in Figure 4.5.
4.4 Results and Discussion
This section presents the analysis executed to evaluate the performance of the
proposed evolutionary mining model to infer useful knowledge from genomic and
proteomic data that can be employed to construct reliable prediction systems us-
ing the SVM and BDT learning models. Firstly, stratified 5−fold CV procedure
is employed to randomly partition each dataset into training-validation sets as
illustrated in Appendix A. At each iteration, the SVM and BDT learning models
that are discussed in Chapter 2, were trained using the training set that con-
tains only the discovered biomarkers, and then validated using the corresponding
validation set as shown in Appendix B. Over CV iterations, the average predic-
tive performance of the classification models is estimated using the quantitative
quality metric, AUC. The experimentally obtained results are presented together
with the discussion first, for the ovarian cancer dataset in the following subsec-
tion, followed by METABRIC, breast invasive carcinoma datasets with ER and
PR groups and the integrated datasets with ER and PR groups.
4.4.1 Results and Discussion of Ovarian Cancer Dataset
This dataset (which is discussed in Section 3.6) was utilised in the preliminary ex-
periments conducted in this research to develop the proposed evolutionary mining
model and assess its outputs. Initially, the 5−fold CV procedure divided ovarian
cancer dataset randomly into training-validation sets, as shown in Appendix A
- Table 1. To examine the consistency of selection of the evolutionary mining
model over the variations in the data, the CV procedure was iterated 50 times.
In other words, the 5−fold CV procedure was re-partitioned randomly 10 times
to generate 50 different training sets, which were used by the evolutionary mining
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Figure 4.6: Scatter plots matrix of the stable predictors (index) of ovarian cancer
dataset.
model to produce 50 subsets of features. Then, the obtained groups of candidate
features were compared to define a subset of consistently selected predictors. The
outcomes of our experiment identified a subset of 10 stable predictors from the
ovarian cancer dataset, as shown in Figure 4.6. The discovered predictors were
plotted in the X-axis and Y-axis, ascendingly according to their index, as illus-
trated in Figure 4.6.
At this point, it is relevant to observe that the intensity values of the stable
proteins for cancer patients differ significantly from those in the normal group.
Typical biomarkers identification models adopt the idea that the genes or pro-
teins that exhibit the greatest variations across the biological conditions can be
considered as potential biomarkers. Therefore, the detected proteins could act
as potential biomarkers for ovarian cancer. To examine the predictivity of these
proteins, the SVM and BDT classification models were trained using the training
80
4. Evolutionary Mining Model
set restricted to the discovered subset of those proteins and then validated using
the corresponding validation set, as shown in Appendix B - Figure 7, represented
by the confusion matrices and the ROC curve plots of the SVM and BDT models
for the final iteration. The average AUCs of the SVM and BDT classifiers over
50 iterations are 0.9788 and 0.9528 respectively. The experimental outcomes
of ovarian cancer dataset verify that the introduced evolutionary mining model
was able to capture meaningful structure in serum (blood)-derived proteomic
data that can differentiate the serum of patients with ovarian cancer from that of
women without ovarian cancer with a high-level of predictivity and robustness.
4.4.2 Results and Discussion of METABRIC Dataset
The ensemble evolutionary mining model was applied to METABRIC breast can-
cer dataset to extract relevant mRNA markers to the ER and PR status. Ini-
tially, the 5−fold CV procedure divided the METABRIC dataset randomly into
training-validation sets, as shown in Appendix A - Table 1. Repeated CV proce-
dure was employed to examine the sensitivity of the evolutionary mining model
to 50 different training datasets. Therefore, 50 subsets of candidate features were
discovered and the comparison of those subsets led to identifying a list of 10
stable predictors from the METABRIC dataset with ER groups, as shown in Fig-
ure 4.7, as well as 10 stable predictors from the METABRIC dataset with PR
groups, as shown in Figure 4.8. The mRNA markers were plotted in the X-axis
and Y-axis alphabetically using their names, as illustrated in Figure 4.7 and Fig-
ure 4.8. Both figures illustrate how the expression levels of the discovered genes
for ER+/PR+ patients differ significantly from samples with ER/PR-negative,
which verifies the potential of these mRNAs to be indicators for breast cancer
and ER/PR positivity.
Table 4.1: The performance of the SVM and BDT models built on the stable
predictors of METABRIC datasets with ER and PR groups.
METABRIC SVM BDT
ER 0.9854 0.9897
PR 0.9854 0.9832
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Figure 4.7: Scatter plots matrix of the stable predictors of METABRIC dataset
with ER groups.
The predictive power of the identified subsets of robust molecular markers for
both response groups was assessed using the SVM and BDT classifiers, as shown
in Appendix B - Figure 8 and Figure 9, represented by the confusion matrices and
the ROC curve plots of these learning models for the final iteration. The average
AUCs are reported in Table 4.1. The obtained results reveal that the discovered
genes contributed to constructing highly accurate and robust prediction models
for both ER and PR groups as shown in Table 4.1. As a result, the outcomes
of our experiments provide strong evidence that supports the capacity of the
proposed evolutionary mining model to capture interesting complexity from this
HDSSS cancer genomic dataset.
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Figure 4.8: Scatter plots matrix of the stable predictors of METABRIC dataset
with PR groups.
4.4.3 Results and Discussion of Breast Invasive Carci-
noma Datasets
In this section, the evolutionary mining model was applied to the breast inva-
sive carcinoma datasets: (Nature 2012), (Cell 2015), and (Provisional), which
are explained respectively in Sections 3.3.1, 3.3.2, 3.3.3. The aim is to discover
key genes that underlie the biological process of ER and PR. The 5−fold CV
procedure was utilised firstly to divide each dataset into 10 random partitions,
as shown in Appendix A - Table 3. The evolutionary mining model based on the
ensemble approach produced 50 subsets of candidate genes, in order to investi-
gate the gene preferences of the proposed model across different training sets and
detect a subset of stable predictors for each dataset. As discussed in Section 2.10,
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the external validation is necessitated to test the generalisability of the feature
mining model to wider populations. Therefore, the discovered groups of consis-
tently selected predictors were compared to find generic mRNA markers across
(Nature 2012), (Cell 2015), and (Provisional) datasets. The generic biomarkers
will be discussed in the next subsections according to their relevancy to the ER
groups and PR groups.
4.4.3.1 ER Groups
Two biomarkers were found to be generic across the breast invasive carcinoma
datasets, which are {‘ESR1’, ‘AGR3’} as shown in Figure 4.9 - subfigures with
ER, which can illustrate the capability of these biomarkers to distinguish the
samples with ER+ tumours from those with ER- effectively. The discovered mR-
NAs were plotted in the X-axis and Y-axis alphabetically, using their names, as
illustrated in Figure 4.9. Furthermore, the performance of the SVM and BDT
models formed from the training sets that contain only these biomarkers was as-
sessed using the corresponding validation sets, as shown in Appendix B - Figure 10
and Figure 11, represented by the confusion matrices and the ROC curve plots of
these learning models for the final iteration. The average AUCs of both classifiers
over 50 iterations are presented in Table 4.2. The experimental outcomes show
that the SVM and BDT classification models achieved a high level of predictive
performance and robustness over all the datasets, which reflects the robustness
of the identified genes. This is evidence showing that the presented evolutionary
mining model was able to recognise individual markers that are more insensitive
to the variations in the data, while simultaneously maintaining as much of the
knowledge about the input data as possible.
Table 4.2: The performance of the SVM and BDT models built on the generic
biomarkers of the breast invasive carcinoma datasets with ER and PR groups.
Dataset SVM-ER BDT-ER SVM-PR BDT-PR
(Nature 2012) 0.9239 0.9205 0.8555 0.8477
(Cell 2015) 0.9379 0.8958 0.8599 0.8581
(Provisional) 0.9370 0.8954 0.8679 0.8603
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Figure 4.9: Scatter plots matrices of the generic biomarkers of the breast invasive
carcinoma datasets with ER and PR groups.
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4.4.3.2 PR Groups
Three generic biomarkers were recognised across the breast invasive carcinoma
datasets with PR groups, which are {‘PGR’, ‘AGR3’, ‘FGD3’}, as shown in
Figure 4.9 - subfigures with PR. The discovered mRNA markers were plotted in
the X-axis and Y-axis alphabetically using their names, as illustrated in Figure
4.9. Herein, it is important to observe the capability of the detected biomarkers
to differentiate the patients with PR+ tumours from PR-negatives effectively.
That means that the expression levels of these mRNAs differ significantly for
patients in PR+ group from the samples in PR- group. Therefore, the discovered
mRNA markers have the potential to be true biomarkers for breast cancer and PR
positivity. The predictive power of the discovered biomarkers was assessed using
the SVM and BDT models, as shown in Appendix B - Figure 12 and Figure 13,
represented by the confusion matrices and the ROC curve plots of these learning
models for the final iteration. The average AUCs over 50 iterations are reported in
Table 4.2. The experimental results reveal that the classification models achieved
a good level of predictive performance over all the datasets, which reflects the
predictivity and robustness of the discovered biomarkers. This is again another
pieced evidence that demonstrates the capability of the proposed evolutionary
mining model to navigate through the large search space of genomic data and
identify an ensemble subset of robust and reproducible biomarkers.
4.4.4 Results and Discussion of Integrated Breast Invasive
Carcinoma Datasets
The proposed evolutionary mining model was then applied to the integrated
breast invasive carcinoma datasets with ER groups: NCP1, NCP2, NCP3, which
are illustrated respectively in Sections 3.4.1.1, 3.4.1.2, 3.4.1.3. Furthermore, the
evolutionary mining model was applied to the integrated datasets with PR groups:
NC, CN, NP, PN, CP, PC, which are explained respectively in Sections 3.4.2.1,
3.4.2.2, 3.4.2.3, 3.4.2.4, 3.4.2.5, 3.4.2.5. Initially, the 5−fold CV procedure was
employed to partition each dataset into 10 random splits, as shown in Appendix
A - Table 7 with ER groups and Table 8 with PR groups. The internal validation
of the evolutionary mining model was verified over 50 iterations to discover the
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most consistently selected predictors. Then, the external validation was adopted
to detect generic biomarkers from the subsets of stable predictors across the inte-
grated datasets for both response groups. The generic mRNAs will be discussed
in the following subsections based on their relevancy to the ER and PR groups.
4.4.4.1 ER Groups
Two biomarkers were detected to be generic, across the integrated invasive car-
cinoma datasets with ER groups, which are {‘ESR1’, ‘CA12’} as shown in
Figure 4.10. The discovered biomarkers were plotted in the X-axis and Y-axis
alphabetically using their names, as illustrated in Figure 4.10. It can be observed
from this figure the potential of the discovered biomarkers to separate the ER-
positive patients from ER-negatives effectively, which refers to the variability in
their expression levels between ER+ and ER- groups. The predictivity of the
detected mRNA markers was assessed using the SVM and BDT classifiers, as
shown in Appendix B - Figure 14 and Figure 15, represented by the confusion
matrices and the ROC curve plots of these learning models for the final iteration.
The average AUCs over iterations are introduced in Table 4.3.
The obtained results of both classification models reveal a high-level of pre-
dictivity, as well as robustness, which validates the capability of the identified
biomarkers to build highly accurate and reliable prediction systems. This, in
turn, validates the performance of the evolutionary mining model to extract use-
ful knowledge from these integrated datasets. Furthermore, the outcomes of our
experiments show that the BDT classifier achieved a higher level of predictive
performance than the SVM model, which verifies the importance of training this
model using more substantial data, whose response groups are well-balanced.
Table 4.3: The performance of the SVM and BDT models built on the generic
biomarkers of the integrated datasets with ER groups.
Dataset SVM BDT
NCP1 0.9344 0.9654
NCP2 0.9356 0.9635
NCP3 0.9374 0.9664
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Figure 4.10: Scatter plots matrices of the generic biomarkers of the integrated
datasets with ER groups.
4.4.4.2 PR Groups
Four biomarkers were found to be generic between the subsets of stable predic-
tors of the integrated invasive carcinoma datasets with PR groups, which are
{‘AGR3’, ‘FGD3’, ‘PGR’, ‘GFRA1’}, as shown in Figure 4.11. The discov-
ered biomarkers were plotted in the X-axis and Y-axis alphabetically using their
names, as shown in Figure 4.11. It is important to observe how the detected
biomarkers exhibit a discrimination capability among PR+ and PR- groups, in
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Figure 4.11: Scatter plots matrices of the generic biomarkers of the integrated
datasets with PR groups.
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which their expression levels show a significant difference across the samples of
different groups. To examine the predictive power of these biomarkers, the SVM
and BDT learning models were trained and then validated using the training-
validation sets that contain only the generic mRNA markers, as shown in Ap-
pendix B - Figures 16, 17, 18, and 19, represented by the confusion matrices and
the ROC curve plots of these learning models for the final iteration. The average
AUCs over 50 iterations are introduced in Table 4.4. The outcomes of our exper-
iments reveal that the prediction models achieved a high-level of generalisability
and robustness over all the datasets, which demonstrates the relevance of the
discovered biomarkers to the status of PR.
4.5 Discussion
This chapter investigated the usefulness of state-of-the-art evolutionary computa-
tion methods, with the goal of developing an effective knowledge discovery model
from HDSSS omics data. To mitigate the limitations reported in the research lit-
erature, the parallel adaptive search of the GA is integrated with the hybrid eval-
uation measurement, based on univariate and multivariate statistical techniques.
Furthermore, the ensemble mining model is employed to provide additional ran-
domness to the selection process, based on GA and produce an ensemble subset of
robust biomarkers. The experimental outcomes generated from the application of
the evolutionary mining model to the ovarian, METABRIC, and breast invasive
carcinoma datasets individually and collectively for both ER and PR groups are
Table 4.4: The performance of the SVM and BDT models built on the generic
biomarkers of the integrated datasets with PR groups.
Dataset SVM BDT
NC 0.8733 0.9286
CN 0.8712 0.9269
NP 0.8807 0.9301
PN 0.8793 0.9284
CP 0.8760 0.9289
PC 0.8807 0.9319
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presented and discussed in this chapter. The results of our experiments reveal
the capability of the proposed model to detect individual indicators that are ro-
bust to irrelevant variabilities in the input, while simultaneously capturing the
required information to recover the data. Furthermore, these generic molecular
markers exhibit a high-level of predictivity, in which their expression levels show
significant differences between the patients with ER+/PR+ tumours and samples
with ER/PR-negative. A high-level of robustness these biomarkers also exhibit
over multiple independent datasets strongly indicate their pervasiveness amongst
a broad range of breast cancer patients.
Leveraging the merits of traditional statistical techniques with evolutionary
computational methods for the purpose of knowledge discovery from HDSSS
omics data contributed to developing an efficient feature mining model. The
only concern about this feature mining model is that the number of the detected
generic biomarkers across the datasets is small. This has driven our research to
explore state-of-the-art deep neural network models, for inferring high-level ab-
stract features from HDSSS omics data. More specifically, to ascertain whether
the automatically extracted hierarchical features produced by such neural net-
work models will offer a distinct advantage over our current evolutionary mining
model for extracting salient biomarkers from omics data. Therefore, in the next
chapter, we will discuss our innovative Deep Feature Mining Model.
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Deep Mining Model
5.1 Introduction
Learning useful knowledge from high dimensional data automatically, without
the need for hand designed features that require domain expertise or ad-hoc spe-
cific methodologies and techniques, is highly desirable. This kind of automated
learning has the potential to identify high-level abstract representations that aid
predictions relevant to precision medicine. The question is: what are the re-
quired elements of a feature learning algorithm to be able to exploit large and
noisy spaces of omics data effectively and discover robust biomarkers? Given
the fact that omics data are more likely to be non-linear in nature [297], there
is a necessity for nonlinear learning that avoids the linear assumptions of tradi-
tional statistical models, in order to discover enough of the meaningful intricacies
underlying these high-throughput data.
In the literature, it has been shown that the shallow architectures of learn-
ing algorithms could lead to a poor generalisation ability, unless a huge number
of samples and resources are provided [21], therefore, there is a significant re-
quirement for feature learning based on deep architectures. Shallow architectures
are more likely to capture low-level features of the input, encoding more noise,
and lacking the variance in training data to constrain the weights and thus rep-
resentations. With deep architectures, the dimensionality can be substantially
reduced, thus the problem can be further abstracted by learning high-level fea-
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tures from low-level representations, allowing better generalisation performance
and knowledge transfer [24, 38, 176]. This necessitates the need for deep feature
learning models that consist of multiple levels of input transformation of increas-
ing abstractions, in order to mitigate against the curse of dimensionality of omics
data.
In addition to the curse of dimensionality, biomarker discovery from omics
data has the additional problem of small sample sizes such that the number of
variables vastly exceeds the number of observations. Research has shown that for
a small training set, the unsupervised pre-training approach that is discussed in
Chapter 2 produces consistently better generalisation performance and prevents
the risk of overfitting [87]. However, as discussed previously, the dimensional-
ity of omics data is high (i.e. tens of thousands of molecules), and that means
that there is an exponential number of possible input configurations. There-
fore, the available biological samples become even increasingly sparse making the
process of discovering plausible and robust input configurations a very difficult
task. Moreover, in genomic datasets, very few genes are expressed reliably at
biologically significant levels and distinguishably from noise and measurement
variation [32]. Consequently, a new feature learning model is introduced based
on a set of non-linear sparse Auto-Encoders that are deliberately constructed in
an under-complete manner to force the network to find progressively the complex
featural representations necessary to capture enough of the important variations
underlying the biological samples. The proposed deep feature learning model
is utilised to discover and interpret important signals from omics data that aid
prediction relevant to precision medicine.
The proposed deep feature learning model applies multiple levels of projec-
tions to the input features to abstract the problem and capture high-level depen-
dencies for achieving a high-level of generalisability. This would be a powerful
feature learning model for high dimensional classification problems. However,
for the problem of knowledge discovery, it is hard to interpret which subsets of
genes were responsible for deriving such predictions. To overcome the inherent
issue of poor explanatory power associated with the deep learning paradigm, a
new weight interpretation method will be presented that aids the researcher in
opening up the so-called black box of the network to ascertain which genes were
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dominant within its internal representations. An interpretation method that can
provide explainability to the black-box problem is crucial to approach AI, so that
a new horizon of knowledge in a wide range of domains can be discovered. The
novel interpretation technique introduced will aid bioinformatics researchers to
open the black box and thereby discover important biomarkers from the latent
representations form such DL models.
Some existing deep learning methods are able to handle curse of dimensional-
ity issues and improve generalisability. However, this is typically at the expense
of long training times, a need for substantial data to train the models, and lack
of transparency in that it is not able to unambiguously state which input features
are responsible for its behaviour. To alleviate these limitations, a novel deep
feature mining model is introduced in this thesis with an explanatory technique
that can be used for discovering robust molecular markers from HDSSS omics
datasets. Unlike other models, our deep mining model can perform deep clas-
sification whilst simultaneously revealing the key factors underlying its hidden
representations. The output decisions of the proposed model were further vali-
dated using appropriate evaluation metrics and independent model validations,
thus providing significant confidence as to the relevance, robustness, and repro-
ducibility of the discovered biomarkers.
5.2 Experimental Design of the Deep Mining
Model
A new deep feature learning model called a Stacked Sparse Compressed Auto-
Encoder is proposed in this thesis to infer useful knowledge from HDSSS omics
data for modelling reliable prediction systems. The Sparse Compressed Auto-
Encoder (SCAE) is simply a feedforward neural network trained with a variant
of backpropagation to reproduce its input signal on its output layer, resulting in a
hidden or latent feature layer of neurons representing the underlying transforma-
tion performed. The principle idea behind our SCAE model is to transform the
original high dimensional omics data into a reduced feature space so that enough
of the interesting complexity can be retained whilst not requiring additional ob-
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servations to further constrain the model. This reduced description of the omics
data is further realised through a regularisation technique within SCAE that
maximises the likelihood of retaining important input signals describing much of
the variance within the data, whilst filtering out the less important and noisy
signals.
The Stacked Sparse Compressed Auto-Encoder (SSCAE) is composed of a
sequence of SCAE trained in a dependent and co-operative manner, where the
hidden feature layer of one model feeds as input to another. The underlying
complexity of omics data is compactly represented with multiple levels of ab-
straction, therefore, we apply a greedy recursive approach to transforming the
input signals containing tens of thousands of genes into a hidden representation
of a lower dimension and higher abstraction, which is then provided as input to
another SCAE, which encodes this further at a higher abstract level and so on.
The resulting abstract hidden layer is then provided as input to the final layer of
SSCAE (i.e. the output layer), which is a softmax classification layer trained to
classify the input as belonging to either a patient with or without cancer.
In addition, we augmented a novel weight interpretation feature into SSCAE
such that we were able to determine which original features on the input layer
were most highly predictive, positively and negatively associated with the positive
patient groups e.g. cancer, ER+/PR+. Therefore, two types of outcomes were
revealed by our deep mining model, both indicating strong likelihoods of a patient
having cancer. The first outcome indicated a subset of highly positively-weighted
genes whereby the amplifications and gains in the gene expression levels were
associated with the likelihood of a patient having cancer. Conversely, the second
outcome revealed another subset of genes that were highly negatively-weighted
and coincided with significant downregulation in the gene expression levels, and
again indicated the strong likelihood of a patient having cancer.
5.2.1 Auto-Encoder
An autoencoder (AE) is a neural network model that is trained to map an input
x into a hidden representation y using an encoding function f , where g is a
decoding function that transforms y to construct z as closely as possible to x.
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The encoder is a non-linear sigmoid function s that transforms the input vector x
into the hidden representation y, which is expressed as fθ(x) = s(Wx + b) with
parameters θ = {W, b}. The weight matrix W is d′ × d, where d corresponds
to the dimension of x and d′ corresponds to the dimension of y, and b is an
offset vector of dimensionality d′. The decoder is a non-linear sigmoid function
s that transforms back the hidden representation y to construct the vector z
of dimensional d, which is expressed as z = gθ(y), where gθ(y) = s(W
′y + b′)
with the parameters θ′ = {W ′, b′}. The learning process relies on finding the
parameters θ that significantly minimise the cost function, which measures the
discrepancy between the original data x and its reconstruction z.
5.2.2 Sparse Compressed Auto-Encoder
A Sparse Compressed Auto-Encoder (SCAE) is an AE that adds sparsity penalty
to the compressed representations to react to distinctive generic features from
HDSSS data. Sparsity refers to render the units of hidden layers to be at or near
zero so that most factors become irrelevant and few are relevant and insensitive to
irrelevant variations. Under-complete or compressed representations corresponds
to that the code dimensions (i.e code refers to the hidden layer with the lowest
number of dimensions that captures the most abstract features encoded) tend to
be smaller than input dimensions. For the SCAE, z is not supposed to be an
exact reconstruction of x, but rather it is meant to be a rough approximation
(within an allowable error tolerance) that is less sensitive to variations from the
training data leading to avoid the risk of overfitting where very low bias and high
variance might be obtained. Moreover, generating a rough approximation will
force the network to learn some kind of meaningful relationships between vari-
ables. Furthermore, placing constraints on the compressed AE leads to activate
hidden neurons in response to given input contributing to distilling effectively
enough of the interesting complexity underlying the representative samples that
can approximate the input distribution.
Let ρˆi =
1
n
∑n
j=1 aixj be the activation of hidden neuron i over a collection of
training examples. Neuron i is considered active if the average activation value
over all the training examples is close to 1, or inactive if the average value over
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all the training examples is close to 0. Enforcing the constraint ρˆi = ρ, where ρ is
the sparsity parameter, which takes a small values close to zero (e.g. ρ = 0.05).
As explained previously, a low activation value means that the hidden neuron
reacts to a small number of the training examples, which means different groups
of hidden neurons assigned to different statistical features. These patterns of
activation can be statistically more efficient since a large number of possible sets
of features can be activated in response to given input. Therefore, a regulariser
is added to the cost function to enforce the values of ρˆi to be low as follows:
Ωsparsity =
d′∑
i=1
ρ log(
ρ
ρˆi
) + (1− ρ) log( 1− ρ
1− ρˆi ). (5.1)
In order to reduce the magnitude of the weights and avoid the risk of overfitting
so that the learned representations rely on the input features rather than the
deep network structure, L2 regularisation term on the weights is added to the
cost function as follows:
Ωweights =
1
2
L∑
l
n∑
j
k∑
i
(W lji)
2, (5.2)
where L is the number of hidden layers, n is the number of examples, and k is
the number of variables. The loss function of training the SCAE is sparse mean
squared error (MSE) function, which is formulated as follows:
MSE =
1
N
N∑
n=1
K∑
k=1
(xkn − zkn)2 + λ× Ωweights + β × Ωsparsity, (5.3)
where λ controls the impact of the weight regulariser in the cost function, and
β controls the impact of the sparsity regulariser in the cost function. When
handling a high dimensional problem, deep network models involve adjustment
of thousands of weights, thus the optimisation techniques should be applicable
to these large-scaled problems. Several research studies [98, 109, 128, 238] have
shown the feasibility of the scale conjugate gradient descent method to deal with
high dimensional problems in an effective way. Therefore, the SCAE is trained
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with scaled conjugate gradient backpropagation method [212].
5.2.3 Stacked Sparse Compressed Auto-Encoder
The Stacked Sparse Compressed Auto-encoder (SSCAE) can be developed using
a series of SCAEs. The encoding procedure of the SSCAE that has l layers
can be expressed as follows: y = fl(...fi(...f1(x))), where fi is the encoding
function of the module i, while the decoding procedure can be defined as: z =
gl(...gi(...g1(y))), where gi is the decoding function of the level i. A series of CV
experiments are conducted to assess the performance of the selected modules and
identify the best performing one based on validation performance. Therefore,
the SSCAE is designed with four layers of dimensions 500, 200, 100, and 50.
Then, the output of the fourth layer is employed to train the softmax layer for
classification by forcing the output layer of the SSCAE to sum to 1, so that
it is forcing backpropagation to be aware of the whole output layer hence this
activation function transforms a vector rather than a scalar (net input) like a
sigmoid function. The SoftMax neural network layer was trained in a supervised
fashion based on the Cross-Entropy (CE) function:
CE =
1
n
n∑
j=1
k∑
i=1
tij ln yij + (1− tij) ln(1− yij). (5.4)
where n is the total number of the training examples, and k is the number of the
response groups, tij is the ijentry of the group matrix, which is k × n matrix,
and yij is the ith output from the SCAE when the input vector is xj. The CE
function of the SoftMax layer is optimised using the scaled conjugate gradient
method [212]. The response group was represented in the output layer coded as
0 for Normal and 1 for Cancer for ovarian cancer dataset. For the METABRIC
dataset with Estrogen Receptor, the response groups were encoded in the out-
put layer as 0 for Negative Estrogen Receptor (ER-) and 1 for Positive Estrogen
Receptor (ER+). For the METABRIC dataset with Progesterone Receptor, the
response groups were encoded in the output layer as 0 for Negative Progesterone
Receptor (PR-) and 1 for Positive Progesterone Receptor (PR+). The SSCAE
is trained in a supervised fashion based on the CE function of Equation 5.4 and
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Figure 5.1: An illustration of the validation performance of the SSCAE.
the SCG optimisation method [212], using the full training set and then it is
validated using the full corresponding validation set, as shown with performance,
represented by the confusion matrix and the ROC curve plots of Figure 5.1 -
(ovarian cancer dataset at fold 1). To account for variance in the performance
estimation, the SSCAE is trained using variant sets of training samples and the
average predictive performance is reported. Furthermore, the performance of
each trained SCAE module is validated using the MSE, between the validation
set and its reconstruction, which is predicted by the SCAE that was trained on
the corresponding training set as shown in Appendix A. The capability to form
deep feature hierarchies by stacking the unsupervised modules with the SoftMax
classifier results in forming highly non-linear representations that preserve the
key determinants within the original data. The high-level representations cap-
ture high-level dependencies between features, and this leads to discovering the
underlying abstractions needed for solving this complex detection problem.
However, due to the multiple levels of transformations that the SSCAE per-
forms to the input features, it is hard to recognise which subsets of genes or
proteins constituted the latent representations of the SSCAE and were responsi-
ble for playing a significant role in deriving such predictions. This may not be
an issue for some domains because it can easily validate the obtained results.
However, providing explainability to disease diagnosis and prognosis systems is
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a crucial factor to develop a reliable prediction system that can be employed in
clinical practice. Furthermore, stating which phenotypes are responsible for such
predictions increases the certainty in the decision-making process. The difficulty
of deconstructing DL methods remains a major obstacle for employing these ad-
vance techniques in omics data analysis for the goal of biomarker identification.
In this research project, a new interpretation method called deep mining is in-
troduced to decode the mechanism of the SSCAE so that a reduced set of highly
predictive and reliable biomarkers can be derived effectively.
5.2.4 A New Weight Interpretation Method
Several hypotheses, that have been proposed in the literature to justify why the
unsupervised pre-training approach works well, highlighted the importance of
finding the appropriate weights in guiding the learning process towards discover-
ing a good representation similar to the optimisation [177] and regularisation [87]
hypotheses. The learning process of DL models can be described as fitting weight
parameters in a way that can significantly minimise the loss function. For a shal-
low AE, the weight of each variable reflects its contribution on the node’s activity
so that the signal with a larger weight has a greater impact. However, given the
deep architecture of the SSCAE, how can we measure the contribution of each
feature?
When the SSCAE model is trained using the training set, the classification
errors can be back-propagated through the layers of the SSCAE to the input
layer to estimate the individual contribution of each variable. That mean that
the impact of each variable on the classification accuracy is forward-propagated
from the input layer through the layers of the Deep network. Since the weight
is the main indicator of variables importance, the relevancy of each feature can
be detected through leveraging the Input Weight matrix of the SSCAE, with its
Layers Weight matrices. The Input Weight matrix (IW) of the SSCAE is d′× d,
where d corresponds to the dimension of x and d′ corresponds to the dimension of
y(1). The Layer Weight matrix (LWi) of layer l
(i) of the SSCAE is d′ × d, where
d corresponds to the dimension of y(i−1) and d′ corresponds to the dimension of
y(i), and for L layers of the SSCAE. Therefore, leveraging the (IW) of the SSCAE
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Figure 5.2: Histogram of z-scores of the weight vector.
with its Layers Weight (LWs) matrices results in defining the importance of each
variable and as follows:
DM = IW>
L∏
i=1
LW>i . (5.5)
which results in a d×1 weight vector called DM, where d corresponds to the num-
ber of features in the original datasets. Therefore, each gene has a weight score
that indicates its integrated impact over the depth of the SSCAE and reflects
its contribution. The weights of the features in DM are distributed symmetri-
cally and roughly center at 0, and the weight vector DM resembles a normal
distribution, as shown in Figure 5.2 - (ovarian cancer dataset at fold 1). A small
percentage of features in the DM exhibit High Positive (HP) or High Negative
(HN) weight, as shown in Figure 5.2. Two lists of genes with a length of the code
dimension (i.e. 50): 1) with HP weight and 2) with HN weight are detected.
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To examine the consistency of feature extraction of the SSCAE together with
the deep mining model across the variations in the training data, k weight vectors
DMs are obtained over CV iterations, thus k lists of genes with HP weight and
k lists of genes with HN weight are generated. The positive lists are compared to
find the most frequently selected predictors and the negative lists are examined
to declare the most consistently detected predictors. As mentioned previously in
Section 2.10, the generalisability criterion can be considered the highest valida-
tion tool for verifying the outcomes of the feature mining models proposed for
biomarker identification from omics data. Therefore, the discovered subsets of
consistently selected predictors with HP weight are examined to detect generic
molecular markers across multiple independent datasets. By the same way, the
identified subsets of stable predictors with HN weight are investigated to detect
a generic subset of biomarkers over a wide range of independently generated data
samples.
This weight interpretation method expands our deep learning model to include
a feature selection method in addition to the feature extraction capacity already in-
herent within this paradigm. As a result, two smaller subsets of robust molecular
markers are produced, one corresponding to those genes that are highly expressed
for most of the patients from the positive group compared to the negatives; and
the other subset refers to those genes that are highly expressed for most of the
samples in the negative group compared to the positives. Our novel deep mining
model provides yet another arrow within the quiver of bioinformaticians for dis-
covering and evaluating new biomarkers that may help further the endeavour of
producing more effective and personalised medicine.
5.3 Results and Discussion
This section presents the analysis performed to evaluate the empirical perfor-
mance of the proposed SSCAE and deep mining model. Firstly, the strati-
fied 5−fold CV procedure was used to randomly partition each dataset into 10
training-validation random splits, as illustrated in Appendix A. At each itera-
tion, the SSCAE was applied to the training dataset, in order to learn compact
and meaningful representations from its high dimensional space for developing
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a robust DL prediction model. The performance of the SSCAE was validated
using the corresponding validation set, as illustrated in Appendix B, and the
average AUC is reported over iterations. Each trained SCAE module was also
assessed using the MSE, between the validation set and its reconstruction, which
was predicted by the SCAE that was trained using the corresponding training set
as shown in Appendix A.
Simultaneously, the proposed deep mining model was applied at each iteration
to define two lists of candidate features with HP and HN weight. Over CV
iterations, the five identified groups of features with HP weight were compared
to provide a subset of stable predictors for each dataset and by the same way, a
subset of stable predictors with HN weight was produced. The subsets of stable
predictors with HP weight were examined and the subsets of stable predictors
with HN weight were compared to define generic molecular markers across a
wide range of independently generated data samples. The discovered subsets of
the generic biomarkers with HP and HN weight were used to build prediction
models individually and collectively using the SVM and BDT classifiers in order
to evaluate their relevance to the clinical outcomes.
5.3.1 Results and Discussion of Ovarian Cancer Dataset
This section presents and discusses the experimentally obtained results of apply-
ing the proposed SSCAE and deep mining model to the ovarian cancer dataset,
(which is discussed in Section 3.6). Initially, the 5−fold CV procedure was utilised
to divide the dataset randomly into 10 random partitions, as shown in Appendix
A - Table 1. At each iteration, the SSCAE was trained using the training observa-
tions and validated using the corresponding validation set, as shown in Appendix
B - Figure 1, represented by the confusion matrix and the ROC curve plot of
the SSCAE for the final iteration. The average AUC of the SSCAE over CV
iterations is 0.9843. The high performance of the SSCAE reveals that this deep
feature learning model was able to discover a relevant and robust representation
from the ovarian cancer data, thus a highly accurate and reliable prediction model
was formed. Furthermore, the performance of each trained SCAE module was
also evaluated using the MSE between the validation set and its reconstruction
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Figure 5.3: Scatter plots matrix of the stable predictors (index) with HP weight
of ovarian cancer dataset.
as shown in Appendix A - Table 2.
Simultaneously, the deep mining model was executed at each iteration to de-
cipher which combination of key features constituted the latent representations
of the SSCAE. Examining the ten obtained lists of proteins resulted in finding 6
stable predictors with HP weight, as shown in Figure 5.3 and 13 stable predictors
with HN weight, as shown in Figure 5.4. The biomarkers were plotted in the
X-axis and Y-axis ascendingly, using their index, as illustrated in Figures 5.3,
with HP weight and 5.4 with HN weight. At this point, it is relevant to observe
that the intensity values of the stable proteins with HP weight for the patients
who suffer from cancer are more likely to be higher than their intensity values
for most of the normal samples, contrary to the intensity distributions of the
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Figure 5.4: Scatter plots matrix of the stable predictors (index) with HN weight
of ovarian cancer dataset.
stable proteins with HN weight, where their values for the normal observations
are more likely to be higher than their intensity values for most of the ovarian
cancers. Firstly, this demonstrates the efficiency of the proposed SSCAE to cap-
ture intrinsic structure in serum (blood)-derived proteomic data. Secondly, it is
a strong indicator that the proposed deep mining model was able to deconstruct
the SSCAE and interpret its weight matrices effectively, so that the proteomic
patterns that can differentiate between the patients with ovarian cancer from the
women without ovarian cancer were detected in two forms.
The subsets of stable predictors, that are shown in Figures 5.3 and 5.4, were
used separately and collectively to construct the SVM and BDT classifiers and
the average performance of these prediction models is presented in Table 5.1.
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The obtained results show that both classification models achieved a high-level
of accuracy, using the ensemble subset of stable predictors with HP and HN
weight (i.e. All). The experimentally obtained outcomes of METABRIC dataset
is presented in the following section along with a detailed discussion.
5.3.2 Results and Discussion of METABRIC Dataset
This section presents and discusses the experimental outcomes of applying the
SSCAE and deep mining model to the METABRIC dataset with ER and PR
groups, (which is illustrated in Section 3.5). Initially, the 5−fold CV proce-
dure was utilised to divide the dataset randomly into non-overlapping training-
validation sets, as shown in Appendix A - Table 1. At each iteration, the SSCAE
was trained using the training dataset and validated using the corresponding
validation observations as shown in Appendix B - Figure 1 represented by the
confusion matrices and the ROC curve plots of the SSCAE for the final iteration.
The average AUCs of the SSCAE over CV iterations are 0.9884 and 0.9380 for
ER and PR groups respectively. The outcomes of our experiments reveal that the
newly learned features by the SSCAE contributed to developing a highly accu-
rate and robust prediction model. Furthermore, the performance of each trained
SCAE module was validated using the MSE between the validation set and its
reconstruction as shown in Appendix A - Table 2.
For ER groups, the application of the deep mining model, based on the inter-
nal validation over variant groups of samples, generated a subset of 25 consistently
selected predictors with HP weight, to be associated with ER groups, as shown in
Figure 5.5. The mRNA markers were plotted in the X-axis and Y-axis alphabet-
ically using their names, as illustrated in Figure 5.5. This figure illustrates how
the expression levels of the detected genes with HP weight differ significantly be-
Table 5.1: The performance of the SVM and BDT models built on the stable
predictors of ovarian cancer dataset.
SVM-HP SVM-HN SVM-All BDT-HP BDT-HN BDT-All
0.8886 0.8975 0.9227 0.8726 0.8828 0.8964
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Figure 5.5: Scatter plots matrix of the stable predictors with HP weight of
METABRIC dataset with ER groups.
tween ER-positives and ER-negatives. Furthermore, the examination of the five
discovered subsets of candidate genes with HN weight produced 7 stable predic-
tors, as presented in Figure 5.6. As mentioned previously, the mRNA markers
were plotted in the X-axis and Y-axis alphabetically using their names, as illus-
trated in Figure 5.6. It can be observed in this figure that the expression levels
of the recognised set of stable genes with HN weight for the patients with ER+
tumours are more likely to be lower than their expression levels for most of the
samples from ER- group.
For PR groups, investigating the consistency of selection of the proposed SS-
CAE together with the deep mining model resulted in finding 6 consistently
selected predictors with HP weight, as shown in Figure 5.7. The discovered mR-
NAs were plotted in the X-axis and Y-axis alphabetically using their names, as
illustrated in Figure 5.7. This figure demonstrates the discrimination power of
these robust genes to differentiate the patients with PR-positive tumours from
PR- samples effectively. Moreover, the comparison of the selected lists of candi-
date mRNAs with HN weight led to identifying 5 stable predictors as illustrated
in Figure 5.8. The discovered mRNAs were plotted in the X-axis and Y-axis
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Figure 5.6: Scatter plots matrix of the stable predictors with HN weight of
METABRIC dataset with ER groups.
alphabetically using their names, as illustrated in Figure 5.8. It can be observed
in this figure that the expression levels of the discovered set of stable genes with
HN weight are more likely to be higher for the PR-negatives than most of the
patients from PR+ group, as shown in Figure 5.8.
Herein, it is very important to observe that the expression levels of HP
weighted mRNA markers are more likely to be higher for the patients with
ER+/PR+ tumours than most of the ER/PR-negative samples, as shown in
Figures 5.5 and 5.7. In contrast, the biomarkers with HN weight exhibit higher
expression levels for the observations from ER-/PR- groups, compared to the
ER/PR-positive patients, as shown in Figures 5.6 and 5.8. This mechanism
has also been recognised with the experimental outcomes of the ovarian cancer
dataset, where HP weighted proteins exhibit high intensity values for the cancer
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Figure 5.7: Scatter plots matrix of the stable predictors with HP weight of
METABRIC dataset with PR groups.
patients, compared to the normal samples in contrast to the discovered proteins
with HN weight, which show low intensity values for the cancers, in comparison
to the normals. Thus, this is significant evidence that verifies firstly the effec-
tiveness of the SSCAE to discover robustly differentially expressed genes from
HDSSS genomic data and assign reliably HP and HN weight to these potential
biomarkers. Secondly, this demonstrates the capability of deep mining model to
interpret the weight matrices of the SSCAE and identify effectively the key genes
underlying its latent representation that are positively and negatively associated
with breast cancer and ER/PR positivity.
The SVM and BDT classifiers were trained using the selected subsets of stable
mRNA markers with HP and HN weight separately and collectively. The predic-
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Figure 5.8: Scatter plots matrix of the stable predictors with HN weight of
METABRIC dataset with PR groups.
tive performance of the learning models was validated using the corresponding
Table 5.2: The performance of the SVM and BDT models built on the stable
predictors of METABRIC dataset with ER and PR groups.
The subset of SVM BDT
HP genes with ER 0.9820 0.9853
HN genes with ER 0.9023 0.8838
All genes with ER 0.9855 0.9850
HP genes with PR 0.9825 0.9815
HN genes with PR 0.7290 0.7143
All genes with PR 0.9815 0.9824
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validation set and the average AUCs over CV iterations are presented in Table 5.2.
For ER groups, the experimental outcomes show that the HP weighted biomarkers
contributed to constructing more highly accurate and robust prediction models
than HN weighted biomarkers, and integrating the subsets has improved the per-
formance of SVM model only very slightly. Similar findings were also obtained
for PR groups, such that the performance of the classification models built on
the HP weighted biomarkers is significantly higher than its performance when
trained using the mRNA markers with HN weight. Moreover, integrating both
subsets has improved the performance of the BDT model only and very slightly.
5.3.3 Results and Discussion of Breast Invasive Carci-
noma Datasets
This section presents and discusses the application of the proposed SSCAE to-
gether with deep mining interpretation method to the breast invasive carcinoma
datasets: (Nature 2012), (Cell 2015), and (Provisional), which are explained re-
spectively in Sections 3.3.1, 3.3.2, 3.3.3. Initially, the 5−fold CV procedure was
employed to partition each dataset into 10 random training-validation sets, as
shown in Appendix A - Table 3, with ER groups and Table 4 with PR groups. At
each iteration, the SSCAE was trained using the training samples and validated
using the corresponding validation samples, as shown in Appendix B - Figures
2, with ER groups and 3 with PR groups, represented by the confusion matrices
and the ROC curve plots of the SSCAE for the final iteration. Then, the average
predictive performance of the SSCAE is introduced. Furthermore, the perfor-
mance of each trained SCAE module was validated using the MSE between the
validation set and its reconstruction, as shown in Appendix A - Table 5, with ER
groups and Table 6 with PR groups. The outcomes of our experiments for ER
and PR groups will be discussed in the following subsections.
5.3.3.1 ER Groups
The aim of applying the proposed SSCAE to the breast invasive carcinoma
datasets is to extract relevant knowledge for estimating the status of ER. There-
fore, the predictive performance of the SSCAE was assessed using AUC as shown
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in Table 5.3. The obtained results reveal that the SSCAE achieved high-levels
of generalisation and robustness for all of the datasets, which provides strong
evidence that very useful representations were discovered.
The deep mining model based on the internal validation approach was ap-
plied to interpret the weight matrices of the SSCAE. As a result, a subset
of consistently selected predictors with HP weight and a subset of stable pre-
dictors with HN weight, were generated over iterations for each breast can-
cer dataset. Then, the external validation approach was applied to examine
the potential of the proposed SSCAE and deep mining model to generalise to
wider populations. Thus, the outcome was that 16 mRNA markers with HP
weight were found to be generic across the datasets. The generic biomarkers
are: {‘AGR3‘, ‘ESR1’, ‘GFRA1’, ‘SIAH2’, ‘SLC39A6’, ‘SCUBE2’, ‘C6orf97’,
‘ANXA9’, ‘CA12’, ‘NAT1’, ‘GATA3’, ‘PCP2’, ‘FSIP1’, ‘EVL’, ‘LRRC56’, ‘IG-
FALS’}, as shown in Figure 5.9. The discovered mRNAs were plotted in the
X-axis and Y-axis alphabetically using their names, as illustrated in Figure 5.9.
Furthermore, applying the generalisability criterion resulted in finding 16 mRNA
markers with HN weight to be generic across (Nature 2012), (Cell 2015) and
(Provisional) datasets. The generic biomarkers are: {‘PSAT1’, ‘PPP1R14C’,
‘TMEM40’, ‘VGLL1’, ‘C1orf106’, ‘BBOX1’, ‘SOX11’, ‘PROM1’, ‘DKK1’, ‘PAR-
RES1’, ‘S100A8’, ‘S100A9’, ‘TRPV6’, ‘B3GNT5’, ‘KRT16’, ‘KRT81’}, as shown
in Figure 5.10. As mentioned previously, the discovered mRNAs were plotted in
the X-axis and Y-axis alphabetically using their names, as illustrated in Figure
5.10.
Both Figures 5.9 and 5.10 illustrate the capability of the identified biomarkers
with HP and HN weight to separate the patients with ER+ tumours from the ER-
Table 5.3: The performance of the SSCAE of the breast invasive carcinoma
datasets with ER groups.
Dataset AUC
(Nature 2012) 0.9404
(Cell 2015) 0.9406
(Provisional) 0.9385
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Figure 5.9: Scatter plots matrices of the generic biomarkers with HP weight of
the breast invasive carcinoma datasets with ER groups.
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Figure 5.10: Scatter plots matrices of the generic biomarkers with HN weight of
the breast invasive carcinoma datasets with ER groups.
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samples over all the datasets. Herein, it is important to observe that the generic
biomarkers with HP weight are highly expressed for the observations from ER+
group compared to the ER- samples, as shown in Figure 5.9. In contrast, the HN
weighted mRNA markers are highly expressed for the ER-negatives compared
to the ER-positives, as shown in Figures 5.10. This has also been recognised
with the ovarian cancer dataset in Section 5.3.1 and the METABRIC dataset
in Section 5.3.2. Therefore, there is a high potential that HP weight had been
assigned by the SSCAE to the differentially expressed genes or proteins whose
values for the positive cases are more likely to be higher than their values for
the negatives. While the SSCAE had assigned HN weight to the deferentially
expressed genes or proteins whose levels for the negative samples are more likely
to be higher than their levels for the positive patients. Firstly, this mechanism
demonstrates the potential of the SSCAE to exploit the unknown structure of
genomic and proteomic data and capture high-level abstract and generic features.
Secondly, this is strong evidence that supports the validity of the new weight
interpretation method to overcome the issue of poor explanatory power associated
with the deep learning and aid the researcher in opening up the so-called black
box of the network to ascertain which genes were dominant within its internal
representations.
The relevancy of the discovered subsets of the generic mRNA markers with
HP and HN weight to the status of ER was evaluated individually and collectively
using the SVM and BDT classifiers. The average predictive performance of both
prediction models is shown in Table 5.4. The obtained results reveal that SVM
and BDT models built on the generic biomarkers with HP weight achieved higher
levels of performance than when they were trained using the generic biomarkers
Table 5.4: The performance of the SVM and BDT models built on the generic
biomarkers of the breast invasive carcinoma datasets with ER groups.
Dataset SVM-HP SVM-HN SVM-All BDT-HP BDT-HN BDT-All
(Nature 2012) 0.9331 0.8695 0.9304 0.9052 0.8585 0.9034
(Cell 2015) 0.9340 0.8673 0.9340 0.9177 0.8726 0.9300
(Provisional) 0.9388 0.8714 0.9233 0.8847 0.8650 0.9244
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with HN weight. Furthermore, the ensemble subset of the generic biomarkers (i.e.
All) has improved only the predictive performance of the BDT model for (Cell
2015) and (Provisional) datasets. The application of the SSCAE together with
the deep mining model based on the defined assessment criterion: predictivity,
stability, and generalisability to the breast invasive carcinoma datasets produced
two subsets of relevant, robust, and reproducible biomarkers. In this research, it
has been shown how the discovered mRNA markers with HP weight exhibit a pos-
itive association with ER positivity where an inverse association was recognised
between the identified biomarkers with HN weight and high ER levels. A detailed
discussion about the type of relationship between the discovered biomarkers and
breast cancer and ER/PR positivity will be overviewed in Chapter 6.
5.3.3.2 PR Groups
The proposed SSCAE was also applied to the breast invasive carcinoma datasets
to capture relevant knowledge for estimating the status of PR. Therefore, at each
iteration, the SSCAE was trained using the training set and validated using the
corresponding validation observations and its average predictive performance is
shown in Table 5.5. The empirical outcomes show the capability of the SSCAE to
estimate the status of PR over all the datasets with a good-level of predictivity,
which reflects the usefulness of the newly discovered features.
Afterwards, the deep mining model based on the internal validation approach
was applied to identify a subset of consistently selected predictors with HP weight
and a subset of stable predictors with HN weight for each dataset. The inves-
tigation of the generalisation capability of the SSCAE together with the deep
mining model led to detect 10 generic mRNA markers with HP weight across
Table 5.5: The performance of the SSCAE of the breast invasive carcinoma
datasets with PR groups.
Dataset AUC
(Nature 2012) 0.8892
(Cell 2015) 0.8975
(Provisional) 0.8846
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(Nature 2012), (Cell 2015) and (Provisional) datasets. The biomarkers are:
{‘FGD3’, ‘GFRA1’, ‘GRPR’, ‘PGR’, ‘SUSD3’, ‘GREB1’, ‘SIAH2’, ‘SCUBE2’,
‘AGR3’, ‘PGLYRP2’}, as shown in Figure 5.11. The discovered mRNAs were
plotted in the X-axis and Y-axis alphabetically using their names, as illustrated
in Figure 5.11. Furthermore, 10 generic mRNA markers with HN weight were
detected across the breast invasive carcinoma datasets, which are: {‘LAD1’,
‘ATP6V0A4’, ‘NXPH1’, ‘C9orf58’, ‘CLCA2’, ‘FGFR4’, ‘PPP1R1A’, ‘TRPV6’,
‘C1orf115’, ‘TSPAN8’}, as shown in Figure 5.12. The discovered mRNAs were
plotted in the X-axis and Y-axis alphabetically using their names, as illustrated
in Figure 5.12. Figure 5.11 and Figure 5.12 illustrate the capability of the subsets
of discovered biomarkers with HP and HN weight to distinguish the patients with
PR+ tumours from the PR-negative samples over all the datasets.
In these matrices of plots, we can also observe that the expression levels of
HN weighted mRNAs for the PR-negatives are generally higher than their ex-
pression levels for the patients with PR+ tumours, as shown in Figure 5.12, in
contrast to the HP weighted biomarkers whose expression levels for the patients
from the PR+ group are more likely to be higher than most of the samples from
PR- group, as shown in Figure 5.11. The consistency of obtaining this decoding
pattern demonstrates the effective mechanism of the deep mining model for open-
ing up the black box of the SSCAE in a steady way. For further verification, the
performance of the SVM and BDT classifiers trained using the training set that
contains only the selected subsets of the generic biomarkers (separately and collec-
tively) was validated using the corresponding validation set. The average AUCs
over CV iterations are shown in Table 5.6. The outcomes of our experiments
reveal that the SVM and BDT classifiers trained using the generic biomarkers
Table 5.6: The performance of the SVM and BDT models built on the generic
biomarkers of the breast invasive carcinoma datasets with PR groups.
Dataset SVM-HP SVM-HN SVM-All BDT-HP BDT-HN BDT-All
(Nature 2012) 0.8428 0.8040 0.8532 0.8564 0.7885 0.8588
(Cell 2015) 0.8432 0.7994 0.8469 0.8654 0.7990 0.8637
(Provisional) 0.8566 0.8042 0.8521 0.8683 0.8038 0.8726
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Figure 5.11: Scatter plots matrices of the generic biomarkers with HP weight of
the breast invasive carcinoma datasets with PR groups.
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Figure 5.12: Scatter plots matrices of the generic biomarkers with HN weight of
the breast invasive carcinoma datasets with PR groups.
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with HP weight achieved higher levels of performance than when they trained
using the generic biomarkers with HN weight. Furthermore, the integration of
the biomarkers with HP and HN weight (i.e. All) has generally improved the
predictive performance of both classification models very slightly. The utilisation
of the SSCAE to derive cancer markers from breast invasive carcinoma datasets
led to construct accurate and reliable prediction systems. Furthermore, the deep
mining interpretation method contributed adding the explanatory power to that
deep feature learning model and identify two subsets of salient, invariant, and
generic mRNA markers that are associated positively and negatively to breast
cancer and PR positivity.
5.3.4 Results and Discussion of Integrated Breast Invasive
Carcinoma Datasets
The presented SSCAE was applied to the integrated breast invasive carcinoma
datasets with ER groups: NCP1, NCP2, NCP3, which are illustrated respec-
tively in Sections 3.4.1.1, 3.4.1.2, 3.4.1.3. Moreover, the SSCAE was utilised to
learn useful representations from the integrated datasets: NC, CN, NP, PN, CP,
PC, which are explained respectively in Sections 3.4.2.1, 3.4.2.2, 3.4.2.3, 3.4.2.4,
3.4.2.5, 3.4.2.5 for estimating the status of PR. Initially, the 5−fold- CV procedure
is employed to partition each integrated dataset into 10 training-validation sets,
as shown in Appendix A - Tables 7 with ER groups and 8 with PR groups. At
each iteration, the SSCAE was trained using the training samples and validated
using the corresponding validation samples, as shown in Appendix B - Figure 4
with ER groups and Figures 5 and 6 with PR groups, represented by the con-
fusion matrices and the ROC curve plots of the SSCAE for the final iteration.
Furthermore, the performance of each trained SCAE module was validated using
the MSE between the validation set and its reconstruction, as shown in Appendix
A - Table 9 with ER groups and Table 10 with PR groups. The obtained results
of applying the SSCAE to the integrated datasets with ER and PR groups are
presented in the following sections.
120
5. Deep Mining Model
5.3.4.1 ER Groups
The SSCAE was applied to the integrated datasets: NCP1, NCP2, NCP3 for
predicting the status of ER based on learning high-level relevant features. The
average predictive performance of the SSCAE over CV iterations is shown in Table
5.7. The outcomes of our experiments reveal that the SSCAE is performing as a
highly predictive and robust classification model, which reflects its capability to
learn deeply high-level abstract features that fully recovered the data. In addition,
the experimental outcomes show an improvement in the predictive performance
of the SSCAE when trained using the integrated datasets: NCP1, NCP2, NCP3,
compared with its performance using the breast invasive carcinoma datasets with
ER groups separately as shown in Table 5.3. This demonstrates the importance of
having more substantial data and enough representative samples for each response
group for achieving higher-levels of generalisation.
The proposed deep mining model based on the internal and external validation
was also applied to the integrated datasets with ER groups to detect potential
biomarkers on the basis of stability and generalisability. As a result, 12 mRNA
markers with HP weight were found to be generic across the datasets: NCP1,
NCP2, NCP3. The biomarkers are: {‘AGR3’, ‘ANXA9’, ‘C6orf97’, ‘ESR1’,
‘GFRA1’, ‘NAT1’, ‘PCP2’, ‘SIAH2’, ‘SLC39A6’, ‘SCUBE2’, ‘CA12’, GATA3’},
as shown in Figure 5.13. The biomarkers were plotted in the X-axis and Y-axis
alphabetically according to their names, as illustrated in Figure 5.13. This Fig-
ure illustrates the potential of the discovered biomarkers to separate the samples
with ER-positive tumours from the ER-negatives effectively. Moreover, the com-
parison of the identified subsets of stable predictors with HN weight produced 16
generic mRNAs which are {‘B3GNT5’, ‘BBOX1’, ‘Clorf106’, ‘DKK1’, ‘HRASLS’,
Table 5.7: The performance of the SSCAE of the integrated datasets with ER
groups.
Dataset AUC
NCP1 0.9819
NCP2 0.9881
NCP3 0.9886
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‘KRT16’, ‘PPP1R14C’, ‘PPP1R1A’, ‘PROM1’, ‘PSAT1’, ‘PARRES1’, ‘S100A8’,
‘S100A9’, ‘SOX11’, ‘TMEM40’,‘VGLL1’}, as illustrated in Figure 5.14. The mR-
NAs were plotted in the X-axis and Y-axis alphabetically according to their
names, as illustrated in Figure 5.14. This Figure presents the ability of the
detected genes to discriminate the patients with ER+ tumours from the obser-
vations in the ER-negative group effectively.
Herein, with the integrated datasets: NCP1, NCP2, NCP3, we can also ob-
serve that the SSCAE had assigned HP weight to the differentially expressed
genes, which exhibit higher expression levels for the ER+ patients, in compari-
son to their expression levels for the ER-negatives, as shown in Figure 5.13. In
contrast, the HN weights had been assigned to the key genes that are highly
expressed for the ER-negative samples compared to their expression levels for
the ER-positives, as shown in Figure 5.14. This is another strong evidence that
demonstrates firstly the efficacy of the SSCAE to distil relevant variations from
the large and noisy feature spaces of genomic data. Secondly, it promotes the va-
lidity of the proposed deep mining model as a powerful interpretation method that
can deconstruct the internal state of such deep feature learning models and add
explainability for the goal of identifying highly predictive and robust biomarkers
that are related to the disease and the clinical outcome in two forms.
To investigate the predictivity of the discovered subsets of generic biomark-
ers, the performance of the SVM and BDT classifiers built on these subsets of
mRNA markers separately and collectively was validated using the corresponding
validation set and the average AUCs are shown in Table 5.8. Our experimental
obtained results reveal that the SVM and BDT classification models, trained us-
ing the generic biomarkers with HP weight achieved higher-levels of predictive
Table 5.8: The performance of the SVM and BDT models built on the generic
biomarkers of the integrated datasets with ER groups.
Dataset SVM-HP SVM-HN SVM-All BDT-HP BDT-HN BDT-All
NCP1 0.9305 0.8843 0.9328 0.9652 0.9631 0.9664
NCP2 0.9323 0.8879 0.9323 0.9675 0.9661 0.9722
NCP3 0.9341 0.8846 0.9363 0.9710 0.9726 0.9735
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Figure 5.13: Scatter plots matrices of the generic biomarkers with HP weight of
the integrated datasets with ER groups.
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Figure 5.14: Scatter plots matrices of the generic biomarkers with HN weight of
the integrated datasets with ER groups.
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accuracy than when they were constructed using the generic biomarkers with HN
weight. Furthermore, generally, the predictive performance of SVM and BDT
classifiers is improved slightly when they trained using the integrated subset of
generic biomarkers. The outcomes of our experiments also show that the BDT
classification model performed better than the SVM classifier using the integrated
datasets, in comparison to its performance using the breast invasive carcinoma
datasets separately, which reflects the significant impact of having more substan-
tial data, whose response groups are well-balanced on the performance of that
learning model.
5.3.4.2 PR Groups
The SSCAE was also applied to the integrated datasets: NC, CN, NP, PN, CP,
PC, in order to detect relevant features for estimating the status of PR and
the average AUC of the SSCAE is presented in Table 5.9. The outcomes of
our experiments confirm discovering very useful knowledge by the SSCAE by
achieving high-levels of generalisation and robustness for all of the integrated
datasets, as shown in Table 5.9. Furthermore, the obtained results show an
improvement in the generalisation ability of the SSCAE using the integrated
dataset: NC, CN, NP, PN, CP, PC, compared with its performance using the
breast invasive carcinoma datasets with PR groups separately, as shown in Table
5.5. Therefore, the construction of the SSCAE using more substantial data whose
response groups are well-represented can have the great potential to improve the
performance of that deep learning model.
The proposed deep mining model was applied based on the stability and gen-
eralisability criterion to detect HP and HN weighted genes. The obtained results
from our experiments show that 8 mRNA markers with HP weight were found
to be generic across the integrated datasets: NC, CN, NP, PN, CP, PC. The
Table 5.9: The performance of the SSAE of the integrated datasets with PR
groups.
NC CN NP PN CP PC
0.9584 0.9667 0.9647 0.9786 0.9661 0.9527
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Figure 5.15: Scatter plots matrices of the generic biomarkers with HP weight of
the integrated datasets with PR groups.
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Figure 5.16: Scatter plots matrices of the generic biomarkers with HN weight of
the integrated datasets with PR groups.
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biomarkers are: {‘GFRA1’, ‘GRPR’, ‘PGLYRP2’, ‘PGR’, ‘SIAH2’, ‘SUSD3’,
‘FGD3’, ‘GREB1’}, as shown in Figures 5.15. Furthermore, six mRNAs were
found to be generic across the integrated datasets with PR groups. These biomark-
ers are: {‘ATP6V0A4’, ‘NXPH1’, ‘CLCA2’, ‘FGFR4’, ‘LAD1’, ‘C9orf58’}, as il-
lustrated in Figure 5.16. The discovered biomarkers were plotted in the X-axis
and Y-axis alphabetically according to their names, as shown in Figure 5.15 and
Figure 5.16. These Figures illustrate the capability of the recognised mRNAs to
discriminate the samples with PR+ tumours from those in PR- group efficiently.
Furthermore, it can also recognise the consistency of the SSCAE over multiple
independent datasets in assigning HP weight to the deferentially expressed mR-
NAs, whose levels for the PR+ patients are high compared to the PR-negatives,
whereas HN weight had been assigned by the SSCAE to the mRNA markers that
are lowly expressed for the PR-positives, in comparison to the PR-negatives.
These findings assert firstly the feasibility of the SSCAE as an effective feature
learning model that can deeply capture intrinsic structure from HDSSS omics
data. Secondly, our outcomes demonstrate the validity and capability of the
proposed deep mining model for providing explainability to such deep learning
models, which is a crucial element of prediction systems used by health practi-
tioners and decision-making professionals.
The predictive performance of the SVM and BDT classification models built
on training samples restricted to the identified subsets of generic biomarkers (sep-
arately and collectively) was validated using the corresponding validation samples
and the average AUCs are shown in Table 5.10. The obtained results reveal that
Table 5.10: The performance of the SVM and BDT models built on the generic
biomarkers of the integrated datasets with PR groups.
Dataset SVM-HP SVM-HN SVM-All BDT-HP BDT-HN BDT-All
NC 0.8804 0.8195 0.8929 0.9372 0.8728 0.9327
CN 0.8743 0.8132 0.8806 0.9364 0.8728 0.9345
NP 0.8744 0.8167 0.8830 0.9387 0.8889 0.9371
PN 0.8805 0.8242 0.8919 0.9531 0.8921 0.9530
CP 0.8757 0.8162 0.8888 0.9132 0.8724 0.9357
PC 0.8818 0.8302 0.9005 0.9401 0.8713 0.9371
128
5. Deep Mining Model
the subset of generic biomarkers with HP weight contributed to constructing
more highly accurate and robust prediction systems than the subset of generic
biomarkers with HN weight. Furthermore, the integration of the subsets (i.e. All)
has improved the predictive performance of SVM and BDT models slightly. The
obtained results also reveal that the predictive performance of the BDT classifier
is consistently higher than the SVM model for the integrated datasets with ER
and PR groups overall the subsets of generic biomarkers.
5.4 Discussion
This chapter investigated the value of applying state-of-the-art DL methods to
the problem of automatically determining salient biomarkers of cancers of in-
terest from HDSSS omics data. Therefore, the outcome of our investigations
was proposing the SSCAE on the basis of multiple levels of sparse and com-
pressed representations of increasing abstractions, in order to mitigate against
the key challenges that arise from handling HDSSS omics data. In addition, a
novel method of interpreting the internal state of the SSCAE was developed and
proved invaluable for detecting what these deep feature learning models had de-
termined to be salient biomarkers. Considering the challenging issues of HDSSS
omics data, the SSCAE was able to capture enough of the interesting complexity
underlying the available biological samples and spell out a small proportion of
relevant and insensitive factors, therefore the generic biomarkers were discovered
robustly across a wide range of independently generated breast cancer samples.
Furthermore, the empirical findings of our research emphasise the importance of
using more substantial data whose response groups are well-balanced when opti-
mising deep neural networks for high-levels of generalisability and robustness.
The introduction of the new weight interpretation method proposed in this
chapter proved to be very effective in opening up the black box of SSCAE for this
particular task. A detailed evaluation of the SSCAE weights revealed that the
deep neural network had assigned HP weight to those genes, whose expression
levels are more likely to be higher for the positive samples than for the negative
samples. Likewise, the deep network had assigned HN weight for the biomarkers,
whose expression levels are more likely to be higher for the negative samples
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than for the positives. This provides a robust discriminative basis with which
to accurately classify positive and negative samples. The experimental outcomes
provide strong evidence that the proposed deep mining model introduced in this
chapter, is able to robustly identify salient, invariant and generic biomarkers for
breast cancer. The clinical relevance of the detected biomarkers will be discussed
in the following chapter.
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Biomarkers and Bioinformatics
6.1 Introduction
The main objective of validating and evaluating the proposed feature mining
models is to assess their ability to discover robustly relevant knowledge to the
cancers of interest from the HDSSS genomic and proteomic data. Therefore, the
discovered biomarkers for breast cancer and the hormone receptors ER and PR
were estimated in the previous chapters in terms of predictivity, stability, and
reproducibility over multiple datasets that were independently generated and de-
rived from different sets of biological samples. The outcomes of our experiments
reveal that the discovered biomarkers demonstrate computational and biologi-
cal relevance as well as the capability to construct highly accurate and reliable
prediction models. These findings were proved using the most suitable quality
assessment metrics, unlike many biomarker discovery models proposed in the
literature which lacked the utilisation of robust evaluation and independent ex-
perimental validation. Since publicly available genomic and proteomic datasets
are utilised in this research, thus all the required information is provided to allow
the reproducibility of the results.
In addition to the assessment metrics, the verification of the clinical relevance
of the detected biomarkers to breast cancer, ER and PR is another crucial step
that should be adopted to indicate the scientific quality. The assessment of the
clinical relevance of newly discovered biomarkers to a disease or clinically rele-
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vant conditions is usually conducted by bioinformatics studies. Therefore, the
discovered biomarkers will be evaluated in this chapter with respect to their rele-
vance to breast cancer revealed by bioinformatics research in the literature. It is
important to emphasise that, at the time of writing, each study has identified and
discussed the markers for breast cancer individually, and no research has found or
examined the combination of these biomarkers or some of them simultaneously.
Furthermore, this chapter discusses the type of relationship recognised in this
PhD research between each individual molecular marker and ER/PR expression
levels for the goal of better understanding the biological mechanism underlying
the association. Discovering robust biomarkers and identifying their relation to
human breast cancers can allow more personalised medicine approaches to be de-
veloped, which could help in detecting, managing, and treating this heterogeneous
disease.
6.2 Discovered Biomarkers with HP Weight for
ER
This section discusses the relevance of the recognised biomarkers with HP weight
to breast cancer and the hormone receptor ER in term of what has been con-
ducted in the literature from bioinformatics analysis research. Furthermore, the
association between each mRNA marker and the oestrogen receptor observed in
this research will be examined and discussed to understand the type of existent
relationship and provide conclusive evidence.
 {‘ESR1’}. According to Cancer Genetics Website1 “This gene encodes an
estrogen receptor. Estrogen and its receptors are essential for sexual devel-
opment and reproductive function, but also play a role in other tissues such
as bone. Estrogen receptors are also involved in pathological processes, in-
cluding breast cancer, endometrial cancer, and osteoporosis”. Several stud-
ies have explored the relevance of ESR1 gene to breast cancer. Holst et
al. [136] discussed the findings of five studies that showed a correlation be-
tween elevated ESR1 and high ER level. Then, they summarised that “there
1http://www.cancerindex.org/geneweb/ESR1.htm
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Figure 6.1: Scatter plot of ESR1 and GFRA1 of (Nature 2012) dataset with
ER groups, illustrating that the observation 306 from the ER+ group has high
expression levels of (ESR1, GFRA1), which are (4.7657, 4.512) in comparison
to the observation 235 from the ER- group, which has low expression levels of
(ESR1, GFRA1), which are (−4.5636,−4.3411).
is growing evidence that ESR1 gain or amplification is a fairly frequent
event in breast cancer”. Similar findings were found by the study [174],
which confirmed the existence of amplifications and gains of the ESR1 in
breast cancer, where a strong positive correlation between ESR1 and ER
was recognised. In the literature, several researchers have investigated the
role of ESR1 as potential prognostic and predictive biomarkers for breast
cancer [8, 12, 171, 178, 207, 243, 244]. In this thesis, evidence of a positive
correlation was found between the expression patterns of ESR1 and ER,
so that elevated ESR1 contributes to the positivity of ER, as illustrated
in Figure 6.1. The increase of ESR1 mRNA expression levels in the ER+
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tumours was observed over a wide range of breast cancer samples of (Na-
ture 2012), (Cell 2015), (Provisional) and (METABRIC), as well as the
integrated datasets with ER groups: NCP1, NCP2, and NCP3. Therefore,
further investigations can be conducted by domain experts to examine the
potential of ESR1 to be utilised in the early detection and monitoring the
progression of this heterogeneous disease.
 {‘GFRA1’}. GFRA1 has been revealed by Immunohistochemistry (IHC)
as under-expressed in normal tissue and over-expressed in subsets of breast
cancers [34]. Moreover, several studies have shown that GFRA1 exhibits
over-expression in the majority of breast cancers [36, 88, 89, 239, 317]. A
recent study [95] that discussed the emerging role of the GDNF family in
neoplasm has stated that GFRA1 mRNA expression is detected in breast
tumour samples, and is associated with ER expression. Recently, GFRA1
has been identified in [34] as a breast cancer tumour associated antigens.
Bhakta et al. in another recent study [31] have confirmed the abundant
expression of GFRA1 in luminal A breast cancer tissues, whereas minimal or
no expression was observed in most normal tissues. In this thesis, evidence
of a positive correlation was found between GFRA1 mRNA and ER levels,
as presented in Figure 6.1, and across a broad range of breast cancer samples
of (Nature 2012), (Cell 2015), (Provisional) and (METABRIC), as well as
the integrated datasets with ER groups. A more personalised treatment or
monitoring planning for breast cancer could be developed by investigating
further the mechanism underlying the association between the expression
patterns of GFRA1 and ER.
 {‘AGR3’}. The human Anterior Gradient (AGR) family is composed of
three proteins, AGR1, AGR2 and AGR3, all belonging to the protein disul-
fide isomerase (PDI) [5]. AGR3 was identified in [105] as a potential marker
for diagnosis and prognosis of breast cancer from blood, and it was found to
be significantly associated with ER. The research study [222] found AGR3
to be significantly correlated with ER. While the researchers in [295] iden-
tified AGR3 as a potential marker for triple-negative breast cancer. In this
thesis, evidence of a positive association between the expression patterns
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Figure 6.2: Scatter plot of AGR3 and SIAH2 of (Nature 2012) dataset with
ER groups, illustrating that the observation 406 from the ER+ group has high
expression levels of (AGR3, SIAH2), which are (5.5085, 2.9504) in comparison
to the observation 233 from the ER- group, which has low expression levels of
(AGR3, SIAH2), which are (−3.9565,−1.3913).
of AGR3 mRNA and ER, as shown in Figure 6.2, and across the datasets:
(Nature 2012), (Cell 2015), (Provisional) and (METABRIC), as well as
the integrated datasets with ER groups. Identifying a potential molecular
marker in bodily fluids (e.g. serum) can contribute significantly in the early
detection of breast cancer and evaluating the development of this compli-
cated disease. Therefore, further studies are required to gain insights into
the process underlying the association between AGR3 and ER.
 {‘SIAH2’}. In the literature, it has been shown that the expression level
of SIAH2 is correlated with breast cancer aggressiveness and overall patient
survival [3]. According to [54], SIAH2 has been detected mainly in ER+
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tumours. A positive relationship between SIAH2 mRNA and ER expression
levels was detected by the researchers in [149]. Later [298], they found that
in ER+ breast cancer, high levels of SIAH2 associated with unfavorable out-
come in primary breast cancer and treatment outcome in metastatic breast
cancer. Similar results had been described earlier by Chan et al. [49] that
found a high expression level of SIAH2 is associated with an unfavorable
relapse-free survival. Sun et al. [271] recognised SIAH2 to be over-expressed
in invasive breast cancer comparing to normal or ductal carcinoma in situ
tissues. In our biomarker discovery study, a positive relationship between
the expression patterns of SIAH2 and ER was recognised, in which elevated
SIAH2 is observed in the ER+ tumours, as presented in Figure 6.2. The
association were detected across multiple independent datasets: (Nature
2012), (Cell 2015), (Provisional), and (METABRIC) as well as the inte-
grated datasets with ER groups. As a result, this mRNA marker could be
examined further to indicate its contribution to the heterogeneity of breast
cancer.
 {‘C6orf97’}. According to the Gene Copoeia website1, “the function of
Chromosome 6 open reading frame 97 and its encoded protein is not known.
Several genome-wide association studies have implicated the region around
this gene to be involved in breast cancer and bone mineral density”. Zheng et
al. [338] found in a Chinese population, a SNP in the region between C6orf97
and ESR1 increased breast cancer risk where similar findings were detected
in a European population. C6orf97 was found in [80] to be contributed to
the phenotype associated with ER positivity. Yamamoto et al. [325] de-
tected that C6orf97 shows significant worse prognostic values, especially in
luminal B breast cancer. This thesis reveals a positive relationship between
the expression patterns of C6orf97 and ER, as shown in Figure 6.3, and
over multiple independent datasets, which are (Nature 2012), (Cell 2015),
(Provisional), and (METABRIC) as well as the integrated datasets NCP1,
NCP2, and NCP3. These findings can motivate the researchers and the
graduate students in the bioinformatics and biology to conduct functional
1http://genecopoeia.com/gene/hs-c6orf97.html
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Figure 6.3: Scatter plot of C6orf97 and SLC39A6 of (Nature 2012) dataset with
ER groups, illustrating that the observation 142 from the ER+ group has high
expression levels of (C6orf97, SLC39A6), which are (3.1637, 4.6489) in comparison
to the observation 187 from the ER- group, which has low expression levels of
(C6orf97, SLC39A6), which are (−3.5103,−2.0668).
studies of this locus.
 {‘SLC39A6’}: Solute carrier family 39 member 6, according to the NCBI
website1, “zinc is an essential cofactor for hundreds of enzymes. It is in-
volved in protein, nucleic acid, carbohydrate, and lipid metabolism, as well
as in the control of gene transcription, growth, development, and differen-
tiation. SLC39A6 belongs to a subfamily of proteins that show structural
characteristics of zinc transporters”. The research study [288] stated that
SLC39A6 is estrogen regulated and existent in ER+ breast cancer as well
1https://www.ncbi.nlm.nih.gov/gene/25800
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as in tumours that spread to the lymph nodes. Kasper et al. [158] found
that SLC39A6 mRNA and protein level could act as novel biomarkers of
clinical outcome in breast cancer patients. The authors in [274] emphasised
targeting SLC39A6 for the treatment of metastatic breast cancer. Our ge-
nomic analysis study reveals a positive correlation between SLC39A6 and
ER expression levels in breast cancer so that elevated SLC39A6 contributes
to the ER positivity, as illustrated in Figure 6.3. This type of association
was detected over a wide range of breast invasive carcinoma samples. The
potential contribution of SLC39A6 mRNA to ER positivity can be further
examined in order to enable utilising zinc transporter LIV-1 (SLC39A6) in
the construction of the breast cancers prediction systems or the selection
process of optimum therapy.
 {‘ANXA9’}. ANXA9 has been found by a recent study [322] to be signif-
icantly correlated with ESR1. The strong expression of ANXA9 was also
found by [264] to be correlated with the metastasis of breast cancer to the
bone. The research team at Berkeley Lab [141] found ANXA9 to be highly
expressed in approximately half of the patients and a significant relationship
between ANXA9 and aggressive breast cancers was indicated. In this the-
sis, we have demonstrated the existence of high expression levels of ANXA9
mRNA in ER+ tumours, as explained in Figure 6.4, and over multiple
breast invasive carcinoma datasets and the integrated datasets with ER
groups. Therefore, the capability of ANXA9 to be used as a diagnostic or
prognostic marker in the early detection or evaluation of breast cancers can
be further studied, in which the discovered knowledge can be transferred to
personalised and precision medicine.
 {‘NAT1’}. The authors in [305] stated that there is growing evidence that
demonstrates the biological role of NAT1 in the progression of breast cancer
and suggested NAT1 transcripts as candidate prognostic markers in ER+
breast cancer. Adam et al. [4] confirmed NAT-1 mRNA level to be over-
expressed in clinical breast cancers and a strong association of NAT-1 stain-
ing with ER+ tumours was demonstrated. The recent analysis study [45]
in normal, primary breast tissues and breast cancer cell lines has suggested
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Figure 6.4: Scatter plot of ANXA9 and NAT1 of (Nature 2012) dataset with
ER groups, illustrating that the observation 142 from the ER+ group has high
expression levels of (ANXA9, NAT1), which are (3.698, 6.6264) in comparison
to the observation 13 from the ER- group, which has low expression levels of
(ANXA9, NAT1), which are (−3.108,−1.3075).
that NAT1 and ESR1 expression may have overlapping regulation. Fur-
thermore, the NAT1 expression levels were shown in [86] to have a positive
correlation with ER. In this thesis, evidence of a positive correlation was
detected between NAT1 and ER, so that high mRNA levels of NAT1 can be
observed in the patients with ER+ tumours compared to the ER-negative
samples, as shown in Figure 6.4. The association was recognised across a
wide range of breast cancer samples of (Nature 2012), (Cell 2015), (Provi-
sional), and (METABRIC) as well as NCP1, NCP2, and NCP3. Therefore,
targeting the NAT1 gene for further investigations can contribute to explor-
ing more knowledge about this gene and its role in human breast cancers
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Figure 6.5: Scatter plot of CA12 and SCUBE2 of (Nature 2012) dataset with
ER groups, illustrating that the observation 200 from the ER+ group has high
expression levels of (CA12, SCUBE2), which are (3.8954, 5.2376) in comparison
to the observation 373 from the ER- group, which has low expression levels of
(CA12, SCUBE2), which are (-3.15, -3.1562).
and ER positivity.
 {‘CA12’}. CA12 has been recognised by Barnett et al. [17] to be highly
correlated with ERA in human breast tumours. The research study [185]
detected that CA12 and AGR3 are up-regulated in ER+ tumours, while
Watson et al. [311] found CAXII (CA12) to be frequently expressed in
invasive breast carcinoma. This thesis identifies a positive association be-
tween CA12 mRNA and ER, as illustrated in Figure 6.5, and across a wide
range of breast samples of (Nature 2012), (Cell 2015), (Provisional), and
(METABRIC). This provides strong evidence that this gene has the poten-
tial to be a clinical biomarker for human breast cancer and therefore further
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studying is imperative.
 {‘SCUBE2’}: Several studies have detected SCUBE2 expression in pri-
mary invasive breast tumours [91,226,299]. The researchers in [187] claimed
that SCUBE2 plays a major role in suppressing breast-carcinoma-cell mo-
bility and invasiveness. A high degree of correlation was observed in [10] be-
tween the expression levels of ESR1 and several markers, including SCUBE2
and it was found to be related to the ER expression. Herein, our study re-
veals evidence of a correlation between elevated SCUBE2 mRNA and high
ER expression, as presented in Figure 6.5. This association was validated
over multiple breast invasive carcinoma datasets that are collected from
completely different studies. Consequently, further studies are required to
investigate the potential usefulness of this biomarker in the early detection
or evaluation of the progression of breast cancers.
 {‘EVL’}. A recent study [225] has shown that EVL is up-regulated in
ER+ tumours and suppresses invasion, and that EVL levels are reduced in
tumours after anti-estrogenic hormone therapy. Similar funding were found
earlier by Tavares et al. [286] that discovered EVL to be high in luminal
breast tumours. Another study [140] recognised that the expression level
of EVL was higher in breast tumours compared to normal tissues and its
up-regulation was positively associated with the clinical stages of breast
cancer. Moreover, it added that EVL may be implicated in invasion and/or
metastasis of human breast cancer. In this thesis, evidence of a positive
association was discovered between EVL mRNA expression and high ER
levels, as shown in Figure 6.6, and across a wide range of independently
generated breast cancer samples. This supports the potential of this gene
to be a biomarker to ER+ breast cancer, thus further investigations are
required to determine the biological role of the Ena/VASP protein, EVL in
this heterogeneous disease.
 {‘PCP2’}. Little information is available in the literature about this gene,
particularly its relation to breast cancer. Only recently, the genome-wide
association study [245] has identified genes associated with neuropathy in
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Figure 6.6: Scatter plot of EVL and PCP2 of (Nature 2012) dataset with ER
groups, illustrating that the observation 89 from the ER+ group has high ex-
pression levels of (EVL, PCP2), which are (3.3006, 2.5823) in comparison to the
observation 105 from the ER- group, which has low expression levels of (EVL,
PCP2), which are (−2.0036,−0.67983).
patients with head and neck cancer, including PCP2. Therefore, this thesis
is one of the first to show evidence of a positive correlation between PCP2
mRNA and ER, where highly expressed PCP2 contributes to ER positivity,
as illustrated in Figure 6.6. Therefore, further investigations are required
to indicate the clinical relevance of this gene to breast cancer.
 {‘FSIP1’}. FSIP1 is a cancer antigen expressed in the majority of breast
cancer tissues and is associated with poor prognosis [190]. Several research
studies have detected FSIP1 not only as a potential biomarker of breast
cancer, but also as a potential therapeutic target. Liu et al. [196] identified
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Figure 6.7: Scatter plot of FSIP1 and GATA3 of (Nature 2012) dataset with
ER groups, illustrating that the observation 12 from the ER+ group has high
expression levels of (FSIP1, GATA3), which are (7.2055, 2.6464) in comparison
to the observation 175 from the ER- group, which has low expression levels of
(FSIP1, GATA3), which are (−0.949,−4.9429).
FSIP1 as a signaling partner to HER2, and that FSIP inhibition reduces
cell growth and invasiveness in HER2-positive breast cancer cells. A re-
cent study [326] has shown that breast cancer cells and tissues consistently
demonstrated elevated FSIP1 expressions, which correlated with poor over-
all survival. In this thesis, high levels of FSIP1 mRNA expression were
detected mostly in patients with ER+ tumours, as explained in Figure 6.7,
and across various groups of breast cancer samples that are collected from
completely different studies. This provides strong evidence that this gene
could act as a potential biomarker to human breast cancer.
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 {‘GATA3’}. GATA3 has been identified as one of the most frequently
mutated genes in breast cancers. Takaku et al. [278] found that GATA3
zinc finger 2 mutations reprogram the breast cancer transcriptional net-
work. Earlier in [279], they discussed the mutation of GATA3 in breast
cancer, and the potential mechanisms by which mutation may lead to a
growth advantage in cancer. The Significance and therapeutic potential of
GATA3 expression and mutation in breast cancer were reviewed in [78]. In
this thesis, GATA3 was found to be highly expressed in ER+ tumours com-
pared to the samples from the ER- group, as presented in Figure 6.7, and
across several independent datasets, which provides another evidence to the
biological relevance of this gene to the positivity of the hormone receptor
and breast cancer.
 {‘IGFALS’}. Insulin like growth factor (IGF) has been implicated in the
etiology and progression of breast and other cancers. A research study [71]
found genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast
cancer survival among Chinese women. The authors in [74] discovered that
the lack of ALS proteins results in the disruption of the entire IGF cir-
culating system. In our research, it has been shown that elevated levels
of IGFALS mRNA expression were found to be in the patients with ER+
tumours compared to the ER- samples, as illustrated in Figure 6.8, and
across variant independent subsets of breast cancer samples. Therefore,
investigating the role IGFALS might play in ER+ breast cancer is neces-
sary to provide insights and explanations to the biological and pathological
processes of this complicated disease.
 {‘LRRC56’}. Very limited information is available about this gene and
its relevance to breast cancer and the hormone receptors. In this thesis,
evidence of a positive correlation was detected between LRRC56 mRNA
expression and high levels of ER, in which ER+ tumours are more likely
characterised by high expression levels of LRRC56 compared to ER- sam-
ples, as shown in Figure 6.8, and over multiple genomic datasets. Therefore,
targeting LRRC56 for further analysis could result in discovering its func-
tion in the underlying processes of ER+ breast cancer.
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Figure 6.8: Scatter plot of IGFALS and LRRC56 of (Nature 2012) dataset with
ER groups, illustrating that the observation 448 from the ER+ group has high
expression levels of (IGFALS, LRRC56), which are (5.4277, 2.4235) in comparison
to the observation 512 from the ER- group, which has low expression levels of
(IGFALS, LRRC56), which are (−1.2985,−1.8847).
6.3 Discovered Biomarkers with HN Weight
for ER
This section discusses the clinical relevance of the discovered biomarkers
with HN weight with the oestrogen receptor recognised by the bioinformat-
ics research in the literature. Furthermore, the identified association by
this research between the expression levels of these biomarkers and ER will
be explored to gain insight into the type of existent link. The relevance
of the HN weighted mRNA markers to ER positivity will be investigated
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Figure 6.9: Scatter plot of VGLL1 and PPP1R14C of (Nature 2012) dataset
with ER groups, illustrating that the observation 93 from the ER+ group has
low expression levels of (VGLL1, PPP1R14C), which are (−0.54387,−4.3153) in
comparison to the observation 81 from the ER- group, which has high expression
levels of (VGLL1, PPP1R14C), which are (5.0809, 2.7428).
individually in the following points to provide conclusive evidence.
 {‘VGLL1’}. Castilla et al. [47] found that VGLL1 expression is associ-
ated with a triple-negative basal-like phenotype in breast cancer. Li et
al. [185] detected a set of genes including VGLL1 to be under-expressed in
the ER-positive group and over-expressed in the ER-negative group. Re-
cently, Segaert et al. [255] have identified 36 relevant genes to triple-negative
breast cancer data including VGLL1. Lim et al. [186] recognised several a
luminal progenitor signature including VGLL1 for basal tumour develop-
ment. In this thesis, evidence of an inverse correlation was found between
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the expression patterns of VGLL1 and ER, as shown in Figure 6.9, and
over a wide range of independently generated breast cancer samples. This
negative association can be further researched to investigate the potential
of the VGLL1 to be a biomarker to breast cancer, and particularly to triple-
negative breast cancer as discussed above.
 {‘PPP1R14C’}. As mentioned previously in VGLL1, Segaert et al. [255]
have identified 36 genes, including PPP1R14C that are involved in triple-
negative breast cancer. Castilla et al. [47] identified several genes, including
PPP1R14C that are correlated with VGLL1 and miR-934 expression in a
triple-negative basal-like phenotype in breast cancer. In this research, a
negative correlation was detected between PPP1R14C mRNA expression
and ER level, so that the declines in PPP1R14C expression values con-
tribute to the positivity of ER, as illustrated in Figure 6.9. The inverse
association between PPP1R14C and ER positivity was recognised over a
wide range of breast cancer samples, therefore, the mechanism underlying
that relationship should be explored further.
 {‘PROM1’}. According to the NCBI website1, “ Expression of this gene is
associated with several types of cancer”. The researchers in [321] found that
that CD133 mRNA can be a suitable prognostic marker for human breast
cancer. According to the research study [293], CD133 could act as a marker
of breast cancer cells and stem cells. Recently, Zhang et al. [334] have found
several differentially expressed genes including PROM1 that may play im-
portant roles in the process of bone metastasis from breast cancer. As
mentioned previously in VGLL1 and PPP1R14C, Castilla et al. [47] identi-
fied several genes including PROM1 that are most correlated with VGLL1
and miR-934 expression in a triple-negative basal-like phenotype in breast
cancer. As seen in VGLL1, Lim et al. [186] detected several a luminal pro-
genitor signature including PROM1 for basal tumour development. More-
over, some studies have detected the correlation between PROM1 (CD133)
and VGLL1 such as [30,156]. In this thesis, it has been shown that PROM1
mRNA expression is negatively correlated with ER+ tumours, as presented
1https://www.ncbi.nlm.nih.gov/gene/8842
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Figure 6.10: Scatter plot of PROM1 and PSAT1 of (Nature 2012) dataset with
ER groups, illustrating that the observation 336 from the ER+ group has low ex-
pression levels of (PROM1, PSAT1), which are (−4.1265,−6.553) in comparison
to the observation 478 from the ER- group, which has high expression levels of
(PROM1, PSAT1), which are (5.5998,−0.1715).
in Figure 6.10. This inverse association was validated over a large number
of variations in breast samples of (Nature 2012), (Cell 2015), (Provisional),
(METABRIC) as well as the integrated datasets NCP1, NCP2, and NCP3.
The obtained findings reveal that highly expressed PROM1 contribute to
the phenotype associated with ER positivity, thus the examination of that
potential relationship is imperative.
 {‘PSAT1’}. Possemato et al. [235] found that the inhibition of PSAT1
significantly decreased the proliferation of ER-negative breast cancer cells
but not ER-positive breast cancer cells. Gao et al. [103] revealed that the
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expression of PSAT1 was significantly upregulated in ER-negative breast
cancers compared with ER-positive breast cancers, and they added that
PSAT1 up-regulation was correlated with tumour development and poor
prognosis. PSAT1 hyper-methylation and mRNA levels were found in [206]
to be significantly associated with the outcome to tamoxifen treatment in
recurrent disease. In this research, evidence of a negative correlation was
found between PSAT1 and ER, so that the declines in the expression values
of PSAT1 lead to high ER levels, as explained in Figure 6.10. This poten-
tial association was validated across a wide range of breast cancer samples
of (Nature 2012), (Cell 2015), (Provisional), and (METABRIC), as well as
the integrated datasets with ER groups. The clinical relevance of PSAT1
mRNA expression to the positivity of ER requires further studying to de-
clare whether this gene can act as a clinical indicator for breast cancer and
the hormone receptor.
 {‘B3GNT5’}. According to [236], glycolipids may play an important role
in carcinogenesis of breast tumours that are shown by the association of
B3GNT5 and UGCG genes to patient survival. The authors in [294] identi-
fied 12 markers, including B3GNT5 for detection of primary breast cancer.
As mentioned previously in VGLL1 and PPP1R14C, Segaert et al. [255]
have identified 36 relevant genes in triple-negative breast cancer data, in-
cluding B3GNT5. Highly significant correlations were observed in [162]
between cyclooxygenase 2 (COX2) with eight tumour-promoting genes, in-
cluding B3GNT5, which are known to effectively increase the inflammogen-
esis of breast cancer. B3GNT5 levels were found in [344] to be higher in both
ER-negative and PR-negative tumours. This research detects an inverse
correlation between B3GNT5 mRNA expression and ER levels, in which
B3GNT5 is highly expressed in the ER-negatives compared to the ER+
patient, as shown in Figure 6.11, and across a broad range of breast can-
cer samples. The mechanism underlying the relationship between B3GNT5
mRNA and ER levels can be further studied by domain experts to answer
different biological questions of interest.
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Figure 6.11: Scatter plot of B3GNT5 and SOX11 of (Nature 2012) dataset with
ER groups, illustrating that the observation 303 from the ER+ group has low
expression levels of (B3GNT5, SOX11), which are (−2.6707,−2.9344) in compar-
ison to the observation 378 from the ER- group, which has high expression levels
of (B3GNT5, SOX11), which are (3.9505, 4.103).
 {‘SOX11’}. Shepherd et al. [257] found that SOX11 is a critical regulator
of multiple phenotypes of Basal-like breast cancers such as growth, migra-
tion, and invasion. The research study [191] identified that Nuclear SOX11
was observed in (36.2%) and cytoplasmic SOX11 in (44.8%) of breast can-
cer samples. Recently, Wang et al. [308] have found that SOX11 expression
was directly associated with breast cancer stem cell populations. In this
thesis, it has been shown that SOX11 is highly expressed in ER- samples
compared to the ER-positives, as illustrated in Figure 6.11, and across a
large number of independent variations in the breast cancer samples. This
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gene exhibits great distinctions between the ER+ and ER- samples, thus
investigating the potential of SOX11 to be a molecular marker to breast
cancer is required to advance the move towards precision medicine.
 {‘KRT16’}. The study [151] stated that breast tumours can alter the
expression of certain keratins during the process of metastatic develop-
ment and an association was found between KRT16 expression and shorter
relapse-free survival in metastatic breast cancer. The study presented in
[159] detected multiple autoimmune response signature associated with the
development of triple negative breast cancer, involving KRT16. In this
thesis, KRT16 was found to be negatively associated with ER levels, as il-
lustrated in Figure 6.12, and over a wide range of independent breast cancer
samples. This inverse association needs further researching to understand
the biological role of the keratin 16 in human breast cancers and allow more
innovative findings to be discovered.
 {‘TMEM40’}. Little is known in the literature about this gene, particu-
larly, its relevance to breast cancer and ER. Recently, a research study [333]
has stated that TMEM40 gene encodes a protein of 233 amino acids and is
located on chromosome 3p25.2. Moreover, it has found that high expres-
sion of TMEM40 contributes to progressive features of tongue squamous
cell carcinoma. In another recent study [335], the role of TMEM40 in the
tumorigenesis of bladder cancer has been identified and found that it was
upregulated in bladder cancer tissues and cell lines, compared with their
normal counterparts. The clinical relevance of TMEM40 mRNA expression
to breast cancer and oestrogen receptor is not clear in the literature and
evidence of a negative correlation was recognised and validated in this re-
search between the expression pattern of TMEM40 and ER levels, as shown
in Figure 6.12, and over multiple variant subsets of breast samples. These
findings can motivate conducting further investigations to determine the
mechanism underlying that association.
 {‘BBOX1’}. In the literature, very limited information is available about
BBOX1, especially its relevance to breast cancer and ER. The previously
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Figure 6.12: Scatter plot of KRT16 and TMEM40 of (Nature 2012) datasets with
ER groups, illustrating that the observation 255 from the ER+ group has low
expression levels of (KRT16, TMEM40), which are (−2.2758, 0.11) in comparison
to the observation 373 from the ER- group, which has high expression levels of
(KRT16, TMEM40), which are (5.3142, 4.379).
discussed study in VGLL1, PPP1R14C, and PROM1 [47], that mentioned
the association of several genes, including BBOX1 to a triple-negative basal-
like phenotype in breast cancer. This thesis is the first to report evidence
of an inverse correlation to be found between BBOX1 mRNA and ER lev-
els, in which the declines in BBOX1 expression values contribute to ER
positivity, as introduced in Figure 6.13, and across a wide range of breast
cancer samples. The behavior of BBOX1 differs significantly between ER+
tumours and ER-negative ones, which makes it a candidate indicator to
high levels of ER. Therefore, further studies are required to examine the
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Figure 6.13: Scatter plot of BBOX1 and C1orf106 of (Nature 2012) dataset with
ER groups, illustrating that the observation 495 from the ER+ group has low
expression levels of (BBOX1, C1orf106), which are (−0.38025,−2.7811) in com-
parison to the observation 243 from the ER- group, which has high expression
levels of (BBOX1, C1orf106), which are (8.0045, 3.2498).
clinical relevance of this gene to breast cancer.
 {‘C1orf106’}. Recently, Yang et al. [328] have detected 61 differential
expressed genes, including C1orf106 for basal-like breast cancer. Lemetre
in the PhD thesis [179] detected C1orf106 as one of the relevant genes for
breast cancer. In this thesis, a negative correlation was found between
C1orf106 mRNA expression and ER levels, as presented in Figure 6.13.
This inverse association was verified across the (Nature 2012), (Cell 2015),
(Provisional), (METABRIC), NCP1, NCP2, and NCP3. Various biolog-
ical questions could be addressed by examining the biological role of the
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C1orf106 gene in the underlying process of the hormone receptor, ER.
 {‘DKK1’}. It has been shown that DKK1 is involved in a variety of can-
cers. The authors in [157] claimed that Dkk1 might provide insights into the
continued development of novel comprehensive and therapeutic strategies
for breast cancer and its bone metastases. Recently, a research study [221]
found that DKK1 over-expression dramatically inhibits breast cancer cell
migration and invasion, where knockdown of DKK1 promotes migration
and invasion of breast cancer cells. Forget et al. [99] identified DKK1 as
a potential prognostic and diagnostic marker for cohorts of breast cancer
patients with poor prognosis. In this thesis, an inverse correlation between
DKK1 mRNA expression and the positivity of ER was discovered, in which
low expression levels of DKK1 can be found mostly in ER+ tumours com-
pared to ER- samples, as shown in Figure 6.14, and over a wide range
of independently generated breast cancer samples. Therefore, DKK1 can
be investigated further to be utilised for developing various diagnosis and
prognosis systems for detecting and monitoring breast cancer.
 {‘KRT81’}. According to [37], KRT81 is expressed in the human breast
cancer cell line SKBR3, and in metastatic lymph nodes of breast carcinomas
according to [290]. A study [218] found that KRT81 is expressed in normal
breast epithelial cells and breast cancer cells, and suggested that KRT81
contributes to the migration and invasion of breast cancer cells. In this
thesis, KRT81 was found to be negatively associated with the positivity of
ER, in which high expression levels of KRT81 can be found mostly in the
ER- samples compared to the ER-positives, as illustrated in Figure 6.14.
This inverse association was detected across a wide range of independent
breast cancer samples, thus targeting this gene for further researching could
contribute to understanding the role KRT81 might play in the heterogeneity
of breast cancer and the positivity of ER.
 {‘RARRES1’}. Among five breast cancer subtypes, the authors in [59]
found that RARRES1 expression is greatest in basal-like TNBCs, and they
revealed that RARRES1 is a tumour suppressor in TNBC. Coyle et al. [60]
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Figure 6.14: Scatter plot of DKK1 and KRT81 of (Nature 2012) dataset with
ER groups, illustrating that the observation 287 from the ER+ group has low
expression levels of (DKK1, KRT81), which are (−7.716,−0.467) in comparison
to the observation 513 from the ER- group, which has high expression levels of
(DKK1, KRT81), which are (1.7045, 3.7175).
identified RARRES1 as a tumour suppressor in triple-negative breast cancer
cell lines. In this thesis, it has been shown that RARRES1 exhibits low
expression levels for the patients with high ER levels in comparison to
the ER-negative samples, as presented in Figure 6.15, and across multiple
datasets that are collected from different studies. As a result, it is relevant
to examining the potential of RARRES1 to be a target for breast cancer
and ER positivity.
 {‘S100A8’}. S100A8/A9 was detected to be associated with ER loss in
breast cancer in [15]. Zhong et al. [339] found that S100A8 may be asso-
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Figure 6.15: Scatter plot of RARRES1 and S100A8 of (Nature 2012) dataset
with ER groups, illustrating that the observation 288 from the ER+ group has
low expression levels of (RARRES1, S100A8), which are (−2.294,−0.23025) in
comparison to the observation 433 from the ER- group, which has high expression
levels of (RARRES1, S100A8), which are (6.7431, 6.5045).
ciated with lymph nodes metastasis of breast cancer and be a marker for
progression of breast cancer. The authors in [307] detected that ER- and
triple-negative breast cancer samples has significantly higher expression of
S100A8 than samples with other subtypes, thus they suggested S100A8 as
a potential biomarker for relapse in breast cancer patients. In this the-
sis, evidence of a negative correlation was found between the expression
patterns of S100A8 and ER, as clarified in Figure 6.15, and over different
groups of independent breast cancer samples. Thus, considering this gene
in future studies could contribute to understand its role in breast cancer
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and triple-negative breast cancer as discussed above.
 {‘S100A9’}. As mentioned in S100A8, S100A9 was detected to be associ-
ated with ER loss in breast cancer in [15]. The researchers in [182] identified
S100A9 as a novel OM-regulated gene and indicated its involvement in the
growth regulation of breast cancer cells. S100A9 has been recognised in [27]
as a novel therapeutic target for patients with ERPgR breast cancers. This
thesis has shown that the patients with ER+ tumours exhibit low expres-
sion levels of S100A9 mRNA compared to the ER- samples, as explained in
Figure 6.16, and across a wide range of breast cancer samples. As a result,
S100A9 should be investigated further to be employed as a potential target
for ER- patients.
 {‘TRPV6’}. It has been shown that TRPV6 is involved in colon cancer,
breast cancer, prostate cancer, parathyroid cancer and thyroid cancer [265].
TRPV6 was identified in [232] as a novel therapeutic strategy for the treat-
ment of ER- breast cancers. A very recent study [269] revealed TRPV6
as a promising drug target in a variety of cancers, including breast, ovar-
ian, prostate and pancreatic tissues. Herein, we demonstrated a negative
correlation between the expression levels of ER and TRPV6, in which the
drops in TRPV6 mRNA expression could contribute to the positivity of ER,
as shown in Figure 6.16, and over several independent genomic datasets.
Therefore, TRPV6 can be further researched to indicate its contributions
to breast cancer.
 {‘HRASLS’}. Mardine et al. [205] discussed the role of each of the
HRASLS enzymes in cancer, as well as their biochemical function, and
then they concluded that reduced expression of these enzymes can be found
mostly in cancer cells. This thesis reveals a negative association between
the expression patterns of HRASLS mRNA and ER positivity, in which
highly expressed HRASLS can be found mostly in ER-negative samples
than ER-positives, as clarified in Figure 6.17, and across a wide range of
breast cancer samples that are generated independently. Further investiga-
tions are required to indicate its function in breast cancer.
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Figure 6.16: Scatter plot of S100A9 and TRPV6 of (Nature 2012) dataset with
ER groups, illustrating that the observation 231 from the ER+ group has low
expression levels of (S100A9, TRPV6), which are (−1.4145,−0.8875) in compar-
ison to the observation 412 from the ER- group, which has high expression levels
of (S100A9, TRPV6), which are (6.1717, 5.1405).
 {‘PPP1R1A’}. The expression of PPP1R1A in lung, colorectal, and gas-
tric cancer cell lines was different from that of the normal tissues [280]. This
thesis is first to report that PPP1R1A mRNA expression is negatively asso-
ciated with ER+ breast cancer samples, in which the drops in the expression
levels of this gene could lead to high levels of ER expression, as shown in
Figure 6.17, and across independent cancer genomic datasets. Considering
PPP1R1A in future studies could contribute to revealing its biological role
in breast cancer.
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Figure 6.17: Scatter plot of HRASLS and PPP1R1A of (Nature 2012) dataset
with ER groups, illustrating that the observation 159 from the ER+ group has
low expression levels of (HRASLS, PPP1R1A), which are (−4.3462,−2.4207) in
comparison to the observation 432 from the ER- group, which has high expression
levels of (HRASLS, PPP1R1A), which are (3.4473, 3.6841).
6.4 Discovered Biomarkers with HP Weight
for PR
The relevance of the discovered biomarkers with HP weight to the proges-
terone receptor is discussed in this section with respect to current state-
of-the-art bioinformatics research found in the literature. The recognised
relationship in our research between each mRNA marker and PR will be
discussed to provide conclusive evidence about the type of existent associ-
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Figure 6.18: Scatter plot of AGR3 and GFRA1 of (Nature 2012) dataset with
PR groups, illustrating that the observation 241 from the PR+ group has high
expression levels of (AGR3, GFRA1), which are (5.8145, 3.688) in comparison
to the observation 463 from the PR- group, which has low expression levels of
(AGR3, GFRA1), which are (−4.4672,−4.1019).
ation.
 {‘AGR3’}. In this thesis, evidence of a positive correlation was detected
between the AGR3 mRNA expression and PR levels, so that the gains in
AGR3 lead to high PR levels, as shown in Figure 6.18, and across a broad
range of breast cancer samples. The relevance of AGR3 to breast cancer and
the positivity of the hormone receptors in terms of what has been revealed
in the literature by bioinformatics analysis research was discussed earlier
in Section 6.2. Biomarker discovery in bodily fluids can advance the move
towards a new generation of diagnosis and prognosis models.
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 {‘GFRA1’}. A potential relationship between GFRA1 mRNA expression
and PR positivity was recognised in this research, as illustrated in Figure
6.18, and over a large number of variant breast cancer samples. Our findings
reveal GFRA1 mRNA as a strong candidate biomarker for breast cancer
that is positively correlated to the hormone receptor ER and PR, thus
further investigations from biomedical experts are necessitated to indicate
the mechanism underlying the association.
 {‘SCUBE2’}. SCUBE2 mRNA was found to be positively correlated to
PR expression, as presented in Figure 6.19, and over the independent vari-
ations in breast cancer samples. The positive relationship between the
expression patterns of SCUBE2 mRNA and the hormone receptors ER and
PR recognised in this thesis necessities conducting further experiments to
determine the potential of this gene to be a biomarker for human breast
cancers.
 {‘SIAH2’}. Our omics data analysis study detected a positive correlation
between SIAH2 mRNA and PR expression levels, as explained in Figure
6.19, and across a wide range of breast cancer samples. Furthermore, SIAH2
was also detected in this research to have a positive correlation with ER,
and this is discussed in Section 6.2. SIAH2 mRNA and its relevancy to
the hormone receptors ER and PR can be further examined to indicate its
potential in the early detection and management of breast cancers.
 {‘FGD3’}. FGD3 was identified by the attractor metagene methodology
[53] applied to the 2,000 breast cancer sample of METABRIC dataset [62]
and won the Sage Bionetworks-DREAM Breast Cancer Prognosis Chal-
lenge. Willis et al. [318] found that FGD3 mRNA is regulated by ESR1
and it is an important clinical biomarker. FGD3 was detected in [273] to
be a potential prognostic biomarker for breast cancer. Yao et al. [330] iden-
tified nine genes, including FGD3 for breast cancer grading and staging. In
this thesis, FGD3 was detected to be positively correlated to PR expression
levels, as illustrated in Figure 6.20, and across a wide range of breast cancer
samples, thus targeting these mRNAs in further investigations is required
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Figure 6.19: Scatter plot of SCUBE2 and SIAH2 of (Nature 2012) dataset with
PR groups, illustrating that the observation 171 from the PR+ group has high
expression levels of (SCUBE2, SIAH2), which are (4.3738, 2.3989) in comparison
to the observation 232 from the PR- group, which has low expression levels of
(SCUBE2, SIAH2), which are (−2.457,−1.3913).
to approach personalised and precision medicine for breast cancer.
 {‘SUSD3’}. As mentioned previously in FGD3, SUSD3 was also identified
by the attractor metagene methodology [53] as a potential biomarker for
breast cancer. SUSD3 was found in [216] to be a significantly discriminative
gene, and a novel promoter of estrogen-dependent cell proliferation. Zhao et
al. [336] found that the expression of Insulin-like Growth Factor-I Receptor
(IGF-IR) and SUSD3 may be associated with the occurrence and progres-
sion of breast cancer. In this thesis, it has been shown that SUSD3 exhibits
a positive association with PR expression levels so that PR+ tumours are
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Figure 6.20: Scatter plot of FGD3 and SUSD3 of (Nature 2012) dataset with
PR groups, illustrating that the observation 318 from the PR+ group has high
expression levels of (FGD3, SUSD3), which are (4.0443, 5.2162) in comparison
to the observation 185 from the PR- group, which has low expression levels of
(FGD3, SUSD3), which are (−1.4253,−2.309).
characterised by a high expression levels of SUSD3 mRNA compared to
PR- samples, as clarified in Figure 6.20, and across a wide range of breast
cancer samples. The obtained findings provide strong evidence that SUSD3
could act as potential diagnostic and prognostic biomarkers to breast can-
cer and PR, thus targeting this gene in further investigations is required to
understand the role it might play in PR+ breast cancer.
 {‘GRPR’}. According To NCBI website1, GRPR “regulates numerous
functions of the gastrointestinal and central nervous systems. The recep-
1https://www.ncbi.nlm.nih.gov/gene/2925
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tor is aberrantly expressed in numerous cancers such as lung, colon, and
prostate”. Morgat et al. [213] found that GRPR is over-expressed in 83%
of ER-positive tumours, and this over-expression was also found in lymph
node metastases in 94.6% of cases. Results of their recent study [214] on
breast cancer samples have also shown that GRP-R targeting is highly rel-
evant in breast cancer, specifically in ER-positive tumours. High GRPR
mRNA levels were detected in [65] to be more frequent in samples with
positivity for ER mRNA ESR1, or PR mRNA. Dalm et al. [64] recognised
GRPR to be over-expressed on primary breast cancer and thus, they have
investigated the possibility of integrating it with other candidate genes for
receptor-mediated nuclear imaging and therapy. GRPR mRNA was discov-
ered in this thesis to be positively related to PR, as shown in Figure 6.21,
and across independently generated breast cancer samples. Therefore, the
mechanism underlying that association can be further studied to allow more
innovative findings.
 {‘PGLYRP2’}. Shanle et al. [256] identified several ER target genes,
including PGLYRP2 in triple negative breast cancer cells. On the other
hand, the research study [13] recognised that the absence of PGLYRP2
leads to alterations in the expression of the autism risk gene c-Met, and
sex-dependent changes in social behavior, similar to mice with manipulated
microbiota. Herein, the expression of PGLYRP2 mRNA was detected to be
positively associated with the PR levels, as presented in Figure 6.21, and
across independent subsets of breast cancer samples. Thus, further studies
can be conducted to determine the role of PGLYRP2 in the biological or
pathological process of breast cancers.
 {‘GREB1’}. According to NCBI website1, “this gene is an estrogen-
responsive gene that is an early response gene in the estrogen receptor-
regulated pathway. It is thought to play an important role in hormone-
responsive tissues and cancer”. The researchers in [240] found GREB 1 to be
critically involved in the estrogen induced growth of breast cancer cells and
has the potential of being a clinical marker for response to endocrine ther-
1https://www.ncbi.nlm.nih.gov/gene/9687
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Figure 6.21: Scatter plot of GRPR and PGLYRP2 of (Nature 2012) dataset with
PR groups, illustrating that the observation 239 from the PR+ group has high
expression levels of (GRPR, PGLYRP2), which are (6.0467, 4.3773) in comparison
to the observation 295 from the PR- group, which has low expression levels of
(GRPR, PGLYRP2), which are (−0.72033,−1.16177).
apy as well as a potential therapeutic target. Camden et al. [147] found that
GREB1 is a novel progesterone-responsive gene required for progesterone-
driven human endometrial stromal cell (HESC) decidualization. The recent
review study [52] has examined evidence that GREB1 participates in sev-
eral hormone-dependent cancers and could be targeted to treat these cancers
and concluded that the hormone-responsive gene GREB1 plays important
roles in the initiation and progression of some sex hormone-driven cancers.
Similar findings have also been shown recently by the study [133], which de-
tected GREB1 to be an estrogen receptor-regulated tumour promoter that
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Figure 6.22: Scatter plot of GREB1 and PGR of (Nature 2012) dataset with PR
groups, illustrating that the observation 100 from the PR+ group has high ex-
pression levels of (GREB1, PGR), which are (1.262, 5.4402) in comparison to the
observation 380 from the PR- group, which has low expression levels of (GREB1,
PGR), which are (−4.3128,−4.4838).
is frequently expressed in ovarian cancer. In our research, a positive rela-
tionship between GREB1 mRNA expression and PR levels was detected, as
clarified in Figure 6.22, and across a large number of variations in breast
cancer samples. Our findings revealed GREB1 mRNA as a potential indi-
cator to the positivity of PR, therefore, this gene and its relevance to breast
cancer should be investigated further.
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 {‘PGR’}. Progesterone receptor. According to the NCBI website1, PGR
“The encoded protein mediates the physiological effects of progesterone, which
plays a central role in reproductive events associated with the establishment
and maintenance of pregnancy”. The authors in [127] found that the ex-
pression of ESR1, the gene encoding ERα and that SNPs in the PGR gene
predict tumour PGR/PgR expression, and they concluded that ESR1 and
PGR polymorphisms are associated with estrogen and progesterone recep-
tor expression in breast tumours. PGR was identified in this thesis to be
a potential biomarker for the status of PR, as clarified in Figure 6.22, and
over a wide range of variant and independent breast samples. The obtained
findings reveal the potential of PGR gene to be a biomarker to breast cancer
and PR positivity, thus further investigations are required.
6.5 Discovered Biomarkers with HN Weight
for PR
The clinical relevance between the discovered biomarkers with HN weight
and the progesterone receptor will be discussed in regards to bioinformat-
ics analysis studies in the literature. Furthermore, the association of each
mRNA marker to the hormone receptor PR identified in this thesis will be
explored in details in the following points to provide conclusive evidence.
 {‘ATP6V0A4’}. Recently, the authors in [254] have identified fourteen
differentially expressed genes, involving ATP6V0A4 for visceral organ metas-
tasis in breast cancer. Misra et al. [210] found that ZAR2 transcription-
ally represses the ATPase ATP6V0A4 to negatively regulate invasiveness of
breast cancer cells. This thesis observes the ATP6V0A4 gene to be nega-
tively associated with PR status, as clarified in Figure 6.23, and over the
(Nature 2012), (Cell 2015), (Provisional), and (METABRIC) in addition
to the integrated datasets with PR groups. The findings of this research
1https://www.ncbi.nlm.nih.gov/gene/5241
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Figure 6.23: Scatter plot of ATP6V0A4 and LAD1 of (Nature 2012) dataset
with PR groups, illustrating that the observation 169 from the PR+ group has
low expression levels of (ATP6V0A4, LAD1), which are (−4.1855,−1.5495) in
comparison to the observation 364 from the PR- group, which has high expression
levels of (ATP6V0A4, LAD1), which are (4.459, 3.3618).
recommend considering the ATP6V0A4 gene and its link to breast cancer
and PR in future studies to allow unexplored knowledge to be discovered.
 {‘LAD1’}. Recently, Roth et al. [247] have identified LAD1 as a filamin-
binding regulator of actin dynamics in response to the epidermal growth
factor receptor (EGFR) and a marker of aggressive breast tumours. Groger
et al. [115] found several genes, including LAD1 that are correlated signifi-
cantly with impaired pathological complete response (pCR) in breast cancer
patients. The researchers in [118] identified 50 genes, including LAD1 to be
associated with ER in breast cancer. Several biomarkers including LAD1
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were identified in [6] for Luminal A and Basal. In this thesis, evidence of an
inverse correlation was detected between the expression patterns of LAD1
and PR, as illustrated in Figure 6.23, and over a large number of breast can-
cer samples of (Nature 2012), (Cell 2015), (Provisional), and (METABRIC)
as well as the integrated datasets with PR groups. Therefore, this thesis
supports investigating the potential of the LAD1 to be a biomarker for
breast cancers and PR status.
 {‘C9orf58’}. Chromosome 9 open reading frame 58, which is also known as
allograft inflammatory factor 1 like (AIF1L). Recently, Liu et al. [194] have
stated that AIF1L plays a key role in mammary tumorigenesis, and their
findings have suggested AIF1L to be a potential prognostic marker that
plays a vital role in regulating the cytoskeleton in breast cancer. Exclud-
ing this recent study, little is presented in the literature about the clinical
relevance of this gene to breast cancer and the hormone receptors. In this
thesis, C9orf58 was found to be a potential biomarker to breast cancer that
is negatively associated with PR expression levels, as shown in Figure 6.24,
and over a wide range of variant breast cancer samples. Therefore, more
studies can be conducted to understand the biological mechanism under-
lying the inverse association between the expression patterns of C9orf58
mRNA and PR.
 {‘NXPH1’}. A study of genome-wide methylation screen [93] in low-
grade breast cancer identifies several epigenetically altered genes, including
NXPH1 as potential biomarkers for tumour diagnosis. This thesis detected
an inverse relationship between NXPH1 mRNA and PR levels, as presented
in Figure 6.24, and across a wide range of breast cancer samples. The
potential of NXPH1 gene to be a biomarker to breast cancer and PR can
be further researched by biomedical studies to indicate its role in human
breast cancers.
 {‘CLCA2’}. According to NBCI website1, “ In breast cancer, expression
of this gene is down-regulated and the encoded protein may inhibit migra-
1https://www.ncbi.nlm.nih.gov/gene/9635
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Figure 6.24: Scatter plot of C9orf58 and NXPH1 of (Nature 2012) dataset with
PR groups, illustrating that the observation 23 from the PR+ group has low
expression levels of (C9orf58, NXPH1), which are (−3.3423,−1.46) in comparison
to the observation 126 from the PR- group, which has high expression levels of
(C9orf58, NXPH1), which are (2.4937, 6.3407).
tion and invasion while promoting mesenchymal-to-epithelial transition in
cancer cell lines”. Sasaki et al. [252] found CLCA2 to be involved in the p53
tumour suppressor network and it significantly impacts cancer cell migra-
tion and invasion. CLCA2 was found in [184] to be frequently inactivated in
breast cancer, which makes it a strong candidate for the 1p31 breast cancer
tumour suppressor gene. Similar findings were found by [117], which stated
that CLCA2 might act as a tumour suppressor in breast cancer. CLCA2
mRNA was recognised in this thesis as one of the biomarkers that are as-
sociated negatively with PR levels, as presented in Figure 6.26, and over
a wide range of breast samples. Targeting CLCA2 gene for further studies
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Figure 6.25: Scatter plot of CLCA2 and FGFR4 of (Nature 2012) dataset with
PR groups, illustrating that the observation 252 from the PR+ group has low
expression levels of (CLCA2, FGFR4), which are (−3.5682,−2.5823) in compar-
ison to the observation 32 from the PR- group, which has high expression levels
of (CLCA2, FGFR4), which are (6.3023, 1.8037).
can help to determine its role in breast cancer and PR positivity.
 {‘FGFR4’}. According to NBCI website1 website, “The encoded protein
is involved in the regulation of several pathways, including cell proliferation,
cell differentiation, cell migration, lipid metabolism, bile acid biosynthesis,
vitamin D metabolism, glucose uptake, and phosphate homeostasis”. The
recent review study [285] on the role of FGFR4 in cancers has stated that
information on the involvement of FGFR4 in cancers has significantly in-
creased in recent years and concluded targeting FGFR4 as a potential thera-
1https://www.ncbi.nlm.nih.gov/gene/2264
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peutic strategy. Recently, Zhao et al. [337] have found that FGFR4 provides
the conduit to facilitate FGF19 signaling in the progression of breast can-
cer. Another recent study [323] has suggested targeting FGFR4 as a thera-
peutic opportunity for chemoresistant tumours because it increases glucose
metabolism and leads to chemoresistance in breast cancer. Recently, an-
other study [180] has found that FGFR4 is a novel druggable target for
recurrent ER-positive breast cancers. In this PhD study, evidence of an in-
verse association was observed between the expression patterns of FGFR4
and PR, as illustrated in Figure 6.26, and over variant and independent
breast cancer samples of (Nature 2012), (Cell 2015), (Provisional), and
(METABRIC) as well as across the variations in the integrated datasets
with PR groups. More investigations are required to determine the role of
FGFR4 mRNA in breast cancers and more specifically, in the progesterone
receptor.
 {‘PPP1R1A’}. As mentioned previously in Section 6.3, a research study
[280] found that the expression of PPP1R1A in lung, colorectal, and gastric
cancer cell lines was different from that of the normal tissues. This thesis is
the first to report a negative correlation between PPP1R1A mRNA expres-
sion and high levels of ER, as well as PR positivity, as shown in Figure 6.26,
and across independent cancer genomic datasets. Therefore, the potential
of PPP1R1A mRNA expression to be a diagnostic or prognostic markers
to breast cancer and hormone receptors can be further studied in future
research.
 {‘TRPV6’}. As mentioned previously in Section 6.3, TRPV6 was identi-
fied to be negatively associated with ER+ tumours. Moreover, it has been
shown in this research that TRPV6 is lowly expressed in PR+ tumours,
in which the drops in TRPV6 could contribute to the positivity of PR, as
explained in Figure 6.26, and this has been demonstrated over several inde-
pendent breast cancer genomic datasets. Therefore, TRPV6 can be further
studied to indicate its contributions to breast cancer.
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Figure 6.26: Scatter plot of PPP1R1A and TRPV6 of (Nature 2012) dataset
with PR groups, illustrating that the observation 396 from the PR+ group has
low expression levels of (PPP1R1A, TRPV6), which are (−2.6309,−0.37375) in
comparison to the observation 215 from the PR- group, which has high expression
levels of (PPP1R1A, TRPV6), which are (4.18067, 5.1658).
 {‘C1orf115’}. Very limited information is available in the literature about
this gene, particularly its relevance to breast cancers and the hormone re-
ceptors. This thesis is the first to show evidence of an inverse association
between the expression patterns of Clorf115 and PR, in which the PR+
tumours are characterised by low expression levels of Clorf115 mRNA com-
pared to PR- samples, as introduced in Figure 6.27, and over multiple
independent datasets. Therefore, further investigations are necessitated to
identify the biological mechanism underlying that association.
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Figure 6.27: Scatter plot of C1orf115 and TSPAN8 of (Nature 2012) dataset
with PR groups, illustrating that the observation 286 from the PR+ group has
low expression levels of (C1orf115, TSPAN8), which are (−2.3804,−5.9947) in
comparison to the observation 138 from the PR- group, which has high expression
levels of (C1orf115, TSPAN8), which are (2.9592, 3.1603).
 {‘TSPAN8’}. Growing evidence in the literature suggests that TSPAN8
promotes tumour cell migration, invasion, and metastasis in multiple types
of human cancers [108,227]. Zhu et al. [342] have revealed that several genes,
including TSPAN8 are positively correlated in human breast cancer, and
high expression levels of TSPAN8 correlate with poor prognosis. This thesis
demonstrated a negative association between TSPAN8 and PR positivity,
as clarified in Figure 6.27, and across a wide range of breast cancer samples,
thus targeting this gene for further researching could contribute to advance
our knowledge about the role TSPAN8 might play in PR+ breast cancer.
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6.6 Discussion
Previous chapters discussed the fundamental concepts, design, implementation
of the proposed feature mining models as well as validation and evaluation of
the discovered biomarkers. This chapter covered the clinical relevance of the
recognised biomarkers to breast cancer and the hormone receptor ER and PR
according to current bioinformatics research in the literature. Furthermore, con-
clusive evidence of a positive or negative association between each single mRNA
marker and the hormone receptor ER or PR was introduced and verified.
The positive association was observed and validated between the discovered
biomarkers with HP weight and ER, as discussed in Section 6.2, and the HP
weighted biomarkers and PR, as mentioned in Section 6.4. The positive associ-
ation corresponds to the gains in the expression levels of these biomarkers and
its contribution to ER/PR positivity. The inverse correlation was recognised and
demonstrated between the HN weighted biomarkers and ER, as explained in Sec-
tion 6.3, as well as the identified generic biomarkers with HN weight and PR, as
presented in Section 6.5. The negative association refers to the declines in the
expression levels of these mRNA markers and its contribution to high ER/PR
expression level. The emphasis was made in this chapter on conducting further
investigations to examine the potential of the identified groups of biomarkers to
improve breast cancer patient’s health and survival or develop more cost-effective
therapies.
The computational models reported in this thesis effectively extracted knowl-
edge from omics data using a systematic approach to data modelling, analysis
and validation. The discovered mRNA markers could answer different biologi-
cal questions of interest and provide insights and explanations to the biological,
pathological and pharmacological process underlying human breast cancers and
the hormone receptors ER and PR. The assessment of the clinical relevance of the
discovered biomarkers by bioinformatics researchers is essential for inferring con-
clusive evidence that enables to use the recognised molecular markers to construct
diagnostic and prognostic models that can be accepted in clinical practice.
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Conclusion and Future Work
7.1 Introduction
This thesis discusses the fundamental concepts, research problems and directions
for the discovery of robust biomarkers for diseases, such as cancers, from HDSSS
omics data. The detailed and critical discussions presented considered relevant
current state-of-the-art research to establish key limitations and challenges of
employing them in bioinformatics and computational biology. Therefore, the
limitations of existing approaches established by the literature review led to the
proposal of two models, based on computational intelligence and deep learning,
for the extraction, analysis, interpretation and validation of reliable biomarkers
from human molecular data. Furthermore, the availability of data repositories
and portals for different types of cancer genomic data, main requirements for
effective genome analysis and feature mining, and critical aspects for assessing
the outputs of omics data analysis models are all covered and discussed in de-
tails. Then, this thesis introduces the modelling design, analysis, implementation
and application of the novel feature mining model that integrates traditional sta-
tistical techniques and computational intelligence methods for the goal of the
discovery of the underlying structure of the genomic and proteomic data. It
also proposes a general framework for deep feature learning together with an ex-
planatory technique that can be used for discovering robustly high-level abstract
representations from such datasets and reveal key determinants underlying these
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latent representations. The outputs of our computational models were validated
using effective evaluation metrics and independent validations, thus relevant, ro-
bust, and reproducible biomarkers to breast cancer were discovered and verified.
Moreover, the clinical relevance of the discovered biomarkers to human breast
cancers and ER/PR positivity was also discussed in order to provide conclusive
evidence about the type of underlying association.
7.2 Concluding Remarks
Extracting knowledge from omics datasets is a serious challenge for the research
community interested in understanding the cancer genotype and phenotype. Such
datasets are characterised by high dimensionality and relatively small sample sizes
with small signal-to-noise ratios. This significantly challenges existing machine
learning-based solutions due the curse of dimensionality issues, where the addition
of new input features typically requires an exponential number of input observa-
tions (which are commonly unavailable) to discover the underlying structure of
the data that allows these models to generalise well to unseen cases. This also
puts great pressure on data mining models that attempt to separate the signal
from the noise in a bid to discover robust determinants. Increasing the aware-
ness of the key research challenges allow us to introduce more potential solutions,
by understanding the required computational and statistical resources. The po-
tential solutions introduced in this thesis to tackle the challenges of knowledge
discovery from omics data are concluded in the following sections.
7.2.1 Filtering Methods
It is a well-known that much more accurate machine-learning methods are re-
quired to specify and measure phenotypes of complex diseases such as cancer.
In particular, our focus has specifically been to reduce the amount of spurious
positive associations within sophisticated classifier-based systems by proposing
an intelligent feature mining model. One of the key challenges related to de-
riving knowledge from such high dimensional biomedical data is the amount of
noise and the experimental variability. Filtering methods based on the variation
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and entropy criterion were employed to exclude genes that exhibit a variance or
entropy value less than the 10th percentile from further analysis. The resulting
outcomes of filtering methods were that the genomic datasets had less noise or
less unreliable genes that are not expressed at biologically significant levels. The
preliminary quality assessment can be considered an essential step in the process
of biomarker discovery from omics data in order to increase the quality of the
data prior to the modelling and analysis stages. Therefore, the practical impact
of filtering out the least reliably expressed genes led to increasing the potential
of detecting differentially expressed genes.
7.2.2 Evolutionary Mining Model
As mentioned earlier, extracting knowledge from omics datasets is a serious chal-
lenge for machine learning-based solutions due to the curse of dimensionality
issues. To alleviate these limitations , the evolutionary mining model was pro-
posed based on ad-hoc traditional statistical techniques with the computational
evolutionary method to effectively handle the size and complexity of omics data.
Therefore, the proposed model comprises of three main phases, based on differ-
ent selection paradigms, which are univariate, multivariate, and ensemble. The
univariate selection phase is utilised first to eliminate the least promising features
for the next optimisation phase. The multivariate selection phase, based on the
evolutionary method, is used to optimise the search process for finding the best
possible combination of features in the reduced feature space. The ensemble phase
is utilised to enhance the robustness of the finally selected subset of candidate
predictors. Evaluating the performance of the evolutionary mining model reveals
that this multi-staged model was successful to some extents in recognising robust
biomarkers from several HDSSS microarray and mass spectrometry datasets. The
discovered biomarkers exhibited computational and biological relevance and were
capable of developing highly accurate and reliable prediction systems. However,
it has been shown through this research that the number of identified biomarkers
by this mining model that are generic over independently generated breast cancer
samples was small compared to the outputs of the deep mining model.
Therefore, the requirement for multiple levels of feature learning is necessi-
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tated to exploit the unknown structure of HDSSS omics data efficaciously for
capturing enough of its underlying relevant variations. This has motivated us
to explore another direction of research that focuses on unsupervised feature ex-
traction, rather than supervised feature selection, based on state of the art deep
learning for the goal of automatic deep self-taught learning so that the interesting
complexity can be uncovered adequately from the raw high dimensional genomic
and proteomic data. However, the extraction process based on deep learning
methods lacks the transparency and interpretability found in the feature selec-
tion based on the evolutionary mining model. To address this issue, our research
introduces a novel weight interpretation technique that helps to open the black
box of such deep learning models to reveal key determinants underlying its latent
representations.
7.2.3 Deep Mining Model
In this thesis, we critically evaluate the usefulness of state-of-the-art deep neural
network methods for the problem of knowledge discovery from high through-
put biomedical data. The key requirements for automated deep feature learn-
ing model that is able to handle the crucial challenges underlying the problem
of inferring knowledge from HDSSS omics data are discussed and established.
Therefore, the proposed deep feature learning model was introduced, based on
a set of non-linear sparse Auto-encoders, that are deliberately constructed in an
under-complete manner to force the network to find progressively the complex
featural representations necessary to capture the important variations underlying
the biological samples.
As discussed previously, the dimensionality of omics data is high, which means
that there is an exponential number of possible input configurations. Therefore,
the available biological samples become increasingly sparse, making the process of
discovering plausible and robust input configurations a very difficult task. More-
over, very few genes are expressed reliably at biologically significant levels and
distinguishably from noise and measurement variation [32]. Therefore, the Com-
pressed Auto-encoder attempts to reduce the number of biological samples re-
quired to find a small proportion of molecules that can recover a large proportion
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of variations underlying the data. The Sparse Compressed Auto-Encoder endeav-
ours to promote the notion that different aspects are characterised by different
features. Adding the sparsity penalty to the under-complete layers leads to ren-
dering the hidden neurons to be inactive (i.e. at or near zero) so that a small set
of different groups of hidden neurons allocated to different subsets of features. As
a result, a small proportion of potentially relevant and insensitive determinants
is utilised to represent various inputs through multiple levels of feature trans-
formations of the Stacked Sparse Compressed Auto-Encoder. Consequently, the
learning process proceeds successfully using the available samples addressing the
problem of small sample sizes of omics, where the number of molecules vastly
exceeds the number of observations. Furthermore, the computational and sta-
tistical challenges arising from handling the high dimensional spaces of genomic
and proteomic data are tackled, and a high level of efficiency is achieved.
Consequently, the proposed deep feature learning model was very successful
when applying to the individual cancer datasets, as well as the composite datasets,
which are derived from the individual breast invasive carcinoma datasets. The
characteristics of the presented deep feature learning model were very effective
in handling the challenges of cancer genomic datasets and discovering highly
non-linear generic features, capturing high degrees of variation amongst breast
cancer samples. Given its ability to learn complex functional relationships of
varying degrees of abstraction, it is expected that the proposed deep feature
learning model will detect any salient high-level generic features that are latent
yet pervasive across the data.
7.2.4 The weight Interpretation Method
The weight interpretation method was introduced in this thesis to add explana-
tory power to the deep feature learning model by determining the candidate
input features that force the different biomarker classification behaviours. The
detailed evaluation of the deep mining model demonstrates its capacity to open
the black-box of the deep feature learning model by finding robustly the deferen-
tially expressed genes or proteins that exhibit HP or HN weight scores over the
depth of the network. Fundamentally, two types of outcomes were revealed by our
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deep mining model, both indicating strong likelihoods of a patient having cancer.
The first outcome indicated a subset of highly positively-weighted genes whereby
the amplifications and gains in the gene expression levels were associated with the
likelihood of a patient having cancer. Conversely, the second outcome revealed
another subset of genes that were highly negatively-weighted and coincided with
significant downregulation in the gene expression levels, and again indicated the
strong likelihood of a patient having cancer.
This mechanism explains the internal state of the proposed deep feature learn-
ing model, which relies mainly on allocating HP weight to the features that are
highly expressed for the positives in comparison to most of the negatives. In con-
trast, HN weights are allocated by the proposed deep feature learning model to
the features that are lowly expressed for most of the positives in comparison to the
negatives. The detailed evaluation of the proposed weight interpretation method
provides significant evidence that this explanatory technique was very effective
in offering explainability to the deep learning model and detect key determinants
underlying its latent representations. As our deep learning model is problem-
independent and data-driven, it provides a general framework for knowledge dis-
covery applications based on deep feature learning to omics data characterised
by high dimensionality and relatively small sample size.
7.2.5 Discovered Biomarkers
The application of the deep feature learning model together with the deep min-
ing interpretation method to the breast invasive carcinoma datasets results in
detecting relevant, robust, and reproducible biomarkers over a wide range of in-
dependently generated breast cancer samples. The clinical relevance of these
molecular indicators to breast cancer is discussed, in regards to the bioinformat-
ics analysis studies in the literature, where the type of relationship between each
mRNA and the hormone receptor ER and PR recognised in this research is re-
vealed and proved. Some of these biomarkers have been explored individually by
other bioinformatics studies in the literature, in addition to our research. There-
fore, there is growing evidence that the gains or declines in the expression levels
of these biomarkers contribute to human breast cancers and the positivity of the
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hormone receptors ER and PR.
The biomarkers that are detected in this PhD work to have a positive asso-
ciation with ER levels are: {‘AGR3‘, ‘ESR1’, ‘GFRA1’, ‘SIAH2’, ‘SLC39A6’,
‘SCUBE2’, ‘C6orf97’, ‘ANXA9’, ‘CA12’, ‘NAT1’, ‘GATA3’, ‘PCP2’, ‘FSIP1’,
‘EVL’, ‘LRRC56’, ‘IGFALS’}. In the literature, there is increasing evidence about
the existence of some of these biomarkers in breast cancers like {‘ESR1’, ‘GFRA1’,
‘AGR3’, ‘SIAH2’, ‘NAT1’, ‘SCUBE2’, ‘GATA3’}, while {‘C6orf97’, ‘SLC39A6’,
‘ANXA9’, ‘CA12’, ‘EVL’, ‘FSIP1’, ‘IGFALS’, } have been detected by few stud-
ies, where limited information is available about {‘PCP2’, ‘LRRC56’}, which are
recognised for the first time to be positively correlated with ER levels.
The biomarkers that are found in this research to have an inverse corre-
lation with ER positivity are: {‘PSAT1’, ‘PPP1R14C’, ‘TMEM40’, ‘VGLL1’,
‘C1orf106’, ‘BBOX1’, ‘SOX11’, ‘PROM1’, ‘DKK1’, ‘PARRES1’, ‘S100A8’, ‘S100A9’,
‘TRPV6’, ‘B3GNT5’, ‘KRT16’, ‘KRT81’, ‘HRASLS’, ‘PPP1R1A’}. There is
growing evidence in the literature that some of these biomarkers are frequent
events in breast cancer and triple-negative breast cancer, such as {‘VGLL1’,
‘PROM1’, ‘PSAT1’}, while {‘PPP1R14C’, ‘SOX11’, ‘B3GNT5’, ‘KRT16’, ‘DKK1’,
‘ S100A8’, ‘ S100A9’, ‘TRPV6’}, have been discovered by a few studies, where
little is known about {‘TMEM40’, ‘C1orf106’, ‘BBOX1’, ‘KRT81’, ‘RARRES1’,
‘HRASLS’, ‘PPP1R1A’} and their inverse association with the hormone receptor
ER has not yet been recognised.
For the hormone receptor PR, the biomarkers that are discovered in this PhD
study to have a positive association with PR expression levels are: {‘FGD3’,
‘GFRA1’, ‘GRPR’, ‘PGR’, ‘SUSD3’, ‘GREB1’, ‘SIAH2’, ‘SCUBE2’, ‘AGR3’,
‘PGLYRP2’}. In the literature, there is growing evidence that demonstrates
the role of some of these biomarkers in breast cancers and PR positivity such
as {‘FGD3’, ‘SUSD3’, ‘GRPR’, ‘PGR’, ‘GREB1’}. While limited information is
available about the role of {‘AGR3’, ‘GFRA1’, ‘SIAH2’, ‘SCUBE2’, ‘PGLYRP2’}
in high PR levels. The biomarkers that are discovered in this study to be nega-
tively associated with PR expression levels are: {‘LAD1’, ‘ATP6V0A4’, ‘NXPH1’,
‘C9orf58’, ‘CLCA2’, ‘FGFR4’, ‘PPP1R1A’, ‘TRPV6’, ‘C1orf115’, ‘TSPAN8’}.
These biomarkers have also been detected by a few studies in the literature,
whereas the inverse correlation between their expression patterns and the hor-
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mone receptor PR has not yet been recognised.
Furthermore, four subsets of biomarkers from the METABRIC breast cancer
dataset were discovered robustly to be relevant to breast cancers and the hormone
receptors ER and PR. Most of these mRNA markers were also discovered from the
(Nature 2012), (Cell 2015) and (Provisional) datasets, as discussed in Chapter
6. The clinical relevance of these biomarkers is investigated in the literature
individually by bioinformatics research. For example, a very recent state of the
art finding that is congruent with the results of our research is the biomarker
CD24 that is shown in our research to be negatively associated with ER levels.
A very recent study from Stanford University [16] has revealed CD24 as ‘don’t
eat me’ signal, which stops immune cells engulfing and destroying the cancer cell.
The recent study has found CD24 to be present in high quantities on the surface
of both ovarian and triple negative breast cancer cells and was investigated to see
if blocking this could lead to tumour shrinkage.
As a result, this thesis identifies diverse biomarkers that are positively and
negatively associated with breast cancer and the hormone receptor ER and PR.
The new risk determinants can be further investigated by domain experts to
examine the potential of these genes to be clinical markers for the presence and
progression of this heterogeneous disease, in addition to the predictivity, they can
add to the diagnosis and prognosis models. Moreover, more personalised treat-
ments or monitoring plannings for breast cancer could be developed by scouting
the mechanism underlying the association of the expression patterns of these
molecular markers and ER/PR positivity.
Herein, it is important to mention a significant obstacle for biomarker dis-
covery research, which is the need for more effective interdisciplinary research
environments. There are relatively few examples of situations where novel molec-
ular markers originating from the cancer research community has found its way
into routine clinical practice. Effective inter-disciplinary research is therefore
paramount if findings from state-of-the-art machine learning research is to be
truly exploited and brought into the service of precision medicine.
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7.3 Directions for Future Work
Our deep feature learning and mining models drive novel molecular markers for
breast cancer. The discovered biomarkers are reported after the rigorous and
detailed designation of each step of the biomarker discovery process, which al-
low reproducing the molecular markers across independently generated cancer
genomic datasets. Furthermore, it has been shown through this thesis that the
discovered biomarkers are exhibiting clinical relevance potential to the hormone
receptors ER and PR. The breast cancer datasets used in this thesis are publi-
cally available, thus investigating the findings of this thesis by biomedical experts
can contribute in developing approaches for personalised cancer medicine that
can prevent, screen, manage and treat this complicated disease and enhance the
breast cancer patient’s life and survival.
Moving forward, we will investigate the capacity of our deep mining model to
detect generic biomarkers for selected cancers across a range of independent high-
quality genomic samples collected from different studies. This will indicate which
of these the academic and wider biomedical community should explore further.
Furthermore, research studies have shown that complex diseases like cancers are
extremely heterogeneous and caused by the complex interaction of various under-
lying factors, including genetic, genomic, behavioural and environmental effects
and factors. The rise of high quality integrated and multi-modal omics data, such
as the TCGA database which contains a combination of genomic, epigenomic,
proteomic, imaging and clinical data for matched patient groups, will enable us
to develop sophisticated ’integrative models’ that may reveal even more valuable
indicators of disease. We feel this will provide a sound basis for the development
of more effective diagnostic and prognostic systems in the future.
Several studies have constructed various integrative analysis models to inves-
tigate the integration gain of diverse biomedical data. Most of these integrative
studies have adopted clinicogenomic models that rely on combining clinical and
genomic datasets. Clinicogenomic integrative models focus on addressing the
challenges of integrating disparate dimensionalities of clinical and high dimen-
sional genomic datasets. In terms of biological problems, most clinicogenomic
studies use gene expression data from widely available public genomic datasets,
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despite the fact that each of these datasets provides variant aspects about the
cellular activity. Therefore, the next generation of diagnosis and prognosis sys-
tems is to develop approaches for examining the potential interactions between a
range of diversified cancer data.
The development of integrative prediction models from HDSSS genomic data
poses a range of challenging issues that arise due to experimental, computational,
and statistical complexities. All of these challenges were already discussed in our
research paper: “Challenges in Developing Prediction Models for Multi-Modal
High-Throughput Biomedical Data” [9]. The various challenges encountered are
based on the characteristics of the data, the aim of the integration, and the
level of the integration. Furthermore, three integration levels namely the Early,
Intermediate, and Late were illustrated in this paper and the emphasis was made
that the appropriate integration stage can be identified based on the aim of
the analysis model and the characteristics of the datasets. The directions are
introduced briefly in this paper to address these challenges and some possibilities
for future work are discussed.
Therefore, as a direction for future research, we are aiming to design and
implement an integrative analysis model that can leverage various cancer datasets
for answering diverse systems biology questions. The integration gain and the
differences in performances between multi-modal and uni-modal approaches using
multiple datasets and diverse biomedical modalities will be investigated.
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Table 1: The sizes of the training-validation sets of ovarian cancer dataset and
METABRIC dataset with ER and PR groups.
Dataset Training Sets Validation sets
Ovarian Cancer [173, 172, 173, 173, 173] [43, 44, 43, 43, 43]
METABRIC [1524 1523 1523 1523 1523] [380, 381, 381, 381, 381]
Table 2: The average MSE of each SCAE of ovarian cancer dataset and
METABRIC datasets with ER and PR groups.
Dataset L1 L2 L3 L4
Ovarian Cancer 0.0016 0.0010 0.0024 0.0024
METABRIC with ER 0.0356 0.0130 0.0074 0.0037
METABRIC with PR 0.0373 0.0125 0.0079 0.0036
Table 3: The sizes of the training-validation sets of the breast invasive carcinoma
datasets with ER groups.
Dataset Training Sets Validation sets
(Nature 2012) [416, 415, 415, 415, 415] [103, 104, 104, 104, 104]
(Cell 2015) [332, 332, 332, 332, 332] [83, 83, 83, 83, 83]
(Provisional) [416 415 415 415 415] [103, 104, 104, 104, 104]
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Table 4: The sizes of the training-validation sets of the breast invasive carcinoma
datasets with PR groups.
Dataset Training Sets Validation sets
(Nature 2012) [415, 414, 414, 414, 415] [103, 104, 104, 104, 103]
(Cell 2015) [332, 332, 332, 332, 332] [83, 83, 83, 83, 83]
(Provisional) [415, 414, 414, 414, 415] [103, 104, 104, 104, 103]
Table 5: The average MSE of each SCAE of the breast invasive carcinoma datasets
with ER groups.
Layer (Nature 2012) (Cell 2015) (Provisional)
L1 0.1446 0.1363 0.1368
L2 0.0160 0.0147 0.0158
L3 0.0087 0.0084 0.0087
L4 0.0037 0.0041 0.0040
Table 6: The average MSE of each SCAE of the breast invasive carcinoma datasets
with PR groups.
Layer (Nature 2012) (Cell 2015) (Provisional)
L1 0.1334 0.1351 0.1356
L2 0.0158 0.0147 0.0161
L3 0.0089 0.0088 0.0088
L4 0.0038 0.0039 0.0039
Table 7: The sizes of the training-validation sets of the integrated datasets with
ER groups.
Dataset Training Sets Validation sets
NCP1 [583, 582, 582, 582, 583] [145, 146, 146, 146, 145]
NCP2 [520, 520, 520, 520, 520] [130, 130, 130, 130, 130]
NCP3 [584, 583, 583, 583, 583] [145, 146, 146, 146, 146]
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Table 8: The sizes of the training-validation sets of the integrated datasets with
PR groups.
Dataset Training Sets Validation sets
NC [528, 527, 527, 527, 527] [131, 132, 132, 132, 132]
CN [474, 473, 473, 474, 474] [118, 119, 119, 118, 118]
NP [556, 556, 556, 556, 556] [139, 139, 139, 139, 139]
PN [557, 556, 557, 557, 557] [139, 140, 139, 139, 139]
CP [473, 472, 473, 473, 473] [118, 119, 118, 118, 118]
PC [528, 527, 527, 527, 527] [131, 132, 132, 132, 132]
Table 9: The average MSE of each SCAE of the integrated datasets with ER
groups.
Layer NCP1 NCP2 NCP3
L1 0.0827 0.0770 0.0824
L2 0.0194 0.0198 0.0197
L3 0.0096 0.0097 0.0098
L4 0.0045 0.0047 0.0044
Table 10: The average MSE of each SCAE of the integrated datasets with PR
groups.
Layer NC CN NP PN CP PC
L1 0.1049 0.0962 0.0931 0.0846 0.0922 0.1000
L2 0.0188 0.0191 0.0199 0.0198 0.0194 0.0189
L3 0.0091 0.0094 0.0095 0.0094 0.0098 0.0093
L4 0.0041 0.0049 0.0043 0.0043 0.0044 0.0042
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Figure 1: The performance of the SSCAE at the final iteration of ovarian cancer
dataset and METABRIC dataset with ER and PR groups.
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Figure 2: The performance of the SSCAE at the final iteration of the breast
invasive carcinoma datasets with ER groups.
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Figure 3: The performance of the SSCAE at the final iteration of the breast
invasive carcinoma datasets with PR groups.
191
Figure 4: The performance of the SSCAE at the final iteration of the integrated
datasets with ER groups.
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Figure 5: The performance of the SSCAE at the final iteration of the integrated
datasets with PR groups.
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Figure 6: The performance of the SSCAE at the final iteration of the integrated
datasets with PR groups.
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Figure 7: The performance of the SVM and BDT models at the final iteration of
ovarian cancer dataset.
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Figure 8: The performance of the SVM and BDT models at the final iteration of
METABRIC dataset with ER groups.
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Figure 9: The performance of the SVM and BDT models at the final iteration of
METABRIC dataset with PR groups.
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Figure 10: The performance of the SVM model at the final iteration of breast
invasive carcinoma dataset with ER groups.
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Figure 11: The performance of the BDT model at the final iteration of breast
invasive carcinoma dataset with ER groups.
199
Figure 12: The performance of the SVM model at the final iteration of breast
invasive carcinoma dataset with PR groups.
200
Figure 13: The performance of the BDT model at the final iteration of breast
invasive carcinoma dataset with PR groups.
201
Figure 14: The performance of the SVM model at the final iteration of the
integrated dataset with ER groups.
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Figure 15: The performance of the BDT model at the final iteration of the inte-
grated dataset with ER groups.
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Figure 16: The performance of the SVM model at the final iteration for the
integrated dataset with PR groups.
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Figure 17: The performance of the BDT model at the final iteration of the inte-
grated dataset with PR groups.
205
Figure 18: The performance of the SVM model at the final iteration of the
integrated dataset with PR groups.
206
Figure 19: The performance of the BDT model at the final iteration of the inte-
grated dataset with PR groups.
207
References
[1] Ossama Abdel-Hamid, Abdel-rahman Mohamed, Hui Jiang,
Li Deng, Gerald Penn, and Dong Yu. Convolutional neural net-
works for speech recognition. IEEE/ACM Transactions on audio, speech,
and language processing, 22[10]:1533–1545, 2014. 35
[2] Thomas Abeel, Thibault Helleputte, Yves Van de Peer, Pierre
Dupont, and Yvan Saeys. Robust biomarker identification for can-
cer diagnosis with ensemble feature selection methods. Bioinformatics,
26[3]:392–398, 2009. 30, 32
[3] M Gordian Adam, Sonja Matt, Sven Christian, Holger Hess-
Stumpp, Andrea Haegebarth, Thomas G Hofmann, and Car-
olyn Algire. Siah ubiquitin ligases regulate breast cancer cell migration
and invasion independent of the oxygen status. Cell Cycle, 14[23]:3734–
3747, 2015. 135
[4] Paul J Adam, Joanne Berry, Julie A Loader, Kerry L Tyson,
Graham Craggs, Paul Smith, Jackie De Belin, Graham Steers,
Francesco Pezzella, Kris F Sachsenmeir, et al. Arylamine n-
acetyltransferase-1 is highly expressed in breast cancers and conveys en-
hanced growth and resistance to etoposide in vitro. Molecular cancer re-
search, 1[11]:826–835, 2003. 138
[5] Heli I Alanen, Richard A Williamson, Mark J Howard, Anna-
Kaisa Lappi, Heli P Ja¨ntti, Sini M Rautio, Sakari Kellokumpu,
and Lloyd W Ruddock. Functional characterization of erp18, a new
endoplasmic reticulum-located thioredoxin superfamily member. Journal
of Biological Chemistry, 278[31]:28912–28920, 2003. 134
208
REFERENCES
[6] Gabriela Alexe, G. S. Dalgin, Ramakrishna Ramaswamy,
Charles DeLisi, and Gyan Bhanot. Data perturbation independent
diagnosis and validation of breast cancer subtypes using clustering and pat-
terns. Cancer Informatics, 2:243 – 274, 2006. 169
[7] Babak Alipanahi, Andrew Delong, Matthew T Weirauch, and
Brendan J Frey. Predicting the sequence specificities of dna-and rna-
binding proteins by deep learning. Nature biotechnology, 33[8]:831, 2015.
34
[8] Prasanna G Alluri, Corey Speers, and Arul M Chinnaiyan.
Estrogen receptor mutations and their role in breast cancer progression.
Breast Cancer Research, 16[6]:494, 2014. 133
[9] Abeer Alzubaidi. Challenges in developing prediction models for multi-
modal high-throughput biomedical data. In Proceedings of SAI Intelligent
Systems Conference, pages 1056–1069. Springer, 2018. 185
[10] Sarah A Andres and James L Wittliff. Co-expression of genes with
estrogen receptor-α and progesterone receptor in human breast carcinoma
tissue. Hormone molecular biology and clinical investigation, 12[1]:377–390,
2012. 141
[11] Christof Angermueller, Heather Lee, Wolf Reik, and Oliver
Stegle. Accurate prediction of single-cell dna methylation states using
deep learning. BioRxiv, page 055715, 2017. 34
[12] Lindsay Angus, Nick Beije, Agnes Jager, John WM Martens,
and Stefan Sleijfer. Esr1 mutations: Moving towards guiding treat-
ment decision-making in metastatic breast cancer patients. Cancer treat-
ment reviews, 52:33–40, 2017. 133
[13] T Arentsen, Y Qian, S Gkotzis, T Femenia, T Wang, K Udekwu,
H Forssberg, and R Diaz Heijtz. The bacterial peptidoglycan-sensing
molecule Pglyrp2 modulates brain development and behavior. Molecular
Psychiatry, 22:257, nov 2016. 164
209
REFERENCES
[14] Francisco Azuaje. Bioinformatics and biomarker discovery. Wiley On-
line Library, 2010. 1, 19
[15] YI Bao, Antao Wang, and Juanfen Mo. S100a8/a9 is associated with
estrogen receptor loss in breast cancer. Oncology letters, 11[3]:1936–1942,
2016. 155, 157
[16] Amira A Barkal, Rachel E Brewer, Maxim Markovic, Mark
Kowarsky, Sammy A Barkal, Balyn W Zaro, Venkatesh Kr-
ishnan, Jason Hatakeyama, Oliver Dorigo, Layla J Barkal,
et al. Cd24 signalling through macrophage siglec-10 is a target for cancer
immunotherapy. Nature, page 1, 2019. 183
[17] Daniel H Barnett, Shubin Sheng, Tze Howe Charn, Abdul Wa-
heed, William S Sly, Chin-Yo Lin, Edison T Liu, and Benita S
Katzenellenbogen. Estrogen receptor regulation of carbonic anhydrase
xii through a distal enhancer in breast cancer. Cancer Research, 68[9]:3505–
3515, 2008. 140
[18] Hamid Behravan, Jaana M Hartikainen, Maria Tengstro¨m, Ka-
tri Pylka¨s, Robert Winqvist, Veli-Matti Kosma, and Arto
Mannermaa. Machine learning identifies interacting genetic variants con-
tributing to breast cancer risk: A case study in finnish cases and controls.
Scientific reports, 8[1]:13149, 2018. 14
[19] Richard Bellman. Dynamic Programming. Princeton University Press,
Princeton, NJ, USA, 1 edition, 1957. 2
[20] Asa Ben-Hur, Cheng Soon Ong, So¨ren Sonnenburg, Bernhard
Scho¨lkopf, and Gunnar Ra¨tsch. Support vector machines and kernels
for computational biology. PLoS computational biology, 4[10]:e1000173,
2008. 24
[21] Yoshua Bengio. Deep learning of representations for unsupervised and
transfer learning. In Proceedings of ICML Workshop on Unsupervised and
Transfer Learning, pages 17–36, 2012. 92
210
REFERENCES
[22] Yoshua Bengio, Aaron Courville, and Pascal Vincent. Repre-
sentation learning: A review and new perspectives. IEEE transactions on
pattern analysis and machine intelligence, 35[8]:1798–1828, 2013. 34
[23] Yoshua Bengio et al. Learning deep architectures for ai. Foundations
and trends R© in Machine Learning, 2[1]:1–127, 2009. 21
[24] Yoshua Bengio, Pascal Lamblin, Dan Popovici, and Hugo
Larochelle. Greedy layer-wise training of deep networks. pages 153–
160, 2007. 29, 36, 93
[25] Yoav Benjamini and Yosef Hochberg. Controlling the false discovery
rate: a practical and powerful approach to multiple testing. Journal of the
royal statistical society. Series B (Methodological), pages 289–300, 1995. 19
[26] Wendie A Berg. Tailored supplemental screening for breast cancer: what
now and what next? American Journal of Roentgenology, 192[2]:390–399,
2009. 15
[27] Caroline Bergenfelz, Alexander Gaber, Roni Allaoui, Meliha
Mehmeti, Karin Jirstro¨m, Tomas Leanderson, and Karin Lean-
dersson. S100a9 expressed in er- pgr- breast cancers induces inflammatory
cytokines and is associated with an impaired overall survival. British jour-
nal of cancer, 113[8]:1234–1243, 2015. 157
[28] Pablo Bermejo, Luis de la Ossa, Jose´ A Ga´mez, and Jose´ M
Puerta. Fast wrapper feature subset selection in high-dimensional datasets
by means of filter re-ranking. Knowledge-Based Systems, 25[1]:35–44, 2012.
31
[29] Sarah M Bernhardt, Pallave Dasari, David Walsh, Amanda R
Townsend, Timothy J Price, and Wendy V Ingman. Hormonal
modulation of breast cancer gene expression: implications for intrinsic sub-
typing in premenopausal women. Frontiers in oncology, 6:241, 2016. 16
[30] Philippe Bertheau, Elisabeth Turpin, David S Rickman,
Marc Espie´, Aure´lien De Reynie`s, Jean-Paul Feugeas, Louis-
Franc¸ois Plassa, Hany Soliman, Mariana Varna, Anne
211
REFERENCES
De Roquancourt, et al. Exquisite sensitivity of tp53 mutant and basal
breast cancers to a dose-dense epirubicin- cyclophosphamide regimen. PLoS
medicine, 4[3]:e90, 2007. 147
[31] Sunil Bhakta, Lisa M Crocker, Yvonne Chen, Meredith Hazen,
Melissa M Schutten, Dongwei Li, Coenraad Kuijl, Rachana
Ohri, Fiona Zhong, Kirsten A Poon, et al. An anti-gdnf fam-
ily receptor alpha 1 (gfra1) antibody–drug conjugate for the treatment of
hormone receptor–positive breast cancer. Molecular cancer therapeutics,
17[3]:638–649, 2018. 134
[32] Verena E Bichsel, Lance A Liotta, et al. Cancer proteomics: from
biomarker discovery to signal pathway profiling. Cancer journal (Sudbury,
Mass.), 7[1]:69–78, 2001. 49, 93, 179
[33] SE Bleeker, HA Moll, EW Steyerberg, ART Donders, Ger-
arda Derksen-Lubsen, DE Grobbee, and KGM Moons. External
validation is necessary in prediction research:: A clinical example. Journal
of clinical epidemiology, 56[9]:826–832, 2003. 45
[34] Emily E Bosco, R James Christie, Rosa Carrasco, Darrin
Sabol, Jiping Zha, Karma DaCosta, Lee Brown, Maureen
Kennedy, John Meekin, Sandrina Phipps, et al. Preclinical evalu-
ation of a gfra1 targeted antibody-drug conjugate in breast cancer. Onco-
target, 9[33]:22960, 2018. 134
[35] Bernhard E Boser, Isabelle M Guyon, and Vladimir N Vapnik.
A training algorithm for optimal margin classifiers. In Proceedings of the
fifth annual workshop on Computational learning theory, pages 144–152.
ACM, 1992. 24
[36] Anne Boulay, Madlaina Breuleux, Christine Stephan, Caro-
line Fux, Cathrin Brisken, Maryse Fiche, Markus Wartmann,
Michael Stumm, Heidi A Lane, and Nancy E Hynes. The ret re-
ceptor tyrosine kinase pathway functionally interacts with the erα pathway
in breast cancer. Cancer research, 68[10]:3743–3751, 2008. 134
212
REFERENCES
[37] Anne Boulay, Catherine H Re´gnier, Patrick Anglard, Isabelle
Stoll, Catherine Tomasetto, and Marie-Christine Rio. Tran-
scription regulation and protein subcellular localization of the truncated
basic hair keratin hhb1-δn in human breast cancer cells. Journal of Biolog-
ical Chemistry, 276[25]:22954–22964, 2001. 154
[38] Y-lan Boureau, Yann L Cun, et al. Sparse feature learning for
deep belief networks. In Advances in neural information processing systems,
pages 1185–1192, 2008. 93
[39] George EP Box and R Daniel Meyer. An analysis for unreplicated
fractional factorials. Technometrics, 28[1]:11–18, 1986. 29
[40] Norman F Boyd, Helen Guo, Lisa J Martin, Limei Sun, Jen-
nifer Stone, Eve Fishell, Roberta A Jong, Greg Hislop, Anna
Chiarelli, Salomon Minkin, et al. Mammographic density and the
risk and detection of breast cancer. New England Journal of Medicine,
356[3]:227–236, 2007. 15
[41] Ulisses M Braga-Neto and Edward R Dougherty. Is cross-
validation valid for small-sample microarray classification? Bioinformatics,
20[3]:374–380, 2004. 42
[42] Leo Breiman. Classification and regression trees. Routledge, 2017. 28
[43] Frank Z Brill, Donald E Brown, and Worthy N Martin. Fast
generic selection of features for neural network classifiers. IEEE Transac-
tions on Neural Networks, 3[2]:324–328, 1992. 33
[44] Tom Brosch, Roger Tam, Alzheimers Disease Neuroimaging Ini-
tiative, et al. Manifold learning of brain mris by deep learning. In Inter-
national Conference on Medical Image Computing and Computer-Assisted
Intervention, pages 633–640. Springer, 2013. 34
[45] Samantha M Carlisle and David W Hein. Retrospective analysis
of estrogen receptor 1 and n-acetyltransferase gene expression in normal
breast tissue, primary breast tumors, and established breast cancer cell
lines. International journal of oncology, 53[2]:694–702, 2018. 138
213
REFERENCES
[46] J S Carroll. Mechanisms of oestrogen receptor (ER) gene regulation in
breast cancer. European journal of endocrinology, 175[1]:R41–9, jul 2016.
16
[47] Mar´ıa A´ngeles Castilla, Mar´ıa A´ngeles Lo´pez-Garc´ıa,
Mar´ıa Reina Atienza, Juan Manuel Rosa-Rosa, Juan D´ıaz-
Mart´ın, Mar´ıa Luisa Pecero, Begona Vieites, Laura Romero-
Pe´rez, Javier Ben´ıtez, Annarica Calcabrini, et al. Vgll1 ex-
pression is associated with a triple-negative basal-like phenotype in breast
cancer. Endocrine-related cancer, 21[4]:587–599, 2014. 146, 147, 152
[48] Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E
Gross, Selcuk Onur Sumer, Bu¨lent Arman Aksoy, Anders Ja-
cobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson, et al.
The cbio cancer genomics portal: an open platform for exploring multidi-
mensional cancer genomics data, 2012. 51
[49] Peter Chan, Andreas Mo¨ller, Mira CP Liu, Jaclyn E Sceneay,
Christina SF Wong, Nic Waddell, Katie T Huang, Alexander
Dobrovic, Ewan KA Millar, Sandra A O’Toole, et al. The
expression of the ubiquitin ligase siah2 (seven in absentia homolog 2) is
mediated through gene copy number in breast cancer and is associated
with a basal-like phenotype and p53 expression. Breast Cancer Research,
13[1]:R19, 2011. 136
[50] Dingiun Chen, Keith CC Chan, and Xindong Wu. Gene expression
analyses using genetic algorithm based hybrid approaches. In Evolutionary
Computation, 2008. CEC 2008.(IEEE World Congress on Computational
Intelligence). IEEE Congress on, pages 963–969. IEEE, 2008. 33
[51] Jie-Zhi Cheng, Dong Ni, Yi-Hong Chou, Jing Qin, Chui-Mei Tiu,
Yeun-Chung Chang, Chiun-Sheng Huang, Dinggang Shen, and
Chung-Ming Chen. Computer-aided diagnosis with deep learning archi-
tecture: applications to breast lesions in us images and pulmonary nodules
in ct scans. Scientific reports, 6:24454, 2016. 34
214
REFERENCES
[52] Meng Cheng, Stephanie Michalski, and Ramakrishna Komma-
gani. Role for growth regulation by estrogen in breast cancer 1 (greb1) in
hormone-dependent cancers. International journal of molecular sciences,
19[9]:2543, 2018. 165
[53] Wei-Yi Cheng, Tai-Hsien Ou Yang, and Dimitris Anastassiou.
Biomolecular events in cancer revealed by attractor metagenes. PLoS com-
putational biology, 9[2]:e1002920, 2013. 161, 162
[54] Aaron Ciechanover. Proteolysis: from the lysosome to ubiquitin and
the proteasome. Nature reviews Molecular cell biology, 6[1]:79, 2005. 135
[55] Giovanni Ciriello, Michael L Gatza, Andrew H Beck,
Matthew D Wilkerson, Suhn K Rhie, Alessandro Pastore,
Hailei Zhang, Michael McLellan, Christina Yau, Cyriac Kan-
doth, et al. Comprehensive molecular portraits of invasive lobular breast
cancer. Cell, 163[2]:506–519, 2015. 53
[56] Dearbhaile C Collins, Raghav Sundar, Joline SJ Lim, and Tim-
othy A Yap. Towards precision medicine in the clinic: from biomarker dis-
covery to novel therapeutics. Trends in pharmacological sciences, 38[1]:25–
40, 2017. 2
[57] Francis S Collins and Lawrence A Tabak. Nih plans to enhance
reproducibility. Nature, 505[7485]:612–613, 2014. 50
[58] Ronan Collobert, Jason Weston, Le´on Bottou, Michael
Karlen, Koray Kavukcuoglu, and Pavel Kuksa. Natural language
processing (almost) from scratch. Journal of Machine Learning Research,
12[Aug]:2493–2537, 2011. 35
[59] Krysta M Coyle, J Patrick Murphy, Dejan Vidovic, Ahmad
Vaghar-Kashani, Cheryl A Dean, Mohammad Sultan, Derek
Clements, Melissa Wallace, Margaret L Thomas, Amos Hun-
dert, et al. Breast cancer subtype dictates dna methylation and aldh1a3-
mediated expression of tumor suppressor rarres1. Oncotarget, 7[28]:44096,
2016. 154
215
REFERENCES
[60] Krysta M Coyle, Ahmad Vaghar-Kashani, Florence Wong,
Cheryl Dean, Carman Giacomantonio, and Paola Marcato.
Rarres1 is a tumor suppressor in triple-negative breast cancer cell lines,
2014. 154
[61] F H CRICK. On protein synthesis. Symposia of the Society for Experi-
mental Biology, 12:138–163, 1958. 17
[62] Christina Curtis, Sohrab P Shah, Suet-Feung Chin, Gulisa
Turashvili, Oscar M Rueda, Mark J Dunning, Doug Speed,
Andy G Lynch, Shamith Samarajiwa, Yinyin Yuan, et al. The
genomic and transcriptomic architecture of 2,000 breast tumours reveals
novel subgroups. Nature, 486[7403]:346, 2012. 62, 161
[63] Se´Rgio Francisco Da Silva, Marcela Xavier Ribeiro, Joa˜o do
ES Batista Neto, Caetano Traina-Jr, and Agma JM Traina.
Improving the ranking quality of medical image retrieval using a genetic
feature selection method. Decision support systems, 51[4]:810–820, 2011.
33
[64] Simone U Dalm, Willemijne AME Schrijver, Anieta M Sieuw-
erts, Maxime P Look, Angelique CJ Ziel-Van Der Made,
Vanja De Weerd, John W Martens, Paul J Van Diest, Marion
De Jong, and Carolien HM Van Deurzen. Prospects of targeting the
gastrin releasing peptide receptor and somatostatin receptor 2 for nuclear
imaging and therapy in metastatic breast cancer. PloS one, 12[1]:e0170536,
2017. 164
[65] Simone U Dalm, Anieta M Sieuwerts, Maxime P Look, Marleen
Melis, Carolien HM van Deurzen, John A Foekens, Marion
de Jong, and John WM Martens. Clinical relevance of targeting the
gastrin-releasing peptide receptor, somatostatin receptor 2, or chemokine
cxc motif receptor 4 in breast cancer for imaging and therapy. Journal of
Nuclear Medicine, 56[10]:1487–1493, 2015. 164
[66] Padideh Danaee, Reza Ghaeini, and David A Hendrix. A deep
learning approach for cancer detection and relevant gene identification.
216
REFERENCES
In PACIFIC SYMPOSIUM ON BIOCOMPUTING 2017, pages 219–229.
World Scientific, 2017. 38
[67] Chad A Davis, Fabian Gerick, Volker Hintermair, Caroline C
Friedel, Katrin Fundel, Robert Ku¨ffner, and Ralf Zimmer. Re-
liable gene signatures for microarray classification: assessment of stability
and performance. Bioinformatics, 22[19]:2356–2363, 2006. 45
[68] Sarah-Jane Dawson, Oscar M Rueda, Samuel Aparicio, and
Carlos Caldas. A new genome-driven integrated classification of breast
cancer and its implications. The EMBO journal, 32[5]:617–628, 2013. 62
[69] Kenneth A De Jong. Evolutionary computation: a unified approach.
MIT press, 2006. 33, 69
[70] Beatriz De La Iglesia. Evolutionary computation for feature selection
in classification problems. Wiley Interdisciplinary Reviews: Data Mining
and Knowledge Discovery, 3[6]:381–407, 2013. 33
[71] Sandra L Deming, Zefang Ren, Wanqing Wen, Xiao Ou Shu,
Qiuyin Cai, Yu-Tang Gao, and Wei Zheng. Genetic variation in igf1,
igf-1r, igfals, and igfbp3 in breast cancer survival among chinese women: a
report from the shanghai breast cancer study. Breast cancer research and
treatment, 104[3]:309–319, 2007. 144
[72] Meaza Demissie, Barbara Mascialino, Stefano Calza, and Yudi
Pawitan. Unequal group variances in microarray data analyses. Bioinfor-
matics, 24[9]:1168–1174, 2008. 20
[73] Li Deng and Xiao Li. Machine learning paradigms for speech recogni-
tion: An overview. IEEE Transactions on Audio, Speech, and Language
Processing, 21[5]:1060–1089, 2013. 35
[74] Horacio M Domene´, Vivian Hwa, Jesu´s Argente, Jan M Wit,
Cecilia Camacho-Hu¨bner, He´ctor G Jasper, Jesu´s Pozo, Her-
mine A Van Duyvenvoorde, Shoshana Yakar, Olga V Fofanova-
Gambetti, et al. Human acid-labile subunit deficiency: clinical, en-
217
REFERENCES
docrine and metabolic consequences. Hormone Research in Paediatrics,
72[3]:129–141, 2009. 144
[75] David L Donoho et al. High-dimensional data analysis: The curses
and blessings of dimensionality. AMS math challenges lecture, 1[2000]:32,
2000. 20
[76] Marco Dorigo and Mauro Birattari. Ant colony optimization. In
Encyclopedia of machine learning, pages 36–39. Springer, 2011. 33
[77] Marco Dorigo and Gianni Di Caro. Ant colony optimization: a
new meta-heuristic. In Proceedings of the 1999 congress on evolutionary
computation-CEC99 (Cat. No. 99TH8406), 2, pages 1470–1477. IEEE,
1999. 33
[78] Feng Du, Peng Yuan, Teng Wang, Jiuda Zhao, Zitong Zhao,
Yang Luo, and Binghe Xu. The significance and therapeutic potential
of gata3 expression and mutation in breast cancer: a systematic review.
Medicinal research reviews, 35[6]:1300–1315, 2015. 144
[79] Sandrine Dudoit, Jane Fridlyand, and Terence P Speed. Com-
parison of discrimination methods for the classification of tumors using gene
expression data. Journal of the American statistical association, 97[457]:77–
87, 2002. 74
[80] Anita K Dunbier, Helen Anderson, Zara Ghazoui, Elena
Lopez-Knowles, Sunil Pancholi, Ricardo Ribas, Suzanne
Drury, Kally Sidhu, Alexandra Leary, Lesley-Ann Martin,
et al. Esr1 is co-expressed with closely adjacent uncharacterised genes
spanning a breast cancer susceptibility locus at 6q25. 1. PLoS genetics,
7[4]:e1001382, 2011. 136
[81] Kevin Dunne, Padraig Cunningham, and Francisco Azuaje. So-
lutions to instability problems with sequential wrapper-based approaches
to feature selection. Journal of Machine Learning Research, pages 1–22,
2002. 45
218
REFERENCES
[82] Be´atrice Duval and Jin-Kao Hao. Advances in metaheuristics for
gene selection and classification of microarray data. Briefings in bioinfor-
matics, 11[1]:127–141, 2009. 30
[83] Darius M Dziuda. Data mining for genomics and proteomics: analysis
of gene and protein expression data, 1. John Wiley & Sons, 2010. 18
[84] Russell Eberhart and James Kennedy. Particle swarm optimization.
In Proceedings of the IEEE international conference on neural networks, 4,
pages 1942–1948. Citeseer, 1995. 33
[85] Emad Elbeltagi, Tarek Hegazy, and Donald Grierson. Com-
parison among five evolutionary-based optimization algorithms. Advanced
engineering informatics, 19[1]:43–53, 2005. 33
[86] Yumi Endo, Hiroko Yamashita, Satoru Takahashi, Shinya Sato,
Nobuyasu Yoshimoto, Tomoko Asano, Yukari Hato, Yu Dong,
Yoshitaka Fujii, and Tatsuya Toyama. Immunohistochemical deter-
mination of the mir-1290 target arylamine n-acetyltransferase 1 (nat1) as a
prognostic biomarker in breast cancer. Bmc Cancer, 14[1]:990, 2014. 139
[87] Dumitru Erhan, Yoshua Bengio, Aaron Courville, Pierre-
Antoine Manzagol, Pascal Vincent, and Samy Bengio. Why
does unsupervised pre-training help deep learning? Journal of Machine
Learning Research, 11[Feb]:625–660, 2010. 35, 93, 100
[88] S Esseghir, JS Reis-Filho, A Kennedy, M James, MJ O’hare,
R Jeffery, R Poulsom, and CM Isacke. Identification of transmem-
brane proteins as potential prognostic markers and therapeutic targets in
breast cancer by a screen for signal sequence encoding transcripts. The
Journal of Pathology: A Journal of the Pathological Society of Great Britain
and Ireland, 210[4]:420–430, 2006. 134
[89] Selma Esseghir, S Katrina Todd, Toby Hunt, Richard Poul-
som, Ivan Plaza-Menacho, Jorge S Reis-Filho, and Clare M
Isacke. A role for glial cell–derived neurotrophic factor–induced expres-
sion by inflammatory cytokines and ret/gfrα1 receptor up-regulation in
breast cancer. Cancer research, 67[24]:11732–11741, 2007. 134
219
REFERENCES
[90] Ruth Etzioni, Nicole Urban, Scott Ramsey, Martin McIntosh,
Stephen Schwartz, Brian Reid, Jerald Radich, Garnet Ander-
son, and Leland Hartwell. Early detection: The case for early detec-
tion. Nature Reviews Cancer, 3[4]:243, 2003. 15
[91] Cheng Fan, Daniel S Oh, Lodewyk Wessels, Britta Weigelt,
Dimitry SA Nuyten, Andrew B Nobel, Laura J Van’t Veer, and
Charles M Perou. Concordance among gene-expression–based predic-
tors for breast cancer. New England Journal of Medicine, 355[6]:560–569,
2006. 141
[92] Jianqing Fan and Runze Li. Statistical challenges with high di-
mensionality: Feature selection in knowledge discovery. arXiv preprint
math/0602133, 2006. 2
[93] Marta Faryna, Carolin Konermann, Sebastian Aulmann,
Justo Lorenzo Bermejo, Markus Brugger, Sven Diederichs,
Joachim Rom, Dieter Weichenhan, Rainer Claus, Michael
Rehli, et al. Genome-wide methylation screen in low-grade breast can-
cer identifies novel epigenetically altered genes as potential biomarkers for
tumor diagnosis. The FASEB Journal, 26[12]:4937–4950, 2012. 169
[94] Artur J Ferreira and Ma´Rio AT Figueiredo. Efficient feature
selection filters for high-dimensional data. Pattern Recognition Letters,
33[13]:1794–1804, 2012. 30
[95] Graeme C Fielder, Teresa Wen-Shan Yang, Mahalakshmi Raz-
dan, Yan Li, Jun Lu, Jo K Perry, Peter E Lobie, and Dong-Xu
Liu. The gdnf family: A role in cancer? Neoplasia, 20[1]:99–117, 2018.
134
[96] Ronald A Fisher. The use of multiple measurements in taxonomic prob-
lems. Annals of eugenics, 7[2]:179–188, 1936. 20, 73
[97] Patrick L Fitzgibbons, Douglas A Murphy, M Elizabeth H
Hammond, D Craig Allred, and Paul N Valenstein. Recommenda-
tions for validating estrogen and progesterone receptor immunohistochem-
220
REFERENCES
istry assays. Archives of pathology & laboratory medicine, 134[6]:930–935,
2010. 16
[98] Roger Fletcher. Practical methods of optimization. John Wiley & Sons,
2013. 97
[99] MA Forget, S Turcotte, D Beauseigle, J Godin-Ethier, S Pel-
letier, J Martin, S Tanguay, and R Lapointe. The wnt path-
way regulator dkk1 is preferentially expressed in hormone-resistant breast
tumours and in some common cancer types. British journal of cancer,
96[4]:646–653, 2007. 154
[100] Vittorio Fortino, Pia Kinaret, Nanna Fyhrquist, Harri Ale-
nius, and Dario Greco. A robust and accurate method for feature selec-
tion and prioritization from multi-class omics data. PloS one, 9[9]:e107801,
2014. 10, 32, 45
[101] Alex A Freitas. Data mining and knowledge discovery with evolutionary
algorithms. Springer Science & Business Media, 2013. 33
[102] Jianjiong Gao, Bu¨lent Arman Aksoy, Ugur Dogrusoz, Gideon
Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders
Jacobsen, Rileen Sinha, Erik Larsson, et al. Integrative analysis
of complex cancer genomics and clinical profiles using the cbioportal. Sci.
Signal., 6[269]:pl1–pl1, 2013. 51
[103] Song Gao, Anqi Ge, Shouping Xu, Zilong You, Shipeng Ning,
Yashuang Zhao, and Da Pang. Psat1 is regulated by atf4 and enhances
cell proliferation via the gsk3β/β-catenin/cyclin d1 signaling pathway in
er-negative breast cancer. Journal of Experimental & Clinical Cancer Re-
search, 36[1]:179, 2017. 148
[104] Montserrat Garcia-Closas and Stephen Chanock. Genetic sus-
ceptibility loci for breast cancer by estrogen receptor status. Clinical Cancer
Research, 14[24]:8000–8009, 2008. 16
[105] Stefan Garczyk, Saskia von Stillfried, Wiebke Antonopoulos,
Arndt Hartmann, Michael G Schrauder, Peter A Fasching,
221
REFERENCES
Tobias Anzeneder, Andrea Tannapfel, Yavuz Ergo¨nenc, Ruth
Knu¨chel, et al. Agr3 in breast cancer: Prognostic impact and
suitable serum-based biomarker for early cancer detection. PloS one,
10[4]:e0122106, 2015. 134
[106] Robert Gentleman, Vincent Carey, Wolfgang Huber, Rafael
Irizarry, and Sandrine Dudoit. Bioinformatics and computational
biology solutions using R and Bioconductor. Springer Science & Business
Media, 2006. 49
[107] Filippo Geraci, Marco Pellegrini, and M Elena Renda. Amic@:
all microarray clusterings@ once. Nucleic acids research, 36[suppl 2]:W315–
W319, 2008. 21
[108] Sabine Gesierich, Claudia Paret, Dagmar Hildebrand, Ju¨rgen
Weitz, Kaspar Zgraggen, Friedrich H Schmitz-Winnenthal,
Vaclav Horejsi, Osamu Yoshie, Dorothee Herlyn, Leonie K
Ashman, et al. Colocalization of the tetraspanins, co-029 and cd151,
with integrins in human pancreatic adenocarcinoma: impact on cell motil-
ity. Clinical cancer research, 11[8]:2840–2852, 2005. 174
[109] Philip E Gill and Walter Murray. Safeguarded steplength algo-
rithms for optimization using descent methods. 1974. 97
[110] Wilson Wen Bin Goh and Limsoon Wong. Evaluating feature-
selection stability in next-generation proteomics. Journal of bioinformatics
and computational biology, 14[05]:1650029, 2016. 44
[111] David E Goldberg and John H Holland. Genetic algorithms and
machine learning. Machine learning, 3[2]:95–99, 1988. 33
[112] Abhishek Golugula, George Lee, and Anant Madabhushi. Eval-
uating feature selection strategies for high dimensional, small sample size
datasets. In Engineering in Medicine and Biology Society, EMBC, 2011
Annual International Conference of the IEEE, pages 949–952. IEEE, 2011.
45
222
REFERENCES
[113] Royston Goodacre, Seetharaman Vaidyanathan, Warwick B
Dunn, George G Harrigan, and Douglas B Kell. Metabolomics by
numbers: acquiring and understanding global metabolite data. TRENDS
in Biotechnology, 22[5]:245–252, 2004. 18
[114] Peter C Gøtzsche and Margrethe Nielsen. Screening for breast
cancer with mammography. Cochrane database of systematic reviews, [1],
2011. 14
[115] Christian J Gro¨ger, Markus Grubinger, Thomas Waldho¨r,
Klemens Vierlinger, and Wolfgang Mikulits. Meta-analysis of
gene expression signatures defining the epithelial to mesenchymal transi-
tion during cancer progression. PloS one, 7[12]:e51136, 2012. 168
[116] Biomarkers Definitions Working Group, Arthur J Atkin-
son Jr, Wayne A Colburn, Victor G DeGruttola, David L
DeMets, Gregory J Downing, Daniel F Hoth, John A Oates,
Carl C Peck, Robert T Schooley, et al. Biomarkers and surro-
gate endpoints: preferred definitions and conceptual framework. Clinical
Pharmacology & Therapeutics, 69[3]:89–95, 2001. 1
[117] Achim D. Gruber and Bendicht U. Pauli. Tumorigenicity of human
breast cancer is associated with loss of the ca2+-activated chloride channel
clca2. 59[21]:5488–5491, 1999. 170
[118] Sofia Gruvberger, Markus Ringne´r, Yidong Chen, Sujatha
Panavally, Lao H. Saal, A˚ke Borg, Ma˚rten Ferno¨, Carsten
Peterson, and Paul S. Meltzer. Estrogen receptor status in breast
cancer is associated with remarkably distinct gene expression patterns. Can-
cer Research. 168
[119] Martin Gutlein, Eibe Frank, Mark Hall, and Andreas Kar-
wath. Large-scale attribute selection using wrappers. In 2009 IEEE sympo-
sium on computational intelligence and data mining, pages 332–339. IEEE,
2009. 31
223
REFERENCES
[120] Isabelle Guyon and Andre´ Elisseeff. An introduction to variable
and feature selection. Journal of machine learning research, 3[Mar]:1157–
1182, 2003. 30
[121] Francis H. C. Crick. Central dogma of molecular biology. 227:561–3,
09 1970. xi, 17, 18
[122] Nils Y Hammerla, Shane Halloran, and Thomas Ploetz. Deep,
convolutional, and recurrent models for human activity recognition using
wearables. arXiv preprint arXiv:1604.08880, 2016. 35
[123] M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett,
D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L
Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,
et al. American society of clinical oncology/college of american pathol-
ogists guideline recommendations for immunohistochemical testing of es-
trogen and progesterone receptors in breast cancer (unabridged version).
Archives of pathology & laboratory medicine, 134[7]:e48–e72, 2010. 16
[124] Xianlin Han. Neurolipidomics: challenges and developments. Frontiers
in bioscience: a journal and virtual library, 12:2601, 2007. 19
[125] David J Hand. Classifier technology and the illusion of progress. Statistical
science, pages 1–14, 2006. 20
[126] Anne-Claire Haury, Pierre Gestraud, and Jean-Philippe Vert.
The influence of feature selection methods on accuracy, stability and inter-
pretability of molecular signatures. PloS one, 6[12]:e28210, 2011. 31
[127] Daniel L Hertz, N Lynn Henry, Kelley M Kidwell, Dafydd
Thomas, Audrey Goddard, Faouzi Azzouz, Kelly Speth, Lang
Li, Mousumi Banerjee, Jacklyn N Thibert, et al. Esr1 and
pgr polymorphisms affect estrogen and progesterone receptor expression
in breast tumors. American Journal of Physiology-Heart and Circulatory
Physiology, 2016. 167
[128] Magnus Rudolph Hestenes. Conjugate direction methods in optimiza-
tion, 12. Springer Science & Business Media, 2012. 97
224
REFERENCES
[129] Geoffrey Hinton, Li Deng, Dong Yu, George E Dahl, Abdel-
rahman Mohamed, Navdeep Jaitly, Andrew Senior, Vincent
Vanhoucke, Patrick Nguyen, Tara N Sainath, et al. Deep neural
networks for acoustic modeling in speech recognition: The shared views of
four research groups. IEEE Signal processing magazine, 29[6]:82–97, 2012.
35
[130] Geoffrey E Hinton. Connectionist learning procedures. In Machine
Learning, Volume III, pages 555–610. Elsevier, 1990. 34
[131] Geoffrey E Hinton, Simon Osindero, and Yee-Whye Teh. A fast
learning algorithm for deep belief nets. Neural computation, 18[7]:1527–
1554, 2006. 36
[132] Geoffrey E Hinton and Ruslan R Salakhutdinov. Reducing the
dimensionality of data with neural networks. science, 313[5786]:504–507,
2006. 37
[133] Kendra Hodgkinson, Laura A Forrest, Nhung Vuong, Ken-
neth Garson, Bojana Djordjevic, and Barbara C Vanderhy-
den. Greb1 is an estrogen receptor-regulated tumour promoter that is
frequently expressed in ovarian cancer. Oncogene, 37[44]:5873, 2018. 165
[134] John H Holland. Adaptation in natural and artificial systems: an intro-
ductory analysis with applications to biology, control, and artificial intelli-
gence, 1975. 33, 69
[135] John Henry Holland. Nonlinear environments permitting efficient
adaptation. 1967. 33
[136] Frederik Holst, Cathy B Moelans, Martin Filipits, Chris-
tian F Singer, Ronald Simon, and Paul J Van Diest. On the
evidence for esr1 amplification in breast cancer. Nature Reviews Cancer,
12[2]:149, 2012. 132
[137] Regina J Hooley, Liva Andrejeva, and Leslie M Scoutt. Breast
cancer screening and problem solving using mammography, ultrasound, and
magnetic resonance imaging. Ultrasound quarterly, 27[1]:23–47, 2011. 15
225
REFERENCES
[138] Richard P Horgan and Louise C Kenny. omictechnologies: ge-
nomics, transcriptomics, proteomics and metabolomics. The Obstetrician
& Gynaecologist, 13[3]:189–195, 2011. 17
[139] Harold Hotelling. Analysis of a complex of statistical variables into
principal components. Journal of educational psychology, 24[6]:417, 1933.
20
[140] Li-De Hu, Hua-Fei Zou, Shu-Xuan Zhan, and Kai-Ming Cao. Evl
(ena/vasp-like) expression is up-regulated in human breast cancer and its
relative expression level is correlated with clinical stages. Oncology reports,
19[4]:1015–1020, 2008. 141
[141] Zhi Hu, Richard Neve, Yinghui Guan, and Joe Gray. Identification
of new therapeutic targets of breast cancer using sirna technology, 2007. 138
[142] Jianping Hua, Waibhav D Tembe, and Edward R Dougherty. Per-
formance of feature-selection methods in the classification of high-dimension
data. Pattern Recognition, 42[3]:409–424, 2009. 30
[143] Jinjie Huang, Yunze Cai, and Xiaoming Xu. A hybrid genetic algo-
rithm for feature selection wrapper based on mutual information. Pattern
Recognition Letters, 28[13]:1825–1844, 2007. 33
[144] In˜aki Inza, Borja Calvo, Rube´n Arman˜anzas, Endika Ben-
goetxea, Pedro Larran˜aga, and Jose´ A Lozano. Machine learn-
ing: an indispensable tool in bioinformatics. In Bioinformatics methods in
clinical research, pages 25–48. Springer, 2010. 30
[145] John PA Ioannidis. Microarrays and molecular research: noise discovery?
The Lancet, 365[9458]:454–455, 2005. 44
[146] Jeremy Irvin, Pranav Rajpurkar, Michael Ko, Yifan Yu, Sil-
viana Ciurea-Ilcus, Chris Chute, Henrik Marklund, Behzad
Haghgoo, Robyn Ball, Katie Shpanskaya, et al. Chexpert: A
large chest radiograph dataset with uncertainty labels and expert compar-
ison. arXiv preprint arXiv:1901.07031, 2019. 8
226
REFERENCES
[147] Alison J Camden, Maria M Szwarc, Sangappa Chadchan,
Francesco Demayo, Bert W O ’malley, John P Lydon, and Ra-
makrishna Kommagani. Growth regulation by estrogen in breast cancer
1 (greb1) is a novel progesterone-responsive gene required for human en-
dometrial stromal decidualization. Molecular Human Reproduction, 23:1–8,
08 2017. 165
[148] Gareth James, Daniela Witten, Trevor Hastie, and Robert
Tibshirani. An introduction to statistical learning, 112. Springer, 2013.
42
[149] Maurice PHM Jansen, Kirsten Ruigrok-Ritstier, Lambert CJ
Dorssers, Iris L van Staveren, Maxime P Look, Marion E
Meijer-van Gelder, Anieta M Sieuwerts, Jozien Helleman, Ste-
fan Sleijfer, Jan GM Klijn, et al. Downregulation of siah2, an ubiq-
uitin e3 ligase, is associated with resistance to endocrine therapy in breast
cancer. Breast cancer research and treatment, 116[2]:263–271, 2009. 136
[150] Kevin Jarrett, Koray Kavukcuoglu, Yann LeCun, et al. What
is the best multi-stage architecture for object recognition? In Computer
Vision, 2009 IEEE 12th International Conference on, pages 2146–2153.
IEEE, 2009. 37
[151] Simon A. Joosse, Juliane Hannemann, Julia Spo¨tter, Andreas
Bauche, Antje Andreas, Volkmar Mu¨ller, and Klaus Pantel.
Changes in keratin expression during metastatic progression of breast can-
cer: Impact on the detection of circulating tumor cells. Clinical Cancer
Research, 18[4]:993–1003, 2012. 151
[152] Andrew R Joyce and Bernhard Ø Palsson. The model organism as
a system: integrating ’omics’ data sets. Nat Rev Mol Cell Biol, 7:198–210,
2006 Mar 2006. 17
[153] Giuseppe Jurman, Stefano Merler, Annalisa Barla, Silvano
Paoli, Antonio Galea, and Cesare Furlanello. Algebraic stability
indicators for ranked lists in molecular profiling. Bioinformatics, 24[2]:258–
264, January 2008. 44
227
REFERENCES
[154] Md Monirul Kabir, Md Shahjahan, and Kazuyuki Murase. A
new local search based hybrid genetic algorithm for feature selection. Neu-
rocomputing, 74[17]:2914–2928, 2011. 33
[155] Alexandros Kalousis, Julien Prados, and Melanie Hilario. Sta-
bility of feature selection algorithms: a study on high-dimensional spaces.
Knowledge and information systems, 12[1]:95–116, 2007. 45
[156] Jessica Kao, Keyan Salari, Melanie Bocanegra, Yoon-La Choi,
Luc Girard, Jeet Gandhi, Kevin A Kwei, Tina Hernandez-
Boussard, Pei Wang, Adi F Gazdar, et al. Molecular profiling
of breast cancer cell lines defines relevant tumor models and provides a
resource for cancer gene discovery. PloS one, 4[7]:e6146, 2009. 147
[157] Mariz Kasoha, Rainer M Bohle, Anita Seibold, Christoph
Gerlinger, Ingolf Juhasz-Boess, and Erich-Franz Solomayer.
Dickkopf-1 (dkk1) protein expression in breast cancer with special refer-
ence to bone metastases. Clinical & experimental metastasis, 35[8]:763–775,
2018. 154
[158] Grit Kasper, Armin A Weiser, Andreas Rump, Katrin Sparbier,
Edgar Dahl, Arndt Hartmann, Peter Wild, Uta Schwidetzky,
Esmeralda Castan˜os-Ve´lez, and Kerstin Lehmann. Expression
levels of the putative zinc transporter liv-1 are associated with a better out-
come of breast cancer patients. International journal of cancer, 117[6]:961–
973, 2005. 138
[159] Hiroyuki Katayama, Clayton Boldt, Jon J Ladd, Melissa M
Johnson, Timothy Chao, Michela Capello, Jinfeng Suo, Jian-
ning Mao, JoAnn E Manson, Ross Prentice, et al. An autoim-
mune response signature associated with the development of triple-negative
breast cancer reflects disease pathogenesis. Cancer research, 75[16]:3246–
3254, 2015. 151
[160] Benita S Katzenellenbogen, Monica M Montano, Kirk Ekena,
Mary E Herman, and Eileen M McInerney. Antiestrogens: mecha-
228
REFERENCES
nisms of action and resistance in breast cancer. Breast cancer research and
treatment, 44[1]:23–38, 1997. 16
[161] David R Kelley, Jasper Snoek, and John L Rinn. Basset: learning
the regulatory code of the accessible genome with deep convolutional neural
networks. Genome research, 2016. 34
[162] Brian M Kennedy and Randall E Harris. Cyclooxygenase and
lipoxygenase gene expression in the inflammogenesis of breast cancer. In-
flammopharmacology, 26[4]:909–923, 2018. 149
[163] James Kennedy. Particle swarm optimization. In Encyclopedia of ma-
chine learning, pages 760–766. Springer, 2011. 33
[164] Dan Koboldt. The future of cancer genomics. Clinical OMICs, 1[7]:8–10,
2014. 50
[165] Pang Wei Koh, Emma Pierson, and Anshul Kundaje. Denoising
genome-wide histone chip-seq with convolutional neural networks. Bioin-
formatics, 33[14]:i225–i233, 2017. 34
[166] Isaac S Kohane, Atul J Butte, and Alvin Kho. Microarrays for an
integrative genomics. MIT press, 2002. 49
[167] Ron Kohavi and George H John. Wrappers for feature subset selec-
tion. Artificial intelligence, 97[1-2]:273–324, 1997. 31
[168] Teuvo Kohonen. Exploration of very large databases by self-organizing
maps. In Proceedings of International Conference on Neural Networks
(ICNN’97), 1, pages PL1–PL6. IEEE, 1997. 21
[169] Nadezda V Kovalevskaya, Charlotte Whicher, Timothy D
Richardson, Craig Smith, Jana Grajciarova, Xocas Cardama,
Jose´ Moreira, Adrian Alexa, Amanda A McMurray, and
Fiona GG Nielsen. Dnadigest and repositive: connecting the world
of genomic data. PLoS biology, 14[3]:e1002418, 2016. 50
229
REFERENCES
[170] Alex Krizhevsky, Ilya Sutskever, and Geoffrey E Hinton. Im-
agenet classification with deep convolutional neural networks. In Advances
in neural information processing systems, pages 1097–1105, 2012. 35
[171] Yanan Kuang, Bilal Siddiqui, Jiani Hu, Matthew Pun, MacIn-
tosh Cornwell, Gilles Buchwalter, Melissa E Hughes, Nikhil
Wagle, Paul Kirschmeier, Pasi A Ja¨nne, et al. Unraveling the
clinicopathological features driving the emergence of esr1 mutations in
metastatic breast cancer. NPJ breast cancer, 4[1]:22, 2018. 133
[172] Ludmila I Kuncheva and Lakhmi C Jain. Nearest neighbor classi-
fier: Simultaneous editing and feature selection. Pattern recognition letters,
20[11-13]:1149–1156, 1999. 33
[173] Miron Bartosz Kursa. Robustness of random forest-based gene selec-
tion methods. BMC bioinformatics, 15[1]:8, 2014. 32
[174] Anne-Vibeke Laenkholm, Ann Knoop, Bent Ejlertsen, Tine
Rudbeck, Maj-Britt Jensen, Sven Mu¨ller, Anne Elisabeth
Lykkesfeldt, Birgitte Bruun Rasmussen, and Kirsten Vang
Nielsen. Esr1 gene status correlates with estrogen receptor protein levels
measured by ligand binding assay and immunohistochemistry. Molecular
oncology, 6[4]:428–436, 2012. 133
[175] Thomas Navin Lal, Olivier Chapelle, Jason Weston, and
Andre´ Elisseeff. Embedded methods. In Feature extraction, pages 137–
165. Springer, 2006. 30
[176] Hugo Larochelle, Dumitru Erhan, Aaron Courville, James
Bergstra, and Yoshua Bengio. An empirical evaluation of deep archi-
tectures on problems with many factors of variation. In Proceedings of the
24th international conference on Machine learning, pages 473–480. ACM,
2007. 93
[177] Yann LeCun, Yoshua Bengio, and Geoffrey Hinton. Deep learn-
ing. nature, 521[7553]:436, 2015. 34, 100
230
REFERENCES
[178] Jonathan T Lei, Jieya Shao, Jin Zhang, Michael Iglesia,
Doug W Chan, Jin Cao, Meenakshi Anurag, Purba Singh, Xiap-
ing He, Yoshimasa Kosaka, et al. Functional annotation of esr1 gene
fusions in estrogen receptor-positive breast cancer. Cell reports, 24[6]:1434–
1444, 2018. 133
[179] CHRISTOPHE Lemetre. Artificial neural network techniques to inves-
tigate potential interactions between biomarkers. PhD thesis, Nottingham
Trent University, 2010. 153
[180] K M Levine, K Ding, N Priedigkeit, M J Sikora, N Tasdemir,
L Zhu, G C Tseng, R C Jankowitz, D J Dabbs, P F McAuliffe,
A V Lee, and S Oesterreich. Abstract P5-04-21: FGFR4 is a novel
druggable target for recurrent ER-positive breast cancers. Cancer Research,
79[4 Supplement]:P5–04–21—-P5–04–21, 2019. 172
[181] Caiyan Li and Hongzhe Li. Network-constrained regularization and
variable selection for analysis of genomic data. Bioinformatics, 24[9]:1175–
1182, 2008. 20
[182] Cong Li, Fang Zhang, Meihong Lin, and Jingwen Liu. Induction
of s100a9 gene expression by cytokine oncostatin m in breast cancer cells
through the stat3 signaling cascade. Breast cancer research and treatment,
87[2]:123–134, 2004. 157
[183] Lihua Li, Li Chen, D Goldgof, F George, Z Chen, A Rao, J Cra-
gun, R Sutphen, and Johnathan M Lancaster. Integration of
clinical information and gene expression profiles for prediction of chemo-
response for ovarian cancer. In 2005 IEEE Engineering in Medicine and
Biology 27th Annual Conference, pages 4818–4821. IEEE, 2006. 20
[184] Xiurong Li, John K Cowell, and Khalid Sossey-Alaoui. CLCA2
tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer.
Oncogene, 23:1474, feb 2004. 170
[185] Yang Li, Xu-Qing Tang, Zhonghu Bai, and Xiaofeng Dai. Ex-
ploring the intrinsic differences among breast tumor subtypes defined using
231
REFERENCES
immunohistochemistry markers based on the decision tree. Scientific re-
ports, 6:35773, 2016. 140, 146
[186] Elgene Lim, Franc¸ois Vaillant, Di Wu, Natasha C Forrest,
Bhupinder Pal, Adam H Hart, Marie-Liesse Asselin-Labat,
David E Gyorki, Teresa Ward, Audrey Partanen, et al. Aber-
rant luminal progenitors as the candidate target population for basal tumor
development in brca1 mutation carriers. Nature medicine, 15[8]:907, 2009.
146, 147
[187] Yuh-Charn Lin, Yi-Ching Lee, Ling-Hui Li, Chien-Jui Cheng,
and Ruey-Bing Yang. Tumor suppressor scube2 inhibits breast-cancer
cell migration and invasion through the reversal of epithelial–mesenchymal
transition. J Cell Sci, 127[1]:85–100, 2014. 141
[188] Charles X Ling, Jin Huang, and Harry Zhang. Auc: a better
measure than accuracy in comparing learning algorithms. In Conference of
the canadian society for computational studies of intelligence, pages 329–
341. Springer, 2003. 64
[189] Charles X Ling, Jin Huang, Harry Zhang, et al. Auc: a statisti-
cally consistent and more discriminating measure than accuracy. In IJCAI,
3, pages 519–524, 2003. 64
[190] Caigang Liu, Lisha Sun, Jie Yang, Tong Liu, Yongliang Yang,
Se-Min Kim, Xunyan Ou, Yining Wang, Li Sun, Mone Zaidi,
et al. Fsip1 regulates autophagy in breast cancer. Proceedings of the
National Academy of Sciences, 115[51]:13075–13080, 2018. 142
[191] DaoTong Liu, Z Peng, JingYan Han, Fan-Zhong Lin, Xian-Min
Bu, and Qing-Xia Xu. Clinical and prognostic significance of sox11
in breast cancer. Asian Pacific journal of cancer prevention: APJCP,
15[13]:5483–5486, 2014. 150
[192] Huan Liu and Lei Yu. Toward integrating feature selection algorithms
for classification and clustering. IEEE Transactions on knowledge and data
engineering, 17[4]:491–502, 2005. 31
232
REFERENCES
[193] Huiqing Liu, Jinyan Li, and Limsoon Wong. A comparative study on
feature selection and classification methods using gene expression profiles
and proteomic patterns. Genome informatics, 13:51–60, 2002. 19
[194] Peipei Liu, Wenhui Li, Yuanyuan Hu, and Youhong Jiang. Ab-
sence of AIF1L contributes to cell migration and a poor prognosis of breast
cancer. OncoTargets and therapy, 11:5485–5498, sep 2018. 169
[195] Siqi Liu, Sidong Liu, Weidong Cai, Sonia Pujol, Ron Kikinis,
and Dagan Feng. Early diagnosis of alzheimer’s disease with deep learn-
ing. In Biomedical Imaging (ISBI), 2014 IEEE 11th International Sympo-
sium on, pages 1015–1018. IEEE, 2014. 34
[196] Tong Liu, Hao Zhang, Li Sun, Danyu Zhao, Peng Liu, Meisi
Yan, Neeha Zaidi, Sudeh Izadmehr, Animesh Gupta, Wahid Abu-
Amer, Minna Luo, Jie Yang, Xunyan Ou, Yining Wang, Xue-
feng Bai, Yan Wang, Maria I. New, Mone Zaidi, Tony Yuen,
and Caigang Liu. Fsip1 binds her2 directly to regulate breast cancer
growth and invasiveness. Proceedings of the National Academy of Sciences,
114[29]:7683–7688, 2017. 142
[197] Felipe Llinares Lo´pez. Significant Pattern Mining for Biomarker Dis-
covery. PhD thesis, ETH Zurich, 2018. 19
[198] A´ngeles Lo´pez-Lo´pez, A´ngeles Lo´pez-Gonza´lvez, Toma´s Clive
Barker-Tejeda, and Coral Barbas. A review of validated biomarkers
obtained through metabolomics. Expert review of molecular diagnostics,
18[6]:557–575, 2018. 45
[199] Aoife J Lowery, Nicola Miller, Amanda Devaney, Roisin E
McNeill, Pamela A Davoren, Christophe Lemetre, Vladimir
Benes, Sabine Schmidt, Jonathon Blake, Graham Ball, et al.
Microrna signatures predict oestrogen receptor, progesterone receptor
and her2/neu receptor status in breast cancer. Breast cancer research,
11[3]:R27, 2009. 16
233
REFERENCES
[200] Edward M. Rubin, Susan Lucas, Paul Richardson, Daniel
Rokhsar, and Len Pennacchio. Finishing the euchromatic sequence
of the human genome. 431, 09 2004. 2
[201] Shuangge Ma and Jian Huang. Penalized feature selection and classi-
fication in bioinformatics. Briefings in bioinformatics, 9[5]:392–403, 2008.
30
[202] Jacqueline MacArthur, Emily Bowler, Maria Cerezo, Lau-
rent Gil, Peggy Hall, Emma Hastings, Heather Junkins, Aoife
McMahon, Annalisa Milano, Joannella Morales, et al. The
new nhgri-ebi catalog of published genome-wide association studies (gwas
catalog). Nucleic acids research, 45[D1]:D896–D901, 2016. 20
[203] James MacQueen et al. Some methods for classification and analysis
of multivariate observations. In Proceedings of the fifth Berkeley symposium
on mathematical statistics and probability, 1, pages 281–297. Oakland, CA,
USA, 1967. 21
[204] James D Malley, Karen G Malley, and Sinisa Pajevic. Statistical
learning for biomedical data. Cambridge University Press, 2011. 20
[205] Emily B Mardian, Ryan M Bradley, and Robin E Duncan.
The hrasls (pla/at) subfamily of enzymes. Journal of biomedical science,
22[1]:99, 2015. 157
[206] John WM Martens, Inko Nimmrich, Thomas Koenig, Maxime P
Look, Nadia Harbeck, Fabian Model, Antje Kluth, Joan Bolt-
de Vries, Anieta M Sieuwerts, Henk Portengen, et al. Associa-
tion of dna methylation of phosphoserine aminotransferase with response to
endocrine therapy in patients with recurrent breast cancer. Cancer research,
65[10]:4101–4117, 2005. 149
[207] Lesley-Ann Martin, Ricardo Ribas, Nikiana Simigdala, Eugene
Schuster, Sunil Pancholi, Tencho Tenev, Pascal Gellert, Laki
Buluwela, Alison Harrod, Allan Thornhill, et al. Discovery of
naturally occurring esr1 mutations in breast cancer cell lines modelling
endocrine resistance. Nature communications, 8[1]:1865, 2017. 133
234
REFERENCES
[208] Jeanette N McClintick and Howard J Edenberg. Effects of fil-
tering by present call on analysis of microarray experiments. BMC bioin-
formatics, 7[1]:49, 2006. 49
[209] Riccardo Miotto, Li Li, Brian A Kidd, and Joel T Dudley. Deep
patient: an unsupervised representation to predict the future of patients
from the electronic health records. Scientific reports, 6:26094, 2016. 34
[210] Smita Misra and Gautam Chaudhuri. Abstract 3159: Zar2 transcrip-
tionally represses the atpase atp6v0a4 to negatively regulate invasiveness
of breast cancer cells. Cancer Research, 74:3159–3159, 10 2014. 167
[211] Thomas M. Mitchell. Machine Learning. McGraw-Hill, Inc., New York,
NY, USA, 1 edition, 1997. 22
[212] Martin Fodslette Møller. A scaled conjugate gradient algorithm for
fast supervised learning. Neural networks, 6[4]:525–533, 1993. 98, 99
[213] Cle´ment Morgat, Gae´tan MacGrogan, Ve´ronique Brouste,
Vale´rie Ve´lasco, Nicolas Sevenet, Herve´ Bonnefoi, Philippe
Fernandez, Marc Debled, and Elif Hindie. Expression of gastrin-
releasing peptide receptor in breast cancer and its association with patho-
logic, biologic, and clinical parameters: a study of 1,432 primary tumors.
Journal of Nuclear Medicine, 58[9]:1401–1407, 2017. 164
[214] Cle´ment Morgat, Romain Schollhammer, Gae´tan Macgro-
gan, Nicole Barthe, Vale´rie Ve´lasco, Delphine Vimont, Anne-
Laure Cazeau, Philippe Fernandez, and Elif Hindie´. Comparison
of the binding of the gastrin-releasing peptide receptor (grp-r) antagonist
68ga-rm2 and 18f-fdg in breast cancer samples. PloS one, 14[1]:e0210905,
2019. 164
[215] Barry K Moser and Gary R Stevens. Homogeneity of variance in
the two-sample means test. The American Statistician, 46[1]:19–21, 1992.
72
[216] I Moy, V Todorovic´, AD Dubash, JS Coon, James B Parker,
M Buranapramest, CC Huang, Hong Zhao, Kathleen Janee
235
REFERENCES
Green, and Serdar E Bulun. Estrogen-dependent sushi domain con-
taining 3 regulates cytoskeleton organization and migration in breast cancer
cells. Oncogene, 34[3]:323, 2015. 162
[217] Sayan Mukherjee. Classifying microarray data using support vector
machines. In A practical approach to microarray data analysis, pages 166–
185. Springer, 2003. 24
[218] Naoki Nanashima, Kayo Horie, Toshiyuki Yamada, Takeshi
Shimizu, and Shigeki Tsuchida. Hair keratin krt81 is expressed in nor-
mal and breast cancer cells and contributes to their invasiveness. Oncology
reports, 37[5]:2964–2970, 2017. 154
[219] Cancer Genome Atlas Network et al. Comprehensive molecular
portraits of human breast tumours. Nature, 490[7418]:61, 2012. 51
[220] Wing WY Ng, Guangjun Zeng, Jiangjun Zhang, Daniel S Ye-
ung, and Witold Pedrycz. Dual autoencoders features for imbalance
classification problem. Pattern Recognition, 60:875–889, 2016. 37
[221] Jie Niu, Xiao-Meng Li, Xiao Wang, Chao Liang, Yi-Dan Zhang,
Hai-Ying Li, Fan-Ye Liu, Hua Sun, Song-Qiang Xie, and Dong
Fang. Dkk1 inhibits breast cancer cell migration and invasion through sup-
pression of β-catenin/mmp7 signaling pathway. Cancer cell international,
19[1]:168, 2019. 154
[222] Joanna Obacz, Veronika Brychtova, Jan Podhorec, Pavel
Fabian, Petr Dobes, Borivoj Vojtesek, and Roman Hrstka. an-
terior gradient protein 3 is associated with less aggressive tumors and better
outcome of breast cancer patients. OncoTargets and therapy, 8:1523, 2015.
134
[223] Il-Seok Oh, Jin-Seon Lee, and Byung-Ro Moon. Hybrid genetic
algorithms for feature selection. IEEE Transactions on Pattern Analysis &
Machine Intelligence, [11]:1424–1437, 2004. 33
236
REFERENCES
[224] Lydia E Pace and Nancy L Keating. A systematic assessment
of benefits and risks to guide breast cancer screening decisions. Jama,
311[13]:1327–1335, 2014. 15
[225] Marco Padilla-Rodriguez, Sara S Parker, Deanna G Adams,
Thomas Westerling, Julieann I Puleo, Adam W Watson,
Samantha M Hill, Muhammad Noon, Raphael Gaudin, Jesse
Aaron, et al. The actin cytoskeletal architecture of estrogen receptor
positive breast cancer cells suppresses invasion. Nature communications,
9[1]:1–16, 2018. 141
[226] Soonmyung Paik, Gong Tang, Steven Shak, Chungyeul Kim,
Joffre Baker, Wanseop Kim, Maureen Cronin, Frederick L
Baehner, Drew Watson, John Bryant, et al. Gene expression and
benefit of chemotherapy in women with node-negative, estrogen receptor-
positive breast cancer. J Clin Oncol, 24[23]:3726–3734, 2006. 141
[227] CS Park, TK Kim, HG Kim, YJ Kim, MH Jeoung, WR Lee,
NK Go, K Heo, and S Lee. Therapeutic targeting of tetraspanin8 in
epithelial ovarian cancer invasion and metastasis. Oncogene, 35[34]:4540–
4548, 2016. 174
[228] Yudi Pawitan, Stefan Michiels, Serge Koscielny, Arief Gus-
nanto, and Alexander Ploner. False discovery rate, sensitivity and
sample size for microarray studies. Bioinformatics, 21[13]:3017–3024, 2005.
19
[229] Hanchuan Peng, Fuhui Long, and Chris Ding. Feature selection
based on mutual information criteria of max-dependency, max-relevance,
and min-redundancy. IEEE Transactions on pattern analysis and machine
intelligence, 27[8]:1226–1238, 2005. 31
[230] Bernard Pereira, Suet-Feung Chin, Oscar M Rueda, Hans-
Kristian Moen Vollan, Elena Provenzano, Helen A Bard-
well, Michelle Pugh, Linda Jones, Roslin Russell, Stephen-
John Sammut, et al. The somatic mutation profiles of 2,433 breast
237
REFERENCES
cancers refine their genomic and transcriptomic landscapes. Nature com-
munications, 7:11479, 2016. 62
[231] Charles M Perou, Therese Sørlie, Michael B Eisen, Matt Van
De Rijn, Stefanie S Jeffrey, Christian A Rees, Jonathan R
Pollack, Douglas T Ross, Hilde Johnsen, Lars A Akslen, et al.
Molecular portraits of human breast tumours. nature, 406[6797]:747, 2000.
16
[232] Amelia A Peters, Peter T Simpson, Johnathon J Bassett,
Jane M Lee, Leonard Da Silva, Lynne E Reid, Sarah Song,
Marie-Odile Parat, Sunil R Lakhani, Paraic A Kenny, et al.
Calcium channel trpv6 as a potential therapeutic target in estro-
gen receptor–negative breast cancer. Molecular cancer therapeutics,
11[10]:2158–2168, 2012. 157
[233] Trang Pham, Truyen Tran, Dinh Phung, and Svetha
Venkatesh. Deepcare: A deep dynamic memory model for predictive
medicine. In Pacific-Asia Conference on Knowledge Discovery and Data
Mining, pages 30–41. Springer, 2016. 34
[234] Zheng Ping, Yuchao Xia, Tiansheng Shen, Vishwas Parekh,
Gene P Siegal, Isam-Eldin Eltoum, Jianbo He, Dongquan Chen,
Minghua Deng, Ruibin Xi, et al. A microscopic landscape of the in-
vasive breast cancer genome. Scientific reports, 6:27545, 2016. 54
[235] Richard Possemato, Kevin M Marks, Yoav D Shaul, Michael E
Pacold, Dohoon Kim, Kıvanc¸ Birsoy, Shalini Sethumadhavan,
Hin-Koon Woo, Hyun G Jang, Abhishek K Jha, et al. Functional
genomics reveal that the serine synthesis pathway is essential in breast
cancer. Nature, 476[7360]:346, 2011. 148
[236] Ivan O. Potapenko, Torben Lders, Hege G. Russnes, slaug Hel-
land, Therese Srlie, Vessela N. Kristensen, Silje Nord, OleC.
Lingjrde, Anne-Lise Brresen-Dale, and Vilde D. Haakensen.
Glycan-related gene expression signatures in breast cancer subtypes; rela-
tion to survival. Molecular Oncology, 9[4]:861 – 876, 2015. 149
238
REFERENCES
[237] Christopher Poultney, Sumit Chopra, Yann L Cun, et al. Ef-
ficient learning of sparse representations with an energy-based model. In
Advances in neural information processing systems, pages 1137–1144, 2007.
36, 37
[238] Michael James David Powell. Restart procedures for the conjugate
gradient method. Mathematical programming, 12[1]:241–254, 1977. 97
[239] Laszlo Radvanyi, Devender Singh-Sandhu, Scott Gallichan,
Corey Lovitt, Artur Pedyczak, Gustavo Mallo, Kurt Gish,
Kevin Kwok, Wedad Hanna, Judith Zubovits, et al. The
gene associated with trichorhinophalangeal syndrome in humans is overex-
pressed in breast cancer. Proceedings of the National Academy of Sciences,
102[31]:11005–11010, 2005. 134
[240] James M Rae, Michael D Johnson, Joshua O Scheys, Kevin E
Cordero, Jose M Larios, and Marc E Lippman. Greb1 is a crit-
ical regulator of hormone dependent breast cancer growth. Breast cancer
research and treatment, 92[2]:141–149, 2005. 164
[241] Michael L Raymer, William F. Punch, Erik D Goodman,
Leslie A Kuhn, and Anil K Jain. Dimensionality reduction using ge-
netic algorithms. IEEE transactions on evolutionary computation, 4[2]:164–
171, 2000. 33
[242] Anat Reiner, Daniel Yekutieli, and Yoav Benjamini. Identifying
differentially expressed genes using false discovery rate controlling proce-
dures. Bioinformatics, 19[3]:368–375, 2003. 19
[243] Toma´s Reinert, Rodrigo Gonc¸alves, and Jose´ Bines. Implications
of esr1 mutations in hormone receptor-positive breast cancer. Current treat-
ment options in oncology, 19[5]:24, 2018. 133
[244] Tomas Reinert, Everardo D Saad, Carlos H Barrios, and Jose´
Bines. Clinical implications of esr1 mutations in hormone receptor-positive
advanced breast cancer. Frontiers in oncology, 7:26, 2017. 133
239
REFERENCES
[245] Cielito C Reyes-Gibby, Jian Wang, Sai-Ching J Yeung, Patrick
Chaftari, K Yu Robert, Ehab Y Hanna, and Sanjay Shete.
Genome-wide association study identifies genes associated with neuropa-
thy in patients with head and neck cancer. Scientific reports, 8[1]:8789,
2018. 141
[246] Markus Ringne´r. What is principal component analysis? Nature
biotechnology, 26[3]:303, 2008. 21, 29
[247] Lee Roth, Swati Srivastava, Moshit Lindzen, Aldema Sas-Chen,
Michal Sheffer, Mattia Lauriola, Yehoshua Enuka, Ashish
Noronha, Maicol Mancini, Sara Lavi, et al. Silac identifies lad1
as a filamin-binding regulator of actin dynamics in response to egf and a
marker of aggressive breast tumors. Sci. Signal., 11[515]:eaan0949, 2018.
168
[248] David E Rumelhart and James L McClelland. Parallel distributed
processing: explorations in the microstructure of cognition. volume 1. foun-
dations. 1986. 34
[249] Graeme D Ruxton. The unequal variance t-test is an underused alterna-
tive to student’s t-test and the mann–whitney u test. Behavioral Ecology,
17[4]:688–690, 2006. 70
[250] Yvan Saeys, In˜aki Inza, and Pedro Larran˜aga. A review of feature
selection techniques in bioinformatics. bioinformatics, 23[19]:2507–2517,
2007. 30, 31
[251] Steven L Salzberg. C4. 5: Programs for machine learning by j.
ross quinlan. morgan kaufmann publishers, inc., 1993. Machine Learning,
16[3]:235–240, 1994. 28
[252] Yasushi Sasaki, Ryota Koyama, Reo Maruyama, Takehiro Hi-
rano, Miyuki Tamura, Jun Sugisaka, Hiromu Suzuki, Masashi
Idogawa, Yasuhisa Shinomura, and Takashi Tokino. CLCA2, a
target of the p53 family, negatively regulates cancer cell migration and in-
vasion. Cancer biology & therapy, 13[14]:1512–1521, dec 2012. 170
240
REFERENCES
[253] Aarti Sathyanarayana, Shafiq Joty, Luis Fernandez-Luque,
Ferda Ofli, Jaideep Srivastava, Ahmed Elmagarmid, Teresa
Arora, and Shahrad Taheri. Correction of: sleep quality prediction
from wearable data using deep learning. JMIR mHealth and uHealth, 4[4],
2016. 35
[254] C. D. Savci-Heijink, H. Halfwerk, J. Koster, H. M. Horlings,
and M. J. van de Vijver. A specific gene expression signature for visceral
organ metastasis in breast cancer. BMC Cancer, 19[1]:333, Apr 2019. 167
[255] Pieter Segaert, Marta B Lopes, Sandra Casimiro, Susana
Vinga, and Peter J Rousseeuw. Robust identification of target genes
and outliers in triple-negative breast cancer data. Statistical methods in
medical research, page 0962280218794722, 2018. 146, 147, 149
[256] Erin K. Shanle, Zibo Zhao, John Hawse, Kari Wisinski, Sunduz
Keles, Ming Yuan, and Wei Xu. Research Resource: Global Iden-
tification of Estrogen Receptor β Target Genes in Triple Negative Breast
Cancer Cells. Molecular Endocrinology, 27[10]:1762–1775, oct 2013. 164
[257] Jonathan H Shepherd, Ivan P Uray, Abhijit Mazumdar, Anna
Tsimelzon, Michelle Savage, Susan G Hilsenbeck, and Powel H
Brown. The sox11 transcription factor is a critical regulator of basal-like
breast cancer growth, invasion, and basal-like gene expression. Oncotarget,
7[11]:13106, 2016. 150
[258] Leming Shi, Laura H Reid, Wendell D Jones, Richard Shippy,
Janet A Warrington, Shawn C Baker, Patrick J Collins, Fran-
coise De Longueville, Ernest S Kawasaki, Kathleen Y Lee,
et al. The microarray quality control (maqc) project shows inter-and
intraplatform reproducibility of gene expression measurements. Nature
biotechnology, 24[9]:1151, 2006. 45
[259] Andrew K Shiau, Danielle Barstad, Paula M Loria, Lin Cheng,
Peter J Kushner, David A Agard, and Geoffrey L Greene.
The structural basis of estrogen receptor/coactivator recognition and the
antagonism of this interaction by tamoxifen. Cell, 95[7]:927–937, 1998. 16
241
REFERENCES
[260] Hoo-Chang Shin, Matthew R Orton, David J Collins, Simon J
Doran, and Martin O Leach. Stacked autoencoders for unsupervised
feature learning and multiple organ detection in a pilot study using 4d pa-
tient data. IEEE transactions on pattern analysis and machine intelligence,
35[8]:1930–1943, 2013. 37
[261] Wojciech Siedlecki and Jack Sklansky. A note on genetic algo-
rithms for large-scale feature selection. In Handbook of Pattern Recognition
and Computer Vision, pages 88–107. World Scientific, 1993. 33, 68
[262] J Silhava and Pavel Smrz. Additional predictive value of microarray
data compared to clinical variables. In 4th IAPR International Conference
on Pattern Recognition in Bioinformatics, 2009. 20
[263] R John Simes. An improved bonferroni procedure for multiple tests of
significance. Biometrika, 73[3]:751–754, 1986. 19
[264] Marcel Smid, Yixin Wang, Jan GM Klijn, Anieta M Sieuw-
erts, Yi Zhang, David Atkins, John WM Martens, and John A
Foekens. Genes associated with breast cancer metastatic to bone. Journal
of Clinical Oncology, 24[15]:2261–2267, 2006. 138
[265] He Song, Ming Dong, Jianping Zhou, Weiwei Sheng, Xin Li, and
Wei Gao. Expression and prognostic significance of trpv6 in the develop-
ment and progression of pancreatic cancer. Oncology reports, 39[3]:1432–
1440, 2018. 157
[266] Qinbao Song, Jingjie Ni, and Guangtao Wang. A fast clustering-
based feature subset selection algorithm for high-dimensional data. IEEE
transactions on knowledge and data engineering, 25[1]:1–14, 2013. 30
[267] Therese Sørlie, Charles M Perou, Robert Tibshirani, Turid
Aas, Stephanie Geisler, Hilde Johnsen, Trevor Hastie,
Michael B Eisen, Matt Van De Rijn, Stefanie S Jeffrey, et al.
Gene expression patterns of breast carcinomas distinguish tumor subclasses
with clinical implications. Proceedings of the National Academy of Sciences,
98[19]:10869–10874, 2001. 16
242
REFERENCES
[268] Therese Sørlie, Robert Tibshirani, Joel Parker, Trevor
Hastie, James Stephen Marron, Andrew Nobel, Shibing Deng,
Hilde Johnsen, Robert Pesich, Stephanie Geisler, et al. Re-
peated observation of breast tumor subtypes in independent gene expression
data sets. Proceedings of the national academy of sciences, 100[14]:8418–
8423, 2003. 16
[269] John M Stewart. Trpv6 as a target for cancer therapy. Journal of
Cancer, 11[2]:374, 2020. 157
[270] John D Storey and Robert Tibshirani. Statistical significance for
genomewide studies. Proceedings of the National Academy of Sciences,
100[16]:9440–9445, 2003. 19
[271] Jie Sun, Xiaojuan Zhang, Yanchun Han, Juan Zhen, Yuan Meng,
and Min Song. Overexpression of seven in absentia homolog 2 protein in
human breast cancer tissues is associated with the promotion of tumor cell
malignant behavior in in vitro. Oncology reports, 36[3]:1301–1312, 2016.
136
[272] Yijun Sun, Sinisa Todorovic, and Steve Goodison. Local-learning-
based feature selection for high-dimensional data analysis. IEEE transac-
tions on pattern analysis and machine intelligence, 32[9]:1610–1626, 2010.
30
[273] Yuliang Sun, Scooter Willis, Xiaoqian Lin, Justin Achua,
Casey Williams, and Brian Leyland-Jones. Is fgd3 a potentially
prognostic marker for breast cancer, 2017. 161
[274] Django Sussman, Leia M Smith, Martha E Anderson, Steve
Duniho, Joshua H Hunter, Heather Kostner, Jamie B
Miyamoto, Albina Nesterova, Lori Westendorf, Heather A
Van Epps, et al. Sgn–liv1a: A novel antibody–drug conjugate target-
ing liv-1 for the treatment of metastatic breast cancer. Molecular cancer
therapeutics, 13[12]:2991–3000, 2014. 138
243
REFERENCES
[275] Ilya Sutskever, Oriol Vinyals, and Quoc V Le. Sequence to se-
quence learning with neural networks. In Advances in neural information
processing systems, pages 3104–3112, 2014. 35
[276] Anna Louise Swan, Ali Mobasheri, David Allaway, Susan Lid-
dell, and Jaume Bacardit. Application of machine learning to pro-
teomics data: classification and biomarker identification in postgenomics
biology. Omics: a journal of integrative biology, 17[12]:595–610, 2013. 18
[277] Christian Szegedy, Wei Liu, Yangqing Jia, Pierre Sermanet,
Scott Reed, Dragomir Anguelov, Dumitru Erhan, Vincent
Vanhoucke, and Andrew Rabinovich. Going deeper with convolu-
tions. In Proceedings of the IEEE conference on computer vision and pattern
recognition, pages 1–9, 2015. 35
[278] Motoki Takaku, Sara A Grimm, John D Roberts, Kaliopi
Chrysovergis, Brian D Bennett, Page Myers, Lalith Perera,
Charles J Tucker, Charles M Perou, and Paul A Wade. Gata3
zinc finger 2 mutations reprogram the breast cancer transcriptional network.
Nature communications, 9[1]:1–14, 2018. 144
[279] Motoki Takaku, Sara A Grimm, and Paul A Wade. Gata3 in breast
cancer: tumor suppressor or oncogene? Gene Expression The Journal of
Liver Research, 16[4]:163–168, 2015. 144
[280] Satoshi Takakura, Takashi Kohno, Ryokuhei Manda, Aikou
Okamoto, Tadao Tanaka, and Jun Yokota. Genetic alterations
and expression of the protein phosphatase 1 genes in human cancers. In-
ternational journal of oncology, 18[4]:817–824, 2001. 158, 172
[281] Willem Talloen, Djork-Arne´ Clevert, Sepp Hochreiter,
Dhammika Amaratunga, Luc Bijnens, Stefan Kass, and Hin-
rich WH Go¨hlmann. I/ni-calls for the exclusion of non-informative
genes: a highly effective filtering tool for microarray data. Bioinformat-
ics, 23[21]:2897–2902, 2007. 49
244
REFERENCES
[282] Feng Tan, Xuezheng Fu, Yanqing Zhang, and Anu G Bourgeois.
A genetic algorithm-based method for feature subset selection. Soft Com-
puting, 12[2]:111–120, 2008. 33
[283] Jie Tan, John H Hammond, Deborah A Hogan, and Casey S
Greene. Adage-based integration of publicly available pseudomonas
aeruginosa gene expression data with denoising autoencoders illuminates
microbe-host interactions. MSystems, 1[1]:e00025–15, 2016. 38
[284] Jie Tan, Matthew Ung, Chao Cheng, and Casey S Greene. Unsu-
pervised feature construction and knowledge extraction from genome-wide
assays of breast cancer with denoising autoencoders. In Pacific Symposium
on Biocomputing Co-Chairs, pages 132–143. World Scientific, 2014. 38
[285] Shuya Tang, Yilong Hao, Yao Yuan, Rui Liu, and Qianming
Chen. Role of fibroblast growth factor receptor 4 in cancer. Cancer Science,
109[10]:3024, 2018. 171
[286] Sandra Tavares, Andre´ Filipe Vieira, Anna Verena Tauben-
berger, Margarida Arau´jo, Nuno Pimpao Martins, Catarina
Bra´s-Pereira, Anto´nio Polo´nia, Maik Herbig, Clara Barreto,
Oliver Otto, et al. Actin stress fiber organization promotes cell stiff-
ening and proliferation of pre-invasive breast cancer cells. Nature commu-
nications, 8[1]:1–18, 2017. 141
[287] Jeremy MG Taylor, Donna P Ankerst, and Rebecca R An-
dridge. Validation of biomarker-based risk prediction models. Clinical
Cancer Research, 14[19]:5977–5983, 2008. 11, 45
[288] Kathryn M Taylor, Helen E Morgan, Kathryn Smart, Nor-
mawati M Zahari, Sara Pumford, Ian O Ellis, John FR Robert-
son, and Robert I Nicholson. The emerging role of the liv-1 subfamily
of zinc transporters in breast cancer. In Molecular medicine, 13, pages
396–406. Springer, 2007. 137
[289] Dan Theodorescu and Harald Mischak. Mass spectrometry based
proteomics in urine biomarker discovery. World journal of urology,
25[5]:435–443, 2007. 18
245
REFERENCES
[290] C Tomasetto, C Regnier, C Moog-Lutz, MG Mattei,
MP Chenard, R Lidereau, P Basset, and MC Rio. Identifica-
tion of four novel human genes amplified and overexpressed in breast carci-
noma and localized to the q11-q21. 3 region of chromosome 17. Genomics,
28[3]:367–376, 1995. 154
[291] Truyen Tran, Tu Dinh Nguyen, Dinh Phung, and Svetha
Venkatesh. Learning vector representation of medical objects via emr-
driven nonnegative restricted boltzmann machines (enrbm). Journal of
biomedical informatics, 54:96–105, 2015. 34
[292] David Tritchler, Elena Parkhomenko, and Joseph Beyene.
Filtering genes for cluster and network analysis. BMC bioinformatics,
10[1]:193, 2009. 49
[293] Luis Tume, Karen Paco, Roberto Ubidia-Incio, and Jeel Moya.
Cd133 in breast cancer cells and in breast cancer stem cells as another target
for immunotherapy. Gaceta Mexicana de Oncolog´ıa, 15[1]:22–30, 2016. 147
[294] Natsue Uehiro, Fumiaki Sato, Fengling Pu, Sunao Tanaka,
Masahiro Kawashima, Kosuke Kawaguchi, Masahiro Sugimoto,
Shigehira Saji, and Masakazu Toi. Circulating cell-free dna-based
epigenetic assay can detect early breast cancer. Breast Cancer Research,
18[1]:129, 2016. 149
[295] Anita Umesh, Jenny Park, James Shima, Joseph Delaney,
Robert Wisotzkey, Erin Kelly, Elizabeth Beatrice Chiu, Jy-
oti Madhusoodanan, Mamatha Shekar, and Ilya Kupershmidt.
Identification of agr3 as a potential biomarker though public genomic data
analysis of triple-negative (tn) versus triple-positive (tp) breast cancer (bc).,
2012. 134
[296] Ewa Urbanczyk-Wochniak, Alexander Luedemann, Joachim
Kopka, Joachim Selbig, Ute Roessner-Tunali, Lothar
Willmitzer, and Alisdair R Fernie. Parallel analysis of transcript
and metabolic profiles: a new approach in systems biology. EMBO reports,
4[10]:989–993, 2003. 18
246
REFERENCES
[297] Fatemeh Vafaee, Connie Diakos, Michaela B Kirschner, Glen
Reid, Michael Z Michael, Lisa G Horvath, Hamid Alinejad-
Rokny, Zhangkai Jason Cheng, Zdenka Kuncic, and Stephen
Clarke. A data-driven, knowledge-based approach to biomarker discovery:
application to circulating microrna markers of colorectal cancer prognosis.
NPJ systems biology and applications, 4[1]:20, 2018. 92
[298] Kimberly D van der Willik, Mieke M Timmermans, Car-
olien HM van Deurzen, Maxime P Look, Esther A Reijm,
Wendy JHP van Zundert, Rene´e Foekens, Anita MAC
Trapman-Jansen, Michael A den Bakker, Pieter J Westenend,
et al. Siah2 protein expression in breast cancer is inversely related with
er status and outcome to tamoxifen therapy. American journal of cancer
research, 6[2]:270, 2016. 136
[299] Laura J Van’t Veer, Hongyue Dai, Marc J Van De Vijver,
Yudong D He, Augustinus AM Hart, Mao Mao, Hans L Peterse,
Karin Van Der Kooy, Matthew J Marton, Anke T Witteveen,
et al. Gene expression profiling predicts clinical outcome of breast cancer.
nature, 415[6871]:530, 2002. 21, 141
[300] J. Craig Venter, Mark D. Adams, Eugene W. Myers, Peter W.
Li, Richard J. Mural, Granger G. Sutton, Hamilton O. Smith,
Mark Yandell, Cheryl A. Evans, Robert A. Holt, Jeannine D.
Gocayne, Peter Amanatides, Richard M. Ballew, Daniel H.
Huson, Jennifer Russo Wortman, Qing Zhang, Chinnappa D.
Kodira, Xiangqun H. Zheng, Lin Chen, Marian Skupski,
Gangadharan Subramanian, Paul D. Thomas, Jinghui Zhang,
George L. Gabor Miklos, Catherine Nelson, Samuel Broder,
Andrew G. Clark, Joe Nadeau, Victor A. McKusick, Nor-
ton Zinder, Arnold J. Levine, Richard J. Roberts, Mel Simon,
Carolyn Slayman, Michael Hunkapiller, Randall Bolanos,
Arthur Delcher, Ian Dew, Daniel Fasulo, Michael Flanigan,
Liliana Florea, Aaron Halpern, Sridhar Hannenhalli, Saul
Kravitz, Samuel Levy, Clark Mobarry, Knut Reinert, Karin
247
REFERENCES
Remington, Jane Abu-Threideh, Ellen Beasley, Kendra Bid-
dick, Vivien Bonazzi, Rhonda Brandon, Michele Cargill, Ish-
war Chandramouliswaran, Rosane Charlab, Kabir Chaturvedi,
Zuoming Deng, Valentina Di Francesco, Patrick Dunn, Karen
Eilbeck, Carlos Evangelista, Andrei E. Gabrielian, Weiniu
Gan, Wangmao Ge, Fangcheng Gong, Zhiping Gu, Ping Guan,
Thomas J. Heiman, Maureen E. Higgins, Rui-Ru Ji, Zhaoxi Ke,
Karen A. Ketchum, Zhongwu Lai, Yiding Lei, Zhenya Li, Jiayin
Li, Yong Liang, Xiaoying Lin, Fu Lu, Gennady V. Merkulov,
Natalia Milshina, Helen M. Moore, Ashwinikumar K Naik,
Vaibhav A. Narayan, Beena Neelam, Deborah Nusskern, Dou-
glas B. Rusch, Steven Salzberg, Wei Shao, Bixiong Shue, Jing-
tao Sun, Zhen Yuan Wang, Aihui Wang, Xin Wang, Jian Wang,
Ming-Hui Wei, Ron Wides, Chunlin Xiao, and et al. Yan, Chun-
hua. The sequence of the human genome. Science, 291[5507]:1304–1351,
2001. 2
[301] Jorge R Vergara and Pablo A Este´vez. A review of feature selection
methods based on mutual information. Neural computing and applications,
24[1]:175–186, 2014. 30
[302] Jean-Louis Vincent, Jordi Rello, John Marshall, Eliezer
Silva, Antonio Anzueto, Claude D Martin, Rui Moreno, Jef-
frey Lipman, Charles Gomersall, Yasser Sakr, et al. Interna-
tional study of the prevalence and outcomes of infection in intensive care
units. Jama, 302[21]:2323–2329, 2009. 37
[303] Pascal Vincent, Hugo Larochelle, Isabelle Lajoie, Yoshua
Bengio, and Pierre-Antoine Manzagol. Stacked denoising autoen-
coders: Learning useful representations in a deep network with a local de-
noising criterion. Journal of machine learning research, 11[Dec]:3371–3408,
2010. 35
[304] Peter M Visscher, Naomi R Wray, Qian Zhang, Pamela Sklar,
Mark I McCarthy, Matthew A Brown, and Jian Yang. 10 years of
248
REFERENCES
gwas discovery: biology, function, and translation. The American Journal
of Human Genetics, 101[1]:5–22, 2017. 20
[305] Larissa Wakefield, James Robinson, Hilary Long, J Claire Ib-
bitt, Susanna Cooke, Helen C Hurst, and Edith Sim. Arylamine
n-acetyltransferase 1 expression in breast cancer cell lines: A potential
marker in estrogen receptor-positive tumors. Genes, Chromosomes and
Cancer, 47[2]:118–126, 2008. 138
[306] Randall Wald, Taghi M Khoshgoftaar, and Amri Napolitano.
Stability of filter-and wrapper-based feature subset selection. In Tools with
Artificial Intelligence (ICTAI), 2013 IEEE 25th International Conference
on, pages 374–380. IEEE, 2013. 45
[307] Dujuan Wang, Guohong Liu, Balu Wu, Li Chen, Lihua Zeng,
and Yunbao Pan. Clinical significance of elevated s100a8 expression in
breast cancer patients. Frontiers in oncology, 8:496, 2018. 156
[308] Fu-Wen Wang, Xiang Ao, and Shao-Mei Fu. Expression of sox11
and her2 and their association with recurrent breast cancer. Translational
Cancer Research, 8[1]:248–254, 2019. 150
[309] Shuang Wang, Dou Quan, Xuefeng Liang, Mengdan Ning,
Yanhe Guo, and Licheng Jiao. A deep learning framework for re-
mote sensing image registration. ISPRS Journal of Photogrammetry and
Remote Sensing, 2018. 35
[310] Yu Wang, Igor V Tetko, Mark A Hall, Eibe Frank, Axel
Facius, Klaus FX Mayer, and Hans W Mewes. Gene selection
from microarray data for cancer classificationa machine learning approach.
Computational biology and chemistry, 29[1]:37–46, 2005. 20
[311] PH Watson, SK Chia, Charles C Wykoff, C Han, RD Leek,
WS Sly, KC Gatter, P Ratcliffe, and AL Harris. Carbonic an-
hydrase xii is a marker of good prognosis in invasive breast carcinoma.
British journal of cancer, 88[7]:1065, 2003. 140
249
REFERENCES
[312] Geoffrey I Webb. Discovering significant rules. In Proceedings of the
12th ACM SIGKDD international conference on Knowledge discovery and
data mining, pages 434–443. ACM, 2006. 19
[313] Geoffrey I Webb. Discovering significant patterns. Machine learning,
68[1]:1–33, 2007. 19
[314] John N Weinstein, Eric A Collisson, Gordon B Mills, Kenna
R Mills Shaw, Brad A Ozenberger, Kyle Ellrott, Ilya Shmule-
vich, Chris Sander, Joshua M Stuart, Cancer Genome At-
las Research Network, et al. The cancer genome atlas pan-cancer
analysis project. Nature genetics, 45[10]:1113, 2013. 2
[315] Bernard L Welch. The generalization ofstudent’s’ problem when sev-
eral different population variances are involved. Biometrika, 34[1/2]:28–35,
1947. 30
[316] H Gilbert Welch, Philip C Prorok, A James OMalley, and
Barnett S Kramer. Breast-cancer tumor size, overdiagnosis, and
mammography screening effectiveness. New England Journal of Medicine,
375[15]:1438–1447, 2016. 15
[317] John B Welsh, Lisa M Sapinoso, Suzanne G Kern, David A
Brown, Tao Liu, Asne R Bauskin, Robyn L Ward, Nicholas J
Hawkins, David I Quinn, Pamela J Russell, et al. Large-scale de-
lineation of secreted protein biomarkers overexpressed in cancer tissue and
serum. Proceedings of the National Academy of Sciences, 100[6]:3410–3415,
2003. 134
[318] Scooter Willis, Yuliang Sun, Mark Abramovitz, Teng Fei,
Brandon Young, Xiaoqian Lin, Min Ni, Justin Achua, Mered-
ith M Regan, Kathryn P Gray, et al. High expression of fgd3, a
putative regulator of cell morphology and motility, is prognostic of favor-
able outcome in multiple cancers. JCO Precision Oncology, 1:1–13, 2017.
161
[319] Stephan M Winkler, Michael Affenzeller, Witold Jacak, and
Herbert Stekel. Identification of cancer diagnosis estimation models
250
REFERENCES
using evolutionary algorithms: a case study for breast cancer, melanoma,
and cancer in the respiratory system. In Proceedings of the 13th annual
conference companion on Genetic and evolutionary computation, pages 503–
510. ACM, 2011. 33
[320] Ian H Witten and Eibe Frank. Data mining practical learning tools
and techniques with java implementations, 2000. 41
[321] Pu Xia. Cd133 mrna may be a suitable prognostic marker for human
breast cancer. Stem cell investigation, 4, 2017. 147
[322] Bin Xiao, Jianfeng Hang, Ting Lei, Yongyin He, Zhenzhan
Kuang, Li Wang, Lidan Chen, Jia He, Weiyun Zhang, Yang Liao,
et al. Identification of key genes relevant to the prognosis of er-positive and
er-negative breast cancer based on a prognostic prediction system. Molec-
ular biology reports, pages 1–9, 2019. 138
[323] M Xu, S Chen, W Yang, X Cheng, Y Ye, J Mao, X Wu, L Huang,
and J Ji. FGFR4 Links Glucose Metabolism and Chemotherapy Resistance
in Breast Cancer. Cellular Physiology and Biochemistry, 47[1]:151–160,
2018. 172
[324] Bing Xue, Mengjie Zhang, Will N Browne, and Xin Yao. A
survey on evolutionary computation approaches to feature selection. IEEE
Transactions on Evolutionary Computation, 20[4]:606–626, 2016. 33
[325] Mutsuko Yamamoto-Ibusuki, Yutaka Yamamoto, Saori Fuji-
wara, Aiko Sueta, Satoko Yamamoto, Mitsuhiro Hayashi, Mai
Tomiguchi, Takashi Takeshita, and Hirotaka Iwase. C6orf97-esr1
breast cancer susceptibility locus: influence on progression and survival in
breast cancer patients. European Journal of Human Genetics, 23[7]:949,
2015. 136
[326] Meisi Yan, Jinsong Wang, Yanlv Ren, Lin Li, Weidan He, Ying
Zhang, Tong Liu, and Zhigao Li. Over-expression of fsip1 promotes
breast cancer progression and confers resistance to docetaxel via mrp1 sta-
bilization. Cell death & disease, 10[3]:1–13, 2019. 143
251
REFERENCES
[327] Jihoon Yang and Vasant Honavar. Feature subset selection using a
genetic algorithm. In Feature extraction, construction and selection, pages
117–136. Springer, 1998. 33
[328] Kaidi Yang, Jian Gao, and Mao Luo. Identification of key pathways
and hub genes in basal-like breast cancer using bioinformatics analysis.
OncoTargets and therapy, 12:1319, 2019. 153
[329] Pengyi Yang, Yee Hwa Yang, Bing B Zhou, and Albert
Y Zomaya. A review of ensemble methods in bioinformatics. Current
Bioinformatics, 5[4]:296–308, 2010. 32
[330] Fang Yao, Chi Zhang, Wei Du, Chao Liu, and Ying Xu. Identifi-
cation of gene-expression signatures and protein markers for breast cancer
grading and staging. PloS one, 10[9]:e0138213, 2015. 161
[331] Youngjin Yoo, Tom Brosch, Anthony Traboulsee, David KB
Li, and Roger Tam. Deep learning of image features from unlabeled
data for multiple sclerosis lesion segmentation. In International Workshop
on Machine Learning in Medical Imaging, pages 117–124. Springer, 2014.
34
[332] Lei Yu and Huan Liu. Feature selection for high-dimensional data: A
fast correlation-based filter solution. In Proceedings of the 20th international
conference on machine learning (ICML-03), pages 856–863, 2003. 31
[333] Qingyan Zhang, Danhui Huang, Zhenfei Zhang, Yuzhen Feng,
Meiting Fu, Min Wei, Zhou Jueyu, Yuanjin Huang, Shuguang
Liu, and Rong Shi. High expression of tmem40 contributes to progressive
features of tongue squamous cell carcinoma. Oncology Reports, 41, 10 2018.
151
[334] Sen Zhang and Yu Zhang. Seeking for correlative genes and signaling
pathways with bone metastasis from breast cancer by integrated analysis.
Frontiers in Oncology, 9:138, 2019. 147
[335] Zhen-Fei Zhang, Han-Rong Zhang, Qing-Yan Zhang, Shu-Yu
Lai, Yu-Zhen Feng, Yi Zhou, Si-Rong Zheng, Rong Shi, and
252
REFERENCES
Zhou Jueyu. High expression of tmem40 is associated with the malignant
behavior and tumorigenesis in bladder cancer. Journal of Translational
Medicine, 16:9, 12 2018. 151
[336] Shuang Zhao, Shuang-Shuang Chen, Yuan Gu, En-Ze Jiang, and
Zheng-Hong Yu. Expression and clinical significance of sushi domain-
containing protein 3 (susd3) and insulin-like growth factor-i receptor (igf-ir)
in breast cancer. Asian Pac J Cancer Prev, 16[18]:8633–8636, 2015. 162
[337] Xiangdong Zhao, Faliang Xu, Nestor P Dominguez, Yuanping
Xiong, Zhongxun Xiong, Hong Peng, Chloe Shay, and Yong
Teng. Fgfr4 provides the conduit to facilitate fgf19 signaling in breast
cancer progression. Molecular carcinogenesis, 57[11]:1616–1625, 2018. 172
[338] Wei Zheng, Jirong Long, Yu-Tang Gao, Chun Li, Ying Zheng,
Yong-Bin Xiang, Wanqing Wen, Shawn Levy, Sandra L Deming,
Jonathan L Haines, et al. Genome-wide association study identifies a
new breast cancer susceptibility locus at 6q25. 1. Nature genetics, 41[3]:324,
2009. 136
[339] Jing-Min Zhong, Jing Li, An-Ding Kang, San-Qian Huang, Wen-
Bin Liu, Yun Zhang, Zhi-Hong Liu, and Liang Zeng. Protein s100-
a8: A potential metastasis-associated protein for breast cancer determined
via itraq quantitative proteomic and clinicopathological analysis. Oncology
letters, 15[4]:5285–5293, 2018. 155
[340] Jian Zhou and Olga G Troyanskaya. Predicting effects of noncod-
ing variants with deep learning–based sequence model. Nature methods,
12[10]:931, 2015. 34
[341] Jindan Zhu, Amit Pande, Prasant Mohapatra, and Jay J Han.
Using deep learning for energy expenditure estimation with wearable sen-
sors. In E-health Networking, Application & Services (HealthCom), 2015
17th International Conference on, pages 501–506. IEEE, 2015. 35
[342] Rongxuan Zhu, Olivier Gires, Liqun Zhu, Jun Liu, Junjian Li,
Hao Yang, Gaoda Ju, Jing Huang, Weiyu Ge, Yi Chen, et al.
253
REFERENCES
Tspan8 promotes cancer cell stemness via activation of sonic hedgehog sig-
naling. Nature communications, 10[1]:1–14, 2019. 174
[343] Qin Zou, Lihao Ni, Tong Zhang, and Qian Wang. Deep learning
based feature selection for remote sensing scene classification. IEEE Geosci.
Remote Sensing Lett., 12[11]:2321–2325, 2015. 35
[344] Marketa Zvelebil, Erik Oliemuller, Qiong Gao, Olivia Wans-
bury, Alan Mackay, Howard Kendrick, Matthew J Smalley,
Jorge S Reis-Filho, and Beatrice A Howard. Embryonic mam-
mary signature subsets are activated in brca1-/-and basal-like breast can-
cers. Breast Cancer Research, 15[2]:R25, 2013. 149
254
